Publikationen

1. Abdulrahman Z, Santegoets SJ, Sturm G, Charoentong P, Ijsselsteijn ME, Somarakis A, Höllt T, Finotello F, Trajanoski Z, van Egmond SL, Mustafa DAM, Welters MJP, de Miranda NFCC, van der Burg SH. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. J Immunother Cancer. 2022 Feb;10(2):e004346. doi: 10.1136/jitc-2021-004346. PMID: 35217577   68317
2. Ahmed A, Köhler S, Klotz R, Giese N, Hackert T, Springfeld C, Zörnig I, Jäger D, Halama N. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Oncoimmunology. 2022 Jan 31;11(1):2027148. doi: 10.1080/2162402X.2022.2027148. eCollection 2022.   68329
3. Ahmed A, Klotz R, Köhler S, Giese N, Hackert T, Springfeld C, Jäger D, Halama N. Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. Front Immunol. 2022 Sep 5;13:947407. doi: 10.3389/fimmu.2022.947407. eCollection 2022.   68258
4. Aktas B, Fehm TN, Welslau M, Müller V, Lüftner D, Schütz F, Fasching PA, Janni W, Thomssen C, Witzel I, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Banys-Paluchowski M, Kolberg-Liedtke C, Hartkopf AD, Wöckel A, Kolberg HC, Stickeler E, Harbeck N, Schneeweiss A. Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):922-931. doi: 10.1055/a-1912-7362. eCollection 2022 Sep. PMID: 36110891  68029
5. Alex K, Winkler EC. The Mutual Benefit of the Integration of Philosophy and Bioethics – Our Experience from an Interdisciplinary Research Project on (Epi-)Genome Editing. Am. J. Bioeth. 2022; 22(12):61-63.    69843
6. Amant F, Nekljudova V, Maggen C, Seither F, Neven P, Cardonick EH, Schmatloch S, Van Calsteren K, Cordes T, de Haan J, Lok CAR, Flock F, Boere IA, Gziri MM, Solbach C, Lefrère H, Schneeweiss A, Witzel I, Seiler S, Loibl S. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. Eur J Cancer. 2022 Jul;170:54-63. doi: 10.1016/j.ejca.2022.04.014. Epub 2022 May 17. PMID: 35594612  68188
7. Anger M, Wendelborn C, Winkler EC, Schickhardt C. Neither carrots nor sticks? Challenges surrounding data sharing from the perspective of research funding agencies-A qualitative expert interview study. PLoS One. 2022 Sep 7;17(9):e0273259. doi: 10.1371/journal.pone.0273259. eCollection 2022    68353
8. Apostolidis L, Kowalscheck L, Weber TF, Godel T, Bendszus M, Kauczor HU, Jäger D, Schlemmer HP, Bäumer P. Dorsal Root Ganglion Morphometric Changes Under Oxaliplatin Treatment : Longitudinal Assessment by Computed Tomography. Clin Neuroradiol. 2022 Jun;32(2):547-556. doi: 10.1007/s00062-021-01083-5. Epub 2021 Sep 9.    68355
9. Avancini A, Belluomini L, Tregnago D, Trestini I, Lanza M, Milella M, Wiskemann J, Pilotto S. oncology: It is time to make a change. Patient Educ Couns. 2022 Jul;105(7):2629-2631. doi: 10.1016/j.pec.2022.01.019.     68360
10. Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fasching P, Fehm T, Gluz O, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Gerber B. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. Geburtshilfe Frauenheilkd. 2022 Sep 30;82(10):1031-1043. doi: 10.1055/a-1904-6231. eCollection 2022 Oct. PMID: 36186147    68044
11. Bauer N, Sperlich B, Holmberg HC, Engel FA. Effects of High-Intensity Interval Training in School on the Physical Performance and Health of Children and Adolescents: A Systematic Review with Meta-Analysis. Sports Med Open. 2022;8(1):50. Published 2022 Apr 11. doi:10.1186/s40798-022-00437-8    71271
12. Bauer N, Wiskemann J, Rosenberger F. (2022). Praxisbeispiel HIIT in der Onkologie. B&G Bewegungstherapie und Gesundheitssport, 38(04), 189-192.    71285
13. Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S; GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059.     68037
14. Bochtler T, Wohlfromm T, Hielscher T, Stichel D, Pouyiourou M, Kraft B, Neumann O, Endris V, von Deimling A, Stenzinger A, Krämer A. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes Cancer. 2022 Sep;61(9):551-560. doi: 10.1002/gcc.23047. Epub 2022 Apr 30   69130
15. Bohaumilitzky L, Kluck K, Hüneburg R, Gallon R, Nattermann J, Kirchner M, Kristiansen G, Hommerding O, Pfuderer PL, Wagner L, Echterdiek F, Kösegi S, Müller N, Fischer K, Nelius N, Hartog B, Borthwick G, Busch E, Haag GM, Bläker H, Möslein G, von Knebel Doeberitz M, Seppälä TT, Ahtiainen M, Mecklin JP, Bishop DT, Burn J, Stenzinger A, Budczies J, Kloor M, Ahadova A. The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology. 2022 Mar;162(3):907-919.e10. doi: 10.1053/j.gastro.2021.11.029.   68319
16. Bonetti E, Jenzer M, Nientiedt C, Kaczorowski A, Geisler C, Zschäbitz S, Jäger D, Hohenfellner M, Duensing S, Reimold P. Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period. Urol Int. 2022 Apr 27:1-10. doi: 10.1159/000524097.  68021
17. Bormann F-J, Brosius-Gersdorf F, Gräb-Schmidt E, Henn W, Ilkilic I, Inthorn J, Krones T, Lanzerath D, Lipp V, Marckmann G, Probst SM, Salloch S, Schildmann J, Schneider I, Taupitz J, Winkler EC. Stellungnahme der Zentralen Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer. Ärztliche Verantwortung an den Grenzen der Sinnhaftigkeit medizinischer Maßnahmen. Zum Umgang mit „Futility“. Deutsches Ärzteblatt, 2022.  70130
18. Borst L, Sluijter M, Sturm G, Charoentong P, Santegoets SJ, van Gulijk M, van Elsas MJ, Groeneveldt C, van Montfoort N, Finotello F, Trajanoski Z, Kiełbasa SM, van der Burg SH, van Hall T. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. Int J Cancer. 2022 Feb 15;150(4):688-704. doi: 10.1002/ijc.33859.   68318
19. Brockmoeller S, Echle A, Laleh NG, Eiholm S, Malmstrøm ML, Kuhlmann TP, Levic K, Grabsch HI, West NP, Saldanha OL, Kouvidi K, Bono A, Heij LR, Brinker TJ, Gögenür I, Quirke P, Kather JN. Deep Learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. J Pathol. 2022 Mar;256(3):269-281. doi: 10.1002/path.5831. doi: 10.1002/path.5831.    68362
20. Buendgens L, Cifci D, Ghaffari Laleh N, van Treeck M, Koenen MT, Zimmermann HW, Herbold T, Lux TJ, Hann A, Trautwein C, Kather JN. Weakly supervised end-to- end artificial intelligence in gastrointestinal endoscopy. Sci Rep. 2022 Mar 22;12(1):4829. doi: 10.1038/s41598-022-08773-1. PMID: 35318364; PMCID: PMC8941159.    70855
21. Bujan Rivera J, Kühl R, Zech U, Hendricks A, Luft T, Dreger P, Friedmann-Bette B, Betz TM, Wiskemann J. Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) - design and rational of a randomized controlled trial. BMC Cancer. 2022 Apr 22;22(1):440. doi: 10.1186/s12885-022-09497-1.   68369
22. Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, […], Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Lo RC, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. Apostolidis L, Lang K, Sisic L, Busch E, Ahadova A, Wullenkord R, Nienhüser H, Billeter A, Müller-Stich B, Kloor M, Jaeger D, Haag GM. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol. 2022 Dec;77(6):1586-1597. doi: 10.1016/j.jhep.2022.07.019. Epub 2022 Aug 18. PMID: 35987274   68367  
23. Campbell KL, Cormie P, Weller S, Alibhai SMH, Bolam KA, Campbell A, Cheville AL, Dalzell MA, Hart NH, Higano CS, Lane K, Mansfield S, McNeely ML, Newton RU, Quist M, Rauw J, Rosenberger F, Santa Mina D, Schmitz KH, Winters-Stone KM, Wiskemann J, Goulart J. Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals. JCO Oncol Pract. 2022 May;18(5):e697-e709. doi: 10.1200/OP.21.00454. Epub 2022 Jan 6.   68371
24. Charbel A, Tavernar L, Albrecht T, Brinkmann F, Verheij J, Roos E, Vogel MN, Köhler B, Springfeld C, Brobeil A, Schirmacher P, Singer S, Mehrabi A, Roessler S, Goeppert B. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. Br J Cancer. 2022 Nov;127(9):1603-1614. doi: 10.1038/s41416-022-01933-0.    68259
25. Chung KH, Park SB, Streckmann F, Wiskemann J, Mohile N, Kleckner AS, Colloca L, Dorsey SG, Kleckner IR. Mechanisms, Mediators, and Moderators of the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy. Cancers (Basel). 2022 Feb 26;14(5):1224. doi: 10.3390/cancers14051224.   68374
26. Cifci D, Foersch S, Kather JN. Artificial intelligence to identify genetic alterations in conventional histopathology. J Pathol. 2022 Jul;257(4):430-444. doi: 10.1002/path.5898. Epub 2022 Apr 21.    68378
27. Clauss D, Roetzer I, Tjaden C, Hackert T, Wiskemann J, Steindorf K. Nutrition Intake and Nutrition Status of Pancreatic Cancer Patients: Cross-Sectional and Longitudinal Analysis of a Randomized Controlled Exercise Intervention Study. Nutr Cancer. 2022;74(10):3492-3500.  doi: 10.1080/01635581.2022.2077382. Epub 2022 May 24    71276
28. Cohen CM, Wentzensen N, Lahrmann B, Tokugawa D, Poitras N, Bartels L, Krauthoff A, Keil A, Miranda F, Castle PE, Lorey T, Hare B, Darragh TM, Grabe N, Clarke MA. Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. Clin Infect Dis.  2022 Oct 29;75(9):1565-1572. doi: 10.1093/cid/ciac211.    68391
29. de Castilhos J, Zamir E, Hippchen T, Rohrbach R, Schmidt S, Hengler S, Schumacher H, Neubauer M, Kunz S, Müller-Esch T, Hiergeist A, Gessner A, Khalid D, Gaiser R, Cullin N, Papagiannarou SM, Beuthien-Baumann B, Krämer A, Bartenschlager R, Jäger D, Müller M, Herth F, Duerschmied D, Schneider J, Schmid RM, Eberhardt JF, Khodamoradi Y, Vehreschild MJGT, Teufel A, Ebert MP, Hau P, Salzberger B, Schnitzler P, Poeck H, Elinav E, Merle U, Stein-Thoeringer CK. Severe dysbiosis and specific Haemophilus and Neisseria signatures as hallmarks of the oropharyngeal microbiome in critically ill COVID-19 patients. Clin Infect Dis. 2022 Aug 24;75(1):e1063-e1071. doi: 10.1093/cid/ciab902.    68377
30. de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, Fehm T, Kreipe H, Christgen M, Kümmel S, Trapp E, Wuerstlein R, Hartkopf A, Clemens M, Reimer T, Häberle L, Fasching PA, Gluz O, Harbeck N. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022 Jun;126(12):1715-1724. doi: 10.1038/s41416-021-01690-6. Epub 2022 Feb 22. PMID: 35194193   68193
31. Dendl K, Finck R, Giesel FL, Kratochwil C, Lindner T, Mier W, Cardinale J, Kesch C, Röhrich M, Rathke H, Gampp H, Ristau J, Adeberg S, Jäger D, Debus J, Haberkorn U, Koerber SA. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):721-731. doi: 10.1007/s00259-021-05488-9.   68395
32. Depenbusch J, Wiskemann J, Haussmann A, Tsiouris A, Schmidt L, Ungar N, Sieverding M, Steindorf K. Impact and Determinants of Structural Barriers on Physical Activity in People with Cancer. Int J Behav Med. 2022 Jun;29(3):308-320. doi: 10.1007/s12529-021-10014-0. Epub 2021 Sep 22   68399
33. Depenbusch J, Haussmann A, Wiskemann J, Tsiouris A, Schmidt L, Sieverding M, Ungar N, Steindorf K. The Relationship between Exercise Self-Efficacy, Intention, and Structural Barriers for Physical Activity after a Cancer Diagnosis. Cancers (Basel). 2022 May 18;14(10):2480. doi: 10.3390/cancers14102480.  68402
34. Dieckmann KP, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C, Dienes T, Zschäbitz S, Paffenholz P, Gschliesser T, Pichler R, Mego M, Bader P, Zengerling F, Heinzelbecker J, Krausewitz P, Krege S, Aurilio G, Aksoy C, Hentrich M, Seidel C, Törzsök P, Nestler T, Majewski M, Hiester A, Buchler T, Vallet S, Studentova H, Schönburg S, Niedersüß-Beke D, Ring J, Trenti E, Heidenreich A, Wülfing C, Isbarn H, Pichlmeier U, Pichler M. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Ther Adv Med Oncol. 2022 Mar 31;14:17588359221086813. doi: 10.1177/17588359221086813. eCollection 2022.PMID: 35386956   68024
35. Dieter SM, Lovecchio D, Pataskar A, Zowada MK, Körner PR, Khalizieva A, van Tellingen O, Jäger D, Glimm H, Agami R. Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene. 2022 Aug;41(32):3953-3968. doi: 10.1038/s41388-022-02400-z. Epub 2022 Jul 7.    68403
36. Ditsch N, Wöcke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm TN, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care (Basel). 2022 Aug;17(4):403-420. doi: 10.1159/000524879. Epub 2022 May 5. PMID: 36156915 Free article. Review.   68040
37. Eckford RD, Gaisser A, Arndt V, Baumann M, Kludt E, Mehlis K, Ubels J, Winkler EC, Weg-Remers S, Schlander M. The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care and Psychological Burden. Front Public Health. 2022 Feb 9;9:788598. doi: 10.3389/fpubh.2021.788598. eCollection 2021.   68412
38. Echle A, Ghaffari Laleh N, Quirke P, Grabsch HI, Muti HS, Saldanha OL, Brockmoeller SF, van den Brandt PA, Hutchins GGA, Richman SD, Horisberger K, Galata C, Ebert MP, Eckardt M, Boutros M, Horst D, Reissfelder C, Alwers E, Brinker TJ, Langer R, Jenniskens JCA, Offermans K, Mueller W, Gray R, Gruber SB, Greenson JK, Rennert G, Bonner JD, Schmolze D, Chang-Claude J, Brenner H, Trautwein C, Boor P, Jaeger D, Gaisa NT, Hoffmeister M, West NP, Kather JN. Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application. ESMO Open. 2022 Apr;7(2):100400. doi: 10.1016/j.esmoop.2022.100400. Epub 2022 Mar 2.   68413
39. El Wajeh M, Jung F, Bongartz D, Kappatou CD, Ghaffari Laleh N, Mitsos A, Kather JN. Can the Kuznetsov Model Replicate and Predict Cancer Growth in Humans? Bull Math Biol. 2022 Sep 29;84(11):130. doi: 10.1007/s11538-022-01075-7. PMID: 36175705; PMCID: PMC9522842.   70858
40. Emanuel A, Krampitz J, Rosenberger F, Kind S, Rötzer I. Nutritional Interventions in Pancreatic Cancer: A Systematic Review. Cancers (Basel). 2022 Apr 28;14(9):2212. doi: 10.3390/cancers14092212.    68414
41. Engel FA, Bauer N. Hochintensives Intervalltraining im Schulsetting–effektiv zur Verbesserung der kardiovaskulären Leistungsfähigkeit? B&G Bewegungstherapie und Gesundheitssport, 2022;38(04), 152-160.    71272
42. Engler T, Fasching PA, Lüftner D, Hartkopf AD, Müller V, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Wallwiener M, Beckmann MW, Hein A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Untch M, Taran FA, Enzinger HM, Krabisch P, Welslau M, Maasberg M, Hempel D, Lux MP, Michel LL, Janni W, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd. 2022 Jul 12;82(10):1055-1067. doi: 10.1055/a-1880-0087. eCollection 2022 Oct. PMID: 36186151  68030
43. Fasching PA, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, Ekici AB, Reis A, Schneeweiss A, Tesch H, Fehm TN, Heinrich G, Beckmann MW, Ruebner M, Huebner H, Lambrechts D, Madden E, Shen J, Romm J, Doheny K, Jenkins GD, Carlson EE, Li L, Fridley BL, Cunningham JM, Janni W, Monteiro ANA, Schaid DJ, Häberle L, Weinshilboum RM, Wang L. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clin Cancer Res. 2022 Aug 2;28(15):3342-3355. doi: 10.1158/1078-0432.CCR-20-4774. PMID: 35653140.   68187
44. Fehm TN, Welslau M, Müller V, Lüftner D, Schütz F, Fasching PA, Janni W, Thomssen C, Witzel I, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Kolberg-Liedtke C, Hartkopf AD, Wöckel A, Kolberg HC, Harbeck N, Stickeler E. Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):912-921. doi: 10.1055/a-1912-7105. eCollection 2022 Sep. PMID: 36110894.      68054
45. Fischer C, Turchinovich A, Feisst M, Riedel F, Haßdenteufel K, Scharli P, Hartkopf AD, Brucker SY, Michel L, Burwinkel B, Schneeweiss A, Wallwiener M, Deutsch TM. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. Int J Mol Sci. 2022 Aug 23;23(17):9535. doi: 10.3390/ijms23179535. PMID: 36076930     68039
46. Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precis Oncol. 2022 Nov;6:e2200006. doi: 10.1200/PO.22.00006. PMID: 36331248  68240
47. Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761.PMID: 35977756  Clinical Trial.   68017
48. Gerber B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Ataseven B, Klare P, Hahn M, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer JU, Rhiem K, Fasching PA, Nekljudova V, Loibl S, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel). 2022 Jan 20;14(3):521. doi: 10.3390/cancers14030521. PMID: 35158789  68195
49. Ghaffari Laleh N, Truhn D, Veldhuizen GP, Han T, van Treeck M, Buelow RD, Langer R, Dislich B, Boor P, Schulz V, Kather JN. Adversarial attacks and adversarial robustness in computational pathology. Nat Commun. 2022 Sep 29;13(1):5711. doi: 10.1038/s41467-022-33266-0. PMID: 36175413; PMCID: PMC9522657.    70861
50. Ghaffari Laleh N, Loeffler CML, Grajek J, Staňková K, Pearson AT, Muti HS, Trautwein C, Enderling H, Poleszczuk J, Kather JN. Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol. 2022 Feb 4;18(2):e1009822. doi: 10.1371/journal.pcbi.1009822. PMID: 35120124; PMCID: PMC8903251.    70868
51. Goeppert B, Stichel D, Toth R, Fritzsche S, Loeffler MA, Schlitter AM, Neumann O, Assenov Y, Vogel MN, Mehrabi A, Hoffmann K, Köhler B, Springfeld C, Weichenhan D, Plass C, Esposito I, Schirmacher P, von Deimling A, Roessler S. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. Gut. 2022 Feb;71(2):391-401. doi: 10.1136/gutjnl-2020-322983. Epub 2021 Jan 19.   68416
52. Götte M, Gauß G, Dirksen U, Driever PH, Basu O, Baumann FT, Wiskemann J, Boos J, Kesting SV. Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus-based recommendations. Pediatr Blood Cancer. 2022 Nov;69(11):e29953. doi: 10.1002/pbc.29953.   68417
53. Götte M, Söntgerath R, Gauß G, Wiskemann J, Buždon M, Kesting S. A National Implementation Approach for Exercise as Usual Care in Pediatric and Adolescent Oncology: Network ActiveOncoKids. Pediatr Exerc Sci. 2022 Nov 1;34(4):219–226. doi: 10.1123/pes.2021-0218. Epub 2022 Jun 14.    68421
54. Golriz M, Ramouz A, Ali-Hasan-Al-Saegh S, Shafiei S, Aminizadeh E, Hammad A,

55. Mieth M, Rupp C, Springfeld C, Hoffmann K, Büchler M, Mehrabi A. Prognostic

    Value of Red Blood Cell Distribution Width (RDW) in the Recurrence of Hepatocellular Carcinoma Following Curative Resection. J Hepatocell Carcinoma. 2022 Oct 31;9:1137-1147. doi: 10.2147/JHC.S380243. PMID: 36338431; PMCID: PMC9635388.    68257

56. Graf J, Sickenberger N, Brusniak K, Matthies LM, Deutsch TM, Simoes E, Plappert C, Keilmann L, Hartkopf A, Walter CB, Hahn M, Engler T, Wallwiener S, Schuetz F, Fasching PA, Schneeweiss A, Brucker SY, Wallwiener M. Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. J Med Internet Res. 2022 Feb 8;24(2):e16128. doi: 10.2196/16128. PMID: 35133288  68239
57. Grapp M, Rosenberger F, Hemlein E, Klein E, Friederich HC, Maatouk I. Acceptability and Feasibility of a Guided Biopsychosocial Online Intervention for Cancer Patients Undergoing Chemotherapy. J Cancer Educ. 2022 Feb;37(1):102-110. doi: 10.1007/s13187-020-01792-4.  64266
58. Grimm MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11. PMID: 35275706. 71281
59. Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Briceno I, Burwinkel B, Camp NJ, Castelao JE, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Ernst K, Evans DG, Figueroa JD, Fink V, Floris G, Fox S, Gabrielson M, Gago-Dominguez M, García-Sáenz JA, González-Neira A, Haeberle L, Haiman CA, Hall P, Hamann U, Harkness EF, Hartman M, Hein A, Hooning MJ, Hou MF, Howell SJ; ABCTB Investigators; kConFab Investigators; Ito H, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kristensen VN, Kwong A, Lambrechts D, Li J, Lubiński J, Manoochehri M, Margolin S, Matsuo K, Taib NAM, Mulligan AM, Nevanlinna H, Newman WG, Offit K, Osorio A, Park SK, Park-Simon TW, Patel AV, Presneau N, Pylkäs K, Rack B, Radice P, Rennert G, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schochter F, Schoemaker MJ, Shen CY, Shibli R, Sinn P, Tapper WJ, Tawfiq E, Teo SH, Teras LR, Torres D, Vachon CM, van Deurzen CHM, Wendt C, Williams JA, Winqvist R, Elwood M, Schmidt MK, García-Closas M, Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur J Cancer. 2022 Sep;173:178-193. doi: 10.1016/j.ejca.2022.06.011. Epub 2022 Aug 4. PMID: 35933885    68041
60. Haag GM, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, Berger AK, Weber TF, Zoernig I, Schaaf M, Waberer L, Müller DW, Al-Batran SE, Halama N, Jaeger D. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial. Eur J Cancer. 2022 May;167:112-122. doi: 10.1016/j.ejca.2022.03.017. Epub 2022 Apr 12.   68022
61. Haun MW, Wildenauer A, Hartmann M, Bleyel C, Becker N, Jäger D, Friederich HC, Tönnies J. Negotiating decisions on aggressive cancer care at end-of-life between patients, family members, and physicians - A qualitative interview study. Front Oncol. 2022 Sep 23;12:870431. doi: 10.3389/fonc.2022.870431. eCollection 2022.    68423
62. Haussmann A, Ungar N, Tsiouris A, Schmidt L, Wiskemann J, Steindorf K, Sieverding M. Better not resting: Carving out attitudes and their associations with physical activity in people with cancer. Eur J Cancer Care (Engl). 2022 Sep;31(5):e13622. doi: 10.1111/ecc.13622.   68425
63. Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022 Sep;172:107-118. doi: 10.1016/j.ejca.2022.05.025.   68427
64. Heinz CN, Echle A, Foersch S, Bychkov A, Kather JN. The future of artificial intelligence in digital pathology - results of a survey across stakeholder groups. Histopathology. 2022 Jun;80(7):1121-1127. doi: 10.1111/his.14659. Epub 2022 May 11. PMID: 35373378.    70870
65. Hiensch AE, Monninkhof EM, Schmidt ME, Zopf EM, Bolam KA, Aaronson NK, Belloso J, Bloch W, Clauss D, Depenbusch J, Lachowicz M, Pelaez M, Rundqvist H, Senkus E, Stuiver MM, Trevaskis M, Urruticoechea A, Rosenberger F, van der Wall E, de Wit GA, Zimmer P, Wengström Y, Steindorf K, May AM. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study. Trials. 2022 Jul 29;23(1):610. doi: 10.1186/s13063-022-06556-7.    68429
66. Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig CE, Scherr AL, Günther M, Albrecht T, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, Fritzsche S, Weiler S, Sobol B, Stenzinger A, Boeck S, Westphalen CB, Schulze-Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreiter S, Siveke J, Bauer S, Glimm H, Brors B, Hüllein J, Hübschmann D, Uhrig S, Horak P, Kreutzfeld S, Banales JM, Springfeld C, Jäger D, Schirmacher P, Roessler S, Ormanns S, Goeppert B, Fröhling S, Köhler BC. Bcl-x L as prognostic marker and potential therapeutic target in cholangiocarcinoma. Liver Int. 2022 Dec;42(12):2855-2870. doi: 10.1111/liv.15392.    68431
67. Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, Siegler G, Ebert MP, Goekkurt E, Mahlberg R, Homann N, Pink D, Bechstein W, Reichardt P, Flach H, Gaiser T, Battmann A, Oduncu FS, Loose M, Sookthai D, Pauligk C, Göetze TO, Al-Batran SE. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022 Nov 10;40(32):3750-3761. doi: 10.1200/JCO.22.00380. Epub 2022 Jun 16. PMID: 35709415.   68262
68. Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Jückstock J, Nabieva N, Schneeweiss A, Tesch H, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Rezai M, Beckmann MW, Fasching PA, Janni W, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel). 2022 Mar 28;14(7):1721. doi: 10.3390/cancers14071721. PMID: 35406491  68066
69. Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf AD, Lux MP, Huober J, Uhrig S, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Hein A, Belleville E, Untch M, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J, Fasching PA, Michel LL. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat. 2023 Jan;197(2):355-368. doi: 10.1007/s10549-022-06795-x. Epub 2022 Nov 21. PMID: 36409394  68242
70. Ihrig A, Hanslmeier T, Grüllich C, Zschäbitz S, Huber J, Greinacher A, Sauer C, Friedrich H-C, Maatouk I. Couples coping with advanced prostate cancer: An explorative study on treatment decision making, mental deterioration, partnership, and psychological burden. 68028
71. Jahn A, Rump A, Widmann TJ, Heining C, Horak P, Hutter B, Paramasivam N, Uhrig S, Gieldon L, Drukewitz S, Kübler A, Bermudez M, Hackmann K, Porrmann J, Wagner J, Arlt M, Franke M, Fischer J, Kowalzyk Z, William D, Weth V, Oster S, Fröhlich M, Hüllein J, Valle González C, Kreutzfeldt S, Mock A, Heilig CE, Lipka DB, Möhrmann L, Hanf D, Oleś M, Teleanu V, Allgäuer M, Ruhnke L, Kutz O, Knurr A, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Metzeler KH, Bitzer M, Schulze-Osthoff K, von Kalle C, Brors B, Stenzinger A, Weichert W, Hübschmann D, Fröhling S, Glimm H, Schröck E, Klink B. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol. 2022 Nov;33(11):1186-1199. doi: 10.1016/j.annonc.2022.07.008.   68434
72. Jungkunz M, Köngeter A, Spitz M, Mehlis K, Cornelius K, Schickhardt C, Winkler EC. Stellungnahme zur Etablierung der sekundären Forschungsnutzung von Behandlungsdaten in Deutschland. Ergebnisse des Verbundprojekts LinCDat: „Learning from Clinical Data. Ethical, Social and Legal Aspects". Forum Marsilius Kolleg, 2022;21: 1-123. https://doi.org/10.11588/fmk.2022.1.91697   68817
73. Jungkunz M, Köngeter A, Mehlis K, Spitz M, Winkler EC, Schickhardt C (2022): Haben Patient*innen die moralische Pflicht, ihre klinischen Daten für Forschung bereitzustellen? Eine kritische Prüfung möglicher Gründe. Ethik Med 34, 195–220. https://doi.org/10.1007/s00481-022-00684-z     68321
74. Kather JN, Ghaffari Laleh N, Foersch S, Truhn D. Medical domain knowledge in domain-agnostic generative AI. NPJ Digit Med. 2022 Jul 11;5(1):90. doi: 10.1038/s41746-022-00634-5. PMID: 35817798; PMCID: PMC9273760.    70872
75. Kayser S, Kramer M, Martínez-Cuadrón D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Ráčil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stölzel F, Ho AD, Thiede C, Stone RM, Röllig C, Montesinos P, Schlenk RF, Levis MJ. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022 Apr 1;107(4):836-843. doi: 10.3324/haematol.2021.278645.   88449
76. Kers J, Bülow RD, Klinkhammer BM, Breimer GE, Fontana F, Abiola AA, Hofstraat R, Corthals GL, Peters-Sengers H, Djudjaj S, von Stillfried S, Hölscher DL, Pieters TT, van Zuilen AD, Bemelman FJ, Nurmohamed AS, Naesens M, Roelofs JJTH, Florquin S, Floege J, Nguyen TQ, 0, Kather JN, Boor P. Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study. Lancet Digit Health. 2022 Jan;4(1):e18-e26. doi: 10.1016/S2589-7500(21)00211-9. Epub 2021 Nov 15. PMID: 34794930.   64272
77. Khajeh E, Moghadam AD, Eslami P, Ali-Hasan-Al-Saegh S, Ramouz A, Shafiei S, Ghamarnejad O, Dezfouli SA, Rupp C, Springfeld C, Carvalho C, Probst P, Mousavizadeh SM, Mehrabi A. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer. 2022 Jan 21;22(1):91. doi: 10.1186/s12885-022-09192-1. PMID: 35062904; PMCID: PMC8781082.   68316
78. Köngeter A, Schickhardt C, Jungkunz M, Bergbold S, Mehlis K, Winkler EC. Patients' Willingness to Provide Their Clinical Data for Research Purposes and Acceptance of Different Consent Models: Findings From a Representative Survey of Patients With Cancer. J Med Internet Res. 2022 Aug 25;24(8):e37665. doi: 10.2196/37665.    68450
79. König J. Kommentar II zum Fall: „Alles, was in unserer Macht steht“. Ethik Med. 2022; 34:693–695.    69842
80. Koeppel M, Peters S, Huber G, Rosenberger F, Wiskemann J. Comment on: "Attempting to Separate Placebo Effects from Exercise in Chronic Pain: A Systematic Review and Meta-analysis". Sports Med. 2022 Apr;52(4):959-960. doi: 10.1007/s40279-021-01621-8.   68451
81. Koeppel M, Eckert K, Huber G. Trends in gross body coordination and cardiorespiratory fitness-a hierarchical Bayesian Analysis of 35 000 2nd Graders. Scand J Med Sci Sports. 2022 Jun;32(6):1026-1040. doi: 10.1111/sms.14146. Epub 2022 Mar 14.   68452
82. Kolberg-Liedtke C, Lüftner D, Brucker SY, Budach W, Denkert C, Fasching PA, Haidinger R, Harbeck N, Huober J, Jackisch C, Janni W, Krug D, Kühn T, Loibl S, Müller V, Schneeweiss A, Thomssen C, Untch M, Thill M. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. Breast Care (Basel). 2022 Jun;17(3):336-345. doi: 10.1159/000517501. Epub 2022 Apr 8. PMID: 35957945   68242
83. Laleh N, Muti HS, Loeffler CML, Echle A, Saldanha OL, Mahmood F, Lu MY, Trautwein C, Langer R, Dislich B, Buelow RD, Grabsch HI, Brenner H, Chang- Claude J, Alwers E, Brinker TJ, Khader F, Truhn D, Gaisa NT, Boor P, Hoffmeister M, Schulz V, Kather JN. Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Med Image Anal. 2022 Jul;79:102474. doi: 10.1016/j.media.2022.102474. Epub 2022 May 4. Erratum in: Med Image Anal. 2022 Nov;82:102622. PMID: 35588568.    70865
84. Laryionava K, Schönstein A, Heußner P, Hiddemann W, Winkler EC*, Wahl H-W*. Experience of Time and Subjective Age When Facing a Limited Lifetime: The Case of Older Adults with Advanced Cancer. J. Aging Health. 2022; 34(4–5):736–749.   69841
85. Lehmann LH, Stein F, Jäger D, Frey N. The Heidelberg cardio-oncology unit (COUNT)-a possible blueprint for improved care of cardio-oncological patients. Clin Res Cardiol. 2022 Feb;111(2):227-229. doi: 10.1007/s00392-021-01894-z. Epub 2021 Jun 28.   68453
86. Li M, Schulte N, Elting F, Winkler EC, Hetjens S, Berger AK, Zschäbitz S, Hofmann J, Hofmann J, Hilbertz L, Kuhn M, Khakzar C, Jesenofsky R, Betge J, Zhan T, Belle S, Ebert MP, Härtel N. Sequential Geriatric Assessment in Older Patients with Colorectal Cancer during Chemotherapy: Subgroup Analysis of a Prospective, Multicenter Study EpiReal 75. Oncol Res Treat. 2022;45(11):670-680. doi: 10.1159/000525101. Epub 2022 Jun 8.PMID: 35675788   68020
87. Lin K, Baenke F, Lai X, Schneider M, Helm D, Polster H, Rao VS, Ganig N, Wong FC, Seifert L, Seifert AM, Jahnke B, Kretschmann N, Ziemssen T, Klupp F, Schmidt T, Schneider M, Han Y, Weber TF, Plodeck V, Nebelung H, Schmitt N, Korell F, Köhler BC, Riediger C, Weitz J, Rahbari NN, Kahlert C. Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation. Mol Cancer. 2022 Apr 1;21(1):91. doi: 10.1186/s12943-022-01562-4. PMID: 35365178    96584
88. Loeffler CML, Ortiz Bruechle N, Jung M, Seillier L, Rose M, Laleh NG, Knuechel R, Brinker TJ, Trautwein C, Gaisa NT, Kather JN. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing? Eur Urol Focus. 2021 Apr 21:S2405-4569(21)00113-9. doi: 10.1016/j.euf.2021.04.007.   64274
89. Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022 Nov;33(11):1149-1158. doi: 10.1016/j.annonc.2022.07.1940. Epub 2022 Aug 9.   68034
90. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol. 2022 Jul;33(7):743-744. doi: 10.1016/j.annonc.2022.04.003. Epub 2022 May 18. PMID: 35595658 No abstract available.   68032
91. Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Thomssen C, Müller V, Fehm TN, Belleville E, Bader S, Untch M, Welslau M, Thill M, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R, Hartkopf AD. Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):215-225. doi: 10.1055/a-1724-9569. eCollection 2022 Feb. PMID: 35169389  68089
92. Malik J, Klammer M, Rolny V, Chan HL, Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, Swiatek-de Lange M. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. Gastroenterol. 2022 Aug 7;28(29):3917-3933. doi: 10.3748/wjg.v28.i29.3917. PMID: 36157551   69581
93. Meixner E, Eichkorn T, Erdem S, König L, Lang K, Lischalk JW, Michel LL, Schneeweiss A, Smetanay K, Debus J, Hörner-Rieber J. Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation. Int J Gynecol Cancer. 2022 Feb;32(2):172-180. doi: 10.1136/ijgc-2021-002906.   68189
94. Meixner E, Hoeltgen L, Hoegen P, König L, Arians N, Michel LL, Smetanay K, Fremd C, Schneeweiss A, Debus J, Hörner-Rieber J. Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118188. doi: 10.1177/15330338221118188. PMID: 35950239   68083
95. Meyer-Schwickerath C, Morawietz C, Baumann FT, Huber G, Wiskemann J. Efficacy of face-to-face behavior change counseling interventions on physical activity behavior in cancer survivors - a systematic review and meta-analysis. Disabil Rehabil. 2022 Sep; 44(19):5386-5401. doi: 10.1080/09638288.2021.1938247.    68454
96. Meyer-Schwickerath C, Köppel M, Kühl R, Bujan J, Tsiouris A, Huber G, Wiskemann J. Health care professionals’ perception of contraindications for physical activity advice in the setting of stem cell transplantation. Support Care Cancer 2022;30(11):9151-9161.    71287
97. Mikuteit M, Zschäbitz S, Erlmeier M, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma. Oncology. 2022;100(10):536-541. doi: 10.1159/000525601. Epub 2022 Jun 27.PMID: 35760058   68018
98. Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.Pathol Res Pract. 2022 Mar;231:153802. doi: 10.1016/j.prp.2022.153802. Epub 2022 Feb 11.PMID: 35180650   68025
99. Mileshkin L, Bochtler T, Gatta G, Kurzrock R, Beringer A, Müller-Ohldach M, Surinach A, Perret C, Thomas M, Gondos A, Krämer A. Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice. Cancers (Basel). 2022 Jun 13;14(12):2905. doi: 10.3390/cancers14122905    69121
100. Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun. 2022 Aug 2;13(1):4485. doi: 10.1038/s41467-022-31866-4.   68455
101. Mohr I, Vogeler M, Pfeiffenberger J, Sprengel SD, Klauss M, Radeleff B, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2022 Jan 25. doi: 10.1007/s00432-021-03900-3.   68315
102. Müller V, Hein A, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Beckmann MW, Schneeweiss A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Meyer J, Wurmthaler LA, Kurbacher CM, Wuerstlein R, Untch M, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Michel LL. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. Eur J Cancer. 2022 Sep;172:13-21. doi: 10.1016/j.ejca.2022.05.015. Epub 2022 Jun 18.   68038
103. Müller V, Welslau M, Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Thomssen C, Witzel I, Fehm TN, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf AD, Kolberg HC, Wöckel A. Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):590-600. doi: 10.1055/a-1811-6148. eCollection 2022 Jun. PMID: 35903715   68043
104. Naderi M, Kordestani H, Sahebi Z, Khedmati Zare V, Amani-Shalamzari S, Kaviani M, Wiskemann J, Molanouri Shamsi M. Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial. BMC Womens Health. 2022 Mar 24;22(1):90. doi: 10.1186/s12905-022-01671-8.    68456
105. Nam D, Chapiro J, Paradis V, Seraphin TP, Kather JN. Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction. JHEP Rep. 2022 Feb 2;4(4):100443. doi: 10.1016/j.jhepr.2022.100443. eCollection 2022 Apr.    68457
106. Neault S, Bossow S, Achard C, Bell JC, Diallo JS, Leber MF, Ungerechts G. Robust eenvelope exchange platform for oncolytic measles virus. J Virol Methods. 2022 Apr;302:114487. doi: 10.1016/j.jviromet.2022.114487.   68458
107. Nees J, Schafferer S, Yuan B, Tang Q, Scheffler M, Hartkopf A, Golatta M, Schneeweiß A, Burwinkel B, Wallwiener M. How previous treatment changes the metabolomic profile in patients with metastatic breast cancer. Arch Gynecol Obstet. 2022 Dec;306(6):2115-2122. doi: 10.1007/s00404-022-06558-5. Epub 2022 Apr 25. PMID: 35467121   68078
108. Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024.   63400
109. Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. Mol Oncol. 2022 Jul;16(14):2733-2746. doi: 10.1002/1878-0261.13256. Epub 2022 Jun 13.PMID: 35621918   69582
110. Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Gjerga E, Hennig S, Schaper S, Na IK, Keller U, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Lüftner D, Busse A. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2022 Feb;162:45-55.. doi: 10.1016/j.ejca.2021.11.025.   68086
111. Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan H. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun. 2022 Apr;6(4):679-691. doi: 10.1002/hep4.1847. Epub 2021 Nov 19.PMID: 34796691   96586
112. Pixberg C, Zapatka M, Hlevnjak M, Benedetto S, Suppelna JP, Heil J, Smetanay K, Michel L, Fremd C, Körber V, Rübsam M, Buschhorn L, Heublein S, Schäfgen B, Golatta M, Gomez C, von Au A, Wallwiener M, Wolf S, Dikow N, Schaaf C, Gutjahr E, Allgäuer M, Stenzinger A, Pfütze K, Kirsten R, Hübschmann D, Sinn HP, Jäger D, Trumpp A, Schlenk R, Höfer T, Thewes V, Schneeweiss A, Lichter P. COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy. ESMO Open. 2022 Nov 21;7(6):100637. doi: 10.1016/j.esmoop.2022.100637.   68033
113. Ploeger C, Schreck J, Huth T, Fraas A, Albrecht T, Charbel A, Ji J, Singer S, Breuhahn K, Pusch S, Köhler BC, Springfeld C, Schirmacher P, Mehrabi A, Goeppert B, Roessler S. STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers (Basel). 2022 Feb 23;14(5):1154. doi: 10.3390/cancers14051154.  68293
114. Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917.   68511
115. Ramdohr F, Fabarius A, Maier B, Bretschneider D, Jauch A, Monecke A, Metzeler KH, Janssen JWG, Schlenk RF, Kayser S. Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report. Front Oncol. 2022 Aug 29;12:960914. doi: 10.3389/fonc.2022.960914. eCollection 2022.    68513
116. Ramouz A, Ali-Hasan-Al-Saegh S, Shafiei S, Fakour S, Khajeh E, Majlesara A, Adeliansedehi A, Probst P, Springfeld C, Chang DH, Rupp C, Carvalho C, Golriz M, Hoffmann K, Mehrabi A. Repeat liver resection for recurrent intrahepatic cholangiocarcinoma: meta-analysis. Br J Surg. 2022 Jun 14;109(7):580-587. doi: 10.1093/bjs/znac075.  68292
117. Ridder DA, Urbansky LL, Witzel HR, Schindeldecker M, Weinmann A, Berndt K, Gerber TS, Köhler BC, Nichetti F, Ludt A, Gehrke N, Schattenberg JM, Heinrich S, Roth W, Straub BK. Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers (Basel). 2022 Jan 15;14(2):430. doi: 10.3390/cancers14020430.PMID: 35053591   69585
118. Russell SJ, Bell JC, Engeland CE, McFadden G. Advances in oncolytic virotherapy. Commun Med (Lond). 2022 Apr 7;2:33. doi: 10.1038/s43856-022-00098-4. eCollection 2022.  68516
119. Saldanha OL, Quirke P, West NP, James JA, Loughrey MB, Grabsch HI, Salto-Tellez M, Alwers E, Cifci D, Ghaffari Laleh N, Seibel T, Gray R, Hutchins GGA, Brenner H, van Treeck M, Yuan T, Brinker TJ, Chang-Claude J, Khader F, Schuppert A, Luedde T, Trautwein C, Muti HS, Foersch S, Hoffmeister M, Truhn D, Kather JN. Swarm learning for decentralized artificial intelligence in cancer histopathology. Nat Med. 2022 Jun;28(6):1232-1239. doi: 10.1038/s41591-022-01768-5. Epub 2022 Apr 25.   68521
120. Schlüter K, Schneider J, Rosenberger F, Wiskemann J. Feasibility of High-Intensity Resistance Training Sessions in Cancer Survivors. J Strength Cond Res. 2022 Sep 1;36(9):2643-2652. doi: 10.1519/JSC.0000000000004279. Epub 2022 Jun 20.    68523
121. Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17. PMID: 34801353 Clinical Trial.   63423
122. Schneider L, Laiouar-Pedari S, Kuntz S, Krieghoff-Henning E, Hekler A, Kather JN, Gaiser T, Fröhling S, Brinker TJ. Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. Eur J Cancer. 2022 Jan;160:80-91. doi: 10.1016/j.ejca.2021.10.007. Epub 2021 Nov 19.     63424
123. Schneider L, Krieghoff-Henning E, Laiouar-Pedari S, Kuntz S, Hekler A, Kather JN, Gaiser T, Fröhling S, Brinker TJ. Response to letter entitled: Re: Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. Eur J Cancer. 2022 Sep;172:403-404. doi: 10.1016/j.ejca.2022.06.001. Epub 2022 Jun 30. PMID: 35781181.   70874
124. Schrammen PL, Ghaffari Laleh N, Echle A, Truhn D, Schulz V, Brinker TJ, Brenner H, Chang-Claude J, Alwers E, Brobeil A, Kloor M, Heij LR, Jäger D, Trautwein C, Grabsch HI, Quirke P, West NP, Hoffmeister M, Kather JN. Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. J Pathol. 2022 Jan;256(1):50-60. doi: 10.1002/path.5800. Epub 2021 Oct 22.  64380
125. Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol. 2022 Feb;40(2):355-361. doi: 10.1007/s00345-021-03905-0. Epub 2022 Jan 7.PMID: 34993564    68027
126. Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022 Sep;3(9):1026-1038. doi: 10.1038/s43018-022-00436-4. Epub 2022 Sep 22   68524
127. Sobol B, Azzam Nieto O, Eberlein EL, Scherr AL, Ismail L, Kessler A, Nader L, Schwab M, Hoffmeister P, Schmitt N, Jäger D, Welte S, Seidensaal K, Christopoulos P, Heilig C, Kriegsmann K, Fröhling S, Kriegsmann M, Hess J, Köhler BC. Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors. Int J Mol Sci. 2022 Jul 16;23(14):7850. doi: 10.3390/ijms23147850.   68525
128. Söntgerath R, Däggelmann J, Kesting SV, Rueegg CS, Wittke TC, Reich S, Eckert KG, Stoessel S, Chamorro-Viña C, Wiskemann J, Wright P, Senn-Malashonak A, Oschwald V, Till AM, Götte M. Physical and functional performance assessment in pediatric oncology: a systematic review. Pediatr Res. 2022 Mar;91(4):743-756. doi: 10.1038/s41390-021-01523-5. Epub 2021 Apr 15.    68527
129. Springfeld C, Neoptolemos JP. CEND-1: a game changer for pancreatic cancer chemotherapy? Lancet Gastroenterol Hepatol. 2022 Oct;7(10):900-902. doi: 10.1016/S2468-1253(22)00197-2.    68255
130. Springfeld C, Neoptolemos JP. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Nat Rev Clin Oncol. 2022 May;19(5):285-286. doi: 10.1038/s41571-022-00612-6.   68256
131. Strobel O, Lorenz P, Hinz U, Gaida M, König AK, Hank T, Niesen W, Kaiser J, Al-Saeedi M, Bergmann F, Springfeld C, Berchtold C, Diener MK, Schneider M, Mehrabi A, Müller-Stich BP, Hackert T, Jäger D, Büchler MW. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Ann Surg. 2022 May 1;275(5):962-971. doi: 10.1097/SLA.0000000000004147. Epub 2020 Jul 7   68543
132. Swain SM, Tan AR, Gianni L, Kuemmel S, Dang CT, Schneeweiss A, O'Shaughnessy J, Liu H, Aguila C, Heeson S, Macharia H, Yang K, Restuccia E, Loibl S. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. Eur J Cancer. 2023 Jan;178:70-81. doi: 10.1016/j.ejca.2022.09.024. Epub 2022 Oct 7. PMID: 36410207    68245
133. Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers (Basel). 2022 Oct 15;14(20):5051. doi: 10.3390/cancers14205051. PMID: 36291835  68248
134. Tabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, Jaeger D, Maio M, Mileshkin L, Melero I. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open. 2022 Apr;7(2):100419. doi: 10.1016/j.esmoop.2022.100419. Epub 2022 Mar 16.   68544
135. Thill M, Wimberger P, Grafe A, Klare P, Luedtke-Heckenkamp K, Reichert D, Zaiss M, Ziegler-Löhr K, Eckl T, Schneeweiss A. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Res Treat. 2022 Nov;196(2):311-321. doi: 10.1007/s10549-022-06710-4. Epub 2022 Sep 12. PMID: 36094611   68031
136. Thill M, Lüftner D, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel). 2022 Aug;17(4):421-429. doi: 10.1159/000524789. Epub 2022 May 2. PMID: 36156913 Free article. Review.   68052
137. Thomssen C, Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Belleville E, Bader S, Untch M, Welslau M, Thill M, Hartkopf AD, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R. Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):206-214. doi: 10.1055/a-1724-9639. eCollection 2022 Feb.   68036
138. Tisch N, Mogler C, Stojanovic A, Luck R, Korhonen EA, Ellerkmann A, Adler H, Singhal M, Schermann G, Erkert L, Patankar JV, Karakatsani A, Scherr AL, Fuchs Y, Cerwenka A, Wirtz S, Köhler BC, Augustin HG, Becker C, Schmidt T, Ruiz de Almodóvar C. Caspase-8 in endothelial cells maintains gut homeostasis and prevents small bowel inflammation in mice. EMBO Mol Med. 2022 Jun 8;14(6):e14121. doi: 10.15252/emmm.202114121. Epub 2022 May 2.PMID: 35491615   69583
139. Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, Mehrabi A, Brockschmidt A, Luedde T, Naumann P, Stenzinger A, Schirmacher P, Longerich T. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.   Erfasst Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, Mehrabi A, Brockschmidt A, Luedde T, Naumann P, Stenzinger A, Schirmacher P, Longerich T. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer. 2022 Nov;127(9):1701-1708. doi: 10.1038/s41416-022-01932-1. Epub 2022 Aug 19. PMID: 35986087   68260
140. Trapp EK, Fasching PA, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, Schumacher C, Heinrich G, Schochter F, de Gregorio A, Tzschaschel M, Rack B, Janni W, Friedl TWP. Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial. Cancers (Basel). 2022 Aug 16;14(16):3949. doi: 10.3390/cancers14163949. PMID: 36010945   68201
141. Valentini J, Fröhlich D, Stolz R, Mahler C, Martus P, Klafke N, Horneber M, Frasch J, Kramer K, Bertz H, Grün B, Tomaschko-Ubeländer K, Joos S; CCC-Integrativ study group. Interprofessional evidence-based counselling programme for complementary and integrative healthcare in patients with cancer: study protocol for the controlled implementation study CCC-Integrativ. BMJ Open. 2022 Feb 11;12(2):e055076. doi: 10.1136/bmjopen-2021-055076. PMID: 35149568; PMCID: PMC8845169.  71283
142. Veinalde R, Pidelaserra-Martí G, Moulin C, Jeworowski LM, Küther L, Buchholz CJ, Jäger D, Ungerechts G, Engeland CE. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory. Mol Ther Oncolytics. 2021 Nov 29;24:43-58. doi: 10.1016/j.omto.2021.11.020. eCollection 2022 Mar 17.   68551
143. Voland A, Köppel M, Wiskemann J. Evaluation des Netzwerk OnkoAktiv aus Patientenperspektive. Modellprojekt zur bewegungstherapeutischen Versorgung onkologischer Patienten. Bewegungstherapie und Gesundheitssport, 2022;38(3): 103-110   71275
144. Wahida A, Buschhorn L, Fröhling S, Jost PJ, Schneeweiss A, Lichter P, Kurzrock R. The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2023 Jan;23(1):43-54. doi: 10.1038/s41568-022-00529-3. Epub 2022 Nov 24. PMID: 36434139 Review.   68035
145. Walle T, Kraske JA, Liao B, Lenoir B, Timke C, von Bohlen Und Halbach E, Tran F, Griebel P, Albrecht D, Ahmed A, Suarez-Carmona M, Jiménez-Sánchez A, Beikert T, Tietz-Dahlfuß A, Menevse AN, Schmidt G, Brom M, Pahl JHW, Antonopoulos W, Miller M, Perez RL, Bestvater F, Giese NA, Beckhove P, Rosenstiel P, Jäger D, Strobel O, Pe'er D, Halama N, Debus J, Cerwenka A, Huber PE. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022 Mar 25;8(12):eabh4050. doi: 10.1126/sciadv.abh4050. Epub 2022 Mar 23.  68329
146. Walle T, Bajaj S, Kraske JA, Rösner T, Cussigh CS, Kälber KA, Müller LJ, Strobel SB, Burghaus J, Kallenberger SM, Stein-Thöringer CK, Jenzer M, Schubert A, Kahle S, Williams A, Hoyler B, Zielske L, Skatula R, Sawall S, Leber MF, Kunes RZ, Krisam J, Fremd C, Schneeweiss A, Krauss J, Apostolidis L, Berger AK, Haag GM, Zschäbitz S, Halama N, Springfeld C, Kirsten R, Hassel JC, Jäger D; NCT ANTICIPATE Investigators, Ungerechts G. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. Nat Cancer. 2022 Jun 17. doi: 10.1038/s43018-022-00398-7. Online ahead of print.   68196
147. Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Thomssen C, Witzel I, Fehm TN, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf AD, Wöckel A, Seliger B, Massa C, Kolberg HC. Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):580-589. doi: 10.1055/a-1811-6106. eCollection 2022 Jun. PMID: 35903719   68200
148. Wessels F, Schmitt M, Krieghoff-Henning E, Kather JN, Nientiedt M, Kriegmair MC, Worst TS, Neuberger M, Steeg M, Popovic ZV, Gaiser T, von Kalle C, Utikal JS, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Deep learning can predict survival directly from histology in clear cell renal cell carcinoma. PLoS One. 2022 Aug 17;17(8):e0272656. doi: 10.1371/journal.pone.0272656. PMID: 35976907; PMCID: PMC9385058.    70875
149. Winkler EC, Knoppers BM. Ethical challenges of precision cancer medicine. Semin Cancer Biol. 2022 Sep;84:263-270. doi: 10.1016/j.semcancer.2020.09.009   68552
150. Zeng Q, Klein C, Caruso S, Maille P HLA, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol. 2022 Jul;77(1):116-127. doi: 10.1016/j.jhep.2022.01.018. Epub 2022 Feb 7.   68553
151. Zenker S, Strech D, Ihrig K, Jahns R, Müller G, Schickhardt C, Schmidt G, Speer R, Winkler E, von Kielmansegg SG, Drepper J. Data protection-compliant broad consent for secondary use of health care data and human biosamples for (bio)medical research: Towards a new German national standard. J Biomed Inform. 2022 Jul;131:104096. doi: 10.1016/j.jbi.2022.104096. Epub 2022 May 25.    68554
152. Zschäbitz S, Mikuteit M, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S. Expression of nectin-4 in papillary renal cell carcinoma. Discov Oncol. 2022 Sep 22;13(1):90. doi: 10.1007/s12672-022-00558-2.PMID: 36136143  68023
153. Zschäbitz S, Erlmeier F, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Mondorf Y, Hartmann A, Ivanyi P, Steffens S. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.J Cancer. 2022 Mar 14;13(6):1706-1712. doi: 10.7150/jca.63509. eCollection 2022.PMID: 35399715   68023
154. Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. Breast Cancer. 2023 Jan;30(1):88-100. doi: 10.1007/s12282-022-01399-1. Epub 2022 Sep 3. PMID: 36057014  68249

1. Ahmed A, Köhler S, Klotz R, Giese N, Lasitschka F, Hackert T, neop C, Zörnig I, Jäger D, Halama N. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2021 Aug 10;10(1):1962135. doi: 10.1080/2162402X.2021.1962135. eCollection 2021.
2. Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R, Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG, Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L, Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP, Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G, Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU, Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V, Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ, Schaaf M, Hausen GZ, Götze TO; Arbeitsgemeinschaft Internistische Onkologie (AIO). Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. Int J Cancer. 2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336. Epub 2020 Oct 23. PMID: 33038277.
3. Albrecht T, Goeppert B, Brinkmann F, Charbel A, Zhang Q, Schreck J, Wilhelm N, Singer S, Köhler BC, Springfeld C, Mehrabi A, Schirmacher P, Kühl AA, Vogel, MN, Jansen H, Utku N, Roessler S. The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers (Basel). 2021 Dec 14;13(24):6272. doi:10.3390/cancers13246272. PMID: 34944891; PMCID: PMC8699724.
4. Albrecht T, Brinkmann F, Albrecht M, Lonsdorf AS, Mehrabi A, Hoffmann K, Kulu Y, Charbel A, Vogel MN, Rupp C, Köhler B, Springfeld C, Schirmacher P, Roessler, S, Goeppert B. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers (Basel). 2021 Apr 2;13(7):1682. doi: 10.3390/cancers13071682. PMID: 33918309; PMCID: PMC8038183.
5. Alex K, Winkler E. Is Dupras and Bunnik’s Framework for Assessing Privacy Risks in Multi-Omic Research and Databases Still Too Exceptionalist? Commentary. The American Journal of Bioethics, 2021, VOL. 21, NO. 12, 80–82. https://doi.org/10.1080/15265161.2021.1991039
6. Allgayer H, Owen R, Wiskemann J, Bussas U, Ulrich CM, Huber G, Steindorf K, Brenner H. Tumor Risk Biomarkers and Physical Activity in Type 2 Diabetes, Patients with Colorectal Cancer and Non-Diabetic Individuals. Endocrine and Metabolic Science. 2021 June; 3:1-6. https://doi.org/10.1016/j.endmts.2021.100091
7. Apostolidis L, Dal Buono A, Merola E, Jann H, Jäger D, Wiedenmann B, Winkler EC, Pavel M. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in  Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers (Basel). 2021 Apr 16;13(8):1936. doi: 10.3390/cancers13081936.
8. Apostolidis L, Schrader J, Jann H, Rinke A, Krug S. Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms. Biology (Basel). 2021 Mar 28;10(4):277. doi: 10.3390/biology10040277.
9. Baumann M, Maier-Hein L, Winkler EC. Kollaterale Depriorisierung. Zur Priorisierung überlebenswichtiger medizinischer Ressourcen. Die politische Meinung Nr. 567, März/April 2021, 66. Jahrgang
10. Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, Fachal L, Michailidou K, Bolla MK, Wang Q, Dennis J, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brenner H, Brucker SY, Cai Q, Campa D, Canzian F, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Colonna S, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dossus L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Engel C, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gao C, García-Closas M, García-Sáenz JA, Ghoussaini M, Giles GG, Goldberg MS, González-Neira A, Guénel P, Gündert M, Haeberle L, Hahnen E, Haiman CA, Hall P, Hamann U, Hartman M, Hatse S, Hauke J, Hollestelle A, Hoppe R, Hopper JL, Hou MF; kConFab Investigators; ABCTB Investigators, Ito H, Iwasaki M, Jager A, Jakubowska A, Janni W, John EM, Joseph V, Jung A, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kosma VM, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Kwong A, Lacey JV, Lambrechts D, Larson NL, Larsson SC, Le Marchand L, Lejbkowicz F, Li J, Long J, Lophatananon A, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Matsuo K, Mavroudis D, Mayes R, Menon U, Milne RL, Mohd Taib NA, Muir K, Muranen TA, Murphy RA, Nevanlinna H, O'Brien KM, Offit K, Olson JE, Olsson H, Park SK, Park-Simon TW, Patel AV, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Rack B, Rennert G, Romero A, Ruebner M, Rüdiger T, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Shah M, Shen CY, Shu XO, Simard J, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Teo SH, Teras LR, Terry MB, Toland AE, Tomlinson I, Truong T, Tseng CC, Untch M, Vachon CM, van den Ouweland AMW, Wang SS, Weinberg CR, Wendt C, Winham SJ, Winqvist R, Wolk A, Wu AH, Yamaji T, Zheng W, Ziogas A, Pharoah PDP, Dunning AM, Easton DF, Pettitt SJ, Lord CJ, Haider S, Orr N, Fletcher O. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. Am J Hum Genet. 2021 Jul 1;108(7):1190-1203. doi: 10.1016/j.ajhg.2021.05.013. Epub 2021 Jun 18.
11. Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel). 2021 Jul 21;13(15):3661. doi: 10.3390/cancers13153661. PMID: 34359564; PMCID: PMC8345152.
12. Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, Czigany Z, Ulmer F, Neumann UP, Heij LR. Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. Liver Cancer. 2021 Jun;10(3):260-274. doi:10.1159/000515303. Epub 2021 May 6. PMID: 34239812; PMCID: PMC8237795.
13. Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, Debus J, Jäger D, Longerich T, Fröhling S, Eils R, Bougatf N, Sax U, Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021 Jun 14:bbab246. doi: 10.1093/bib/bbab246. 63109
14. Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, Schmidt P, Harbottle RP. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci Adv. 2021 Apr 14;7(16):eabf1333. doi: 10.1126/sciadv.abf1333.
15. Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C, Conroy DM, Decker B, Fachal L, Mavaddat N, Ahearn T, Aittomäki K, Antonenkova NN, Arnold N, Arveux P, Ausems MGEM, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Briceno I, Brüning T, Burwinkel B, Cameron DA, Camp NJ, Campbell A, Carracedo A, Castelao JE, Cessna MH, Chanock SJ, Christiansen H, Collée JM, Cordina-Duverger E, Cornelissen S, Czene K, Dörk T, Ekici AB, Engel C, Eriksson M, Fasching PA, Figueroa J, Flyger H, Försti A, Gabrielson M, Gago-Dominguez M, Georgoulias V, Gil F, Giles GG, Glendon G, Garcia EBG, Alnæs GIG, Guénel P, Hadjisavvas A, Haeberle L, Hahnen E, Hall P, Hamann U, Harkness EF, Hartikainen JM, Hartman M, He W, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Hollestelle A, Ho WK, Hooning MJ, Howell A, Humphreys K, Idris F, Jakubowska A, Jung A, Kapoor PM, Kerin MJ, Khusnutdinova E, Kim SW, Ko YD, Kosma VM, Kristensen VN, Kyriacou K, Lakeman IMM, Lee JW, Lee MH, Li J, Lindblom A, Lo WY, Loizidou MA, Lophatananon A, Lubiński J, MacInnis RJ, Madsen MJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, Mavroudis D, McLean C, Meindl A, Mensenkamp AR, Michailidou K, Miller N, Mohd Taib NA, Muir K, Mulligan AM, Nevanlinna H, Newman WG, Nordestgaard BG, Ng PS, Oosterwijk JC, Park SK, Park-Simon TW, Perez JIA, Peterlongo P, Porteous DJ, Prajzendanc K, Prokofyeva D, Radice P, Rashid MU, Rhenius V, Rookus MA, Rüdiger T, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Schürmann P, Shah M, Sohn C, Southey MC, Surowy H, Suvanto M, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tzardi M, Valova Y, van Asperen CJ, Van Dam RM, van den Ouweland AMW, van der Kolk LE, van Veen EM, Wendt C, Williams JA, Yang XR, Yoon SY, Zamora MP, Evans DG, de la Hoya M, Simard J, Antoniou AC, Borg Å, Andrulis IL, Chang-Claude J, García-Closas M, Chenevix-Trench G, Milne RL, Pharoah PDP, Schmidt MK, Spurdle AB, Vreeswijk MPG, Benitez J, Dunning AM, Kvist A, Teo SH, Devilee P, Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021 Feb 4;384(5):428-439. doi: 10.1056/NEJMoa1913948. Epub 2021 Jan 20.
16. Brinker TJ, Kiehl L, Schmitt M, Jutzi TB, Krieghoff-Henning EI, Krahl D, Kutzner H, Gholam P, Haferkamp S, Klode J, Schadendorf D, Hekler A, Fröhling S, Kather JN, Haggenmüller S, von Kalle C, Heppt M, Hilke F, Ghoreschi K, Tiemann M, Wehkamp U, Hauschild A, Weichenthal M, Utikal JS. Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. Eur J Cancer. 2021 Sep;154:227-234. doi: 10.1016/j.ejca.2021.05.026. Epub 2021 Jul 20. PMID: 34298373.
17. Brinker TJ, Schmitt M, Krieghoff-Henning EI, Barnhill R, Beltraminelli H, Braun SA, Carr R, Fernandez-Figueras MT, Ferrara G, Fraitag S, Gianotti R, Llamas-Velasco M, Müller CSL, Perasole A, Requena L, Sangueza OP, Santonja C, Starz H, Vale E, Weyers W, Hekler A, Kather JN, Fröhling S, Krahl D, Holland-Letz T, Utikal JS, Saggini A, Kutzner H. Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists. J Am Acad Dermatol. 2021 Feb 11:S0190-9622(21)00331-5. doi:10.1016/j.jaad.2021.02.009. Epub ahead of print. PMID: 33581189.
18. Brusniak K, Feisst M, Sebesteny L, Hartkopf A, Graf J, Engler T, Schneeweiss A, Wallwiener M, Deutsch TM. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study. JMIR Cancer. 2021 Oct 12;7(4):e25776. doi: 10.2196/25776.
19. Busch E, Ahadova A, Kosmalla K, Bohaumilitzky L, Pfuderer PL, Ballhausen A, Witt J, Wittemann JN, Bläker H, Holinski-Feder E, Jäger D, von Knebel Doeberitz M, Haag GM, Kloor M. Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers. Front Oncol. 2021 Jun 8;11:669774. doi: 10.3389/fonc.2021.669774. eCollection 2021.
20. Busch E, Werft W, Bougatf N, Hackert T, Jäger D, Springfeld C, Berger AK. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature. Pancreas. 2021 Mar 1;50(3):300-305. doi: 10.1097/MPA.0000000000001765.
21. Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, Heining C, Schlenk RF, Cheema P, Jones MR, Drilon A, Trombetta D, Muscarella LA, Tolba K, Gounant V, Cseh A, Solca F, Laskin JJ, Renouf DJ. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. Oncologist. 2021 Jan;26(1):7-16. doi: 10.1634/theoncologist.2020-0379. Epub 2020 Sep 23.
22. Calderaro J, Kather JN. Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers. Gut. 2021 Jun;70(6):1183-1193. doi:10.1136/gutjnl-2020-322880. Epub 2020 Nov 19. PMID: 33214163.
23. J. Chan, A. Quintanal-Villalonga, VR. Gao, Y. Xie, O., V. Allaj, Chaudhary, I. Masilionis, J. Egger, A. Chow, T. Walle, […], D. Pe’er, C.M. Rudin. J.  Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14
24. Debrodt A, Winkler EC. Rückgang von Krankenhausaufnahmen in der Onkologie in und nach dem ersten Lockdown, Editorial. Studie im Fokus, 2021, Heft 2 (April)
25. Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, Heger U, Röhrich M, Kratochwil C, Sathekge M, Jäger D, Debus J, Haberkorn U, Giesel FL.  68 Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4089-4100. doi: 10.1007/s00259-021-05378-0. 63110
26. Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9.
27. Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆. Ann Oncol. 2021 Apr;32(4):500-511. doi: 10.1016/j.annonc.2020.12.016. Epub 2021 Jan 6.
28. Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M, Aktas B. Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Frauenheilkd. 2021 May;81(5):539-548. doi: 10.1055/a-1464-1221. Epub 2021 May 3.
29. Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel). 2021 Jun;16(3):214-227. doi: 10.1159/000516419. Epub 2021 Jun 1.
30. Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, Di Bona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk RF, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla NS, Bernardi M, Fazi P, Annibali O, Mayer K, Voso MT, Vignetti M. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. Blood Adv. 2021 Nov 9;5(21):4370-4379. doi: 10.1182/bloodadvances.2021004649.
31. Eichhorn F, Klotz LV, Kriegsmann M, Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U, Heussel CP, Savai R, Zoernig I, Jaeger D, Thomas M, Hoffmann H, Winter H, Eichhorn ME. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer. 2021 Mar;153:150-157. doi: 10.1016/j.lungcan.2021.01.018. Epub 2021 Jan 21.
32. Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016. doi: 10.1093/jnci/djab004.
33. Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. Ann Oncol. 2021 Dec;32(12):1650. doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.
34. Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
35. Engeland CE, Ungerechts G. Measles Virus as an Oncolytic Immunotherapy. Cancers (Basel). 2021 Feb 1;13(3):544. doi: 10.3390/cancers13030544.
36. Engelmann L, Thierauf J, Koerich Laureano N, Stark HJ, Prigge ES, Horn D, Freier K, Grabe N, Rong C, Federspil P, Zaoui K, Plinkert PK, Rotter N, von Knebel Doeberitz M, Hess J, Affolter A. Organotypic Co-Cultures as a Novel 3D Model for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Aug 18;12(8):2330. doi: 10.3390/cancers12082330
37. Eufinger J, Korbel J, Winkler EC, Kohlbacher O, Stegle O. Genomdaten FAIR und sicher teilen: Das Deutsche Humangenom-Phänom Archiv (GHGA) als Baustein der Nationalen Forschungsdateninfrastruktur. NFDI Sonderausgabe, Bausteine Forschungsdatenmanagement, Nr. 2/2021: S. 86-97. Doi:10.17192.bfdm.2021.2.8349
38. Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18.
39. Fasching PA, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, Polley EC, Lee KY, Gnanaolivu RD, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux MP, Ekici AB, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg HC, Beckmann MW, Reis A, Hartmann A, Janni W, Wimberger P, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD, Couch FJ. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol. 2021 May 20;39(15):1619-1630. doi: 10.1200/JCO.20.01200. Epub 2021 Mar 29.
40. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21.
41. Fresnais M, Yildirim E, Karabulut S, Jäger D, Zörnig I, Benzel J, Pajtler KW, Pfister SM, Burhenne J, Haefeli WE, Longuespée R. Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. Molecules. 2021 Feb 26;26(5):1281. doi: 10.3390/molecules26051281.  63099
42. Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Heinrich G, Häberle L, Fasching PA, Beckmann MW, Coleman RE, Janni W, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 1;7(8):1149-1157. doi: 10.1001/jamaoncol.2021.1854.   63100
43. Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1112-1120. doi: 10.1055/a-1499-8431. Epub 2021 Oct 6.   63101
44. Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd. 2021 Oct 22;81(10):e31. doi: 10.1055/a-1674-1114. eCollection 2021 Oct.
45. Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021 Mar;145:44-52. doi: 10.1016/j.ejca.2020.12.007. Epub 2021 Jan 7.   63102
46. Furlanetto J, Marmé F, Seiler S, Thode C, Untch M, Schmatloch S, Schneeweiss A, Bassy M, Fasching PA, Strik D, Stickeler E, Schem C, Karn T, Grischke EM, Denkert C, van Mackelenbergh M, Müller V, Nekljudova V, Loibl S. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. Eur J Cancer. 2021 Jul;152:193-203. doi: 10.1016/j.ejca.2021.04.038. Epub 2021 Jun 8.   63103
47. Gauß G, Beller R, Boos J, Däggelmann J, Stalf H, Wiskemann J, Götte M. Adverse Events During Supervised Exercise Interventions in Pediatric Oncology-A Nationwide Survey. Front Pediatr. 2021 Aug 19;9:682496. doi: 10.3389/fped.2021.682496. eCollection 2021.  63104
48. Gorgulho J, Roderburg C, Heymann F, Schulze-Hagen M, Beier F, Vucur M, Kather JN, Laleh NG, Tacke F, Brümmendorf TH, Luedde T, Loosen SH. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. Int J Cancer. 2021 Sep 1;149(5):1189-1198. doi: 10.1002/ijc.33610. Epub 2021 May 27. PMID: 33890289.
49. Grimm MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton G, Schmitz M, Folle S, Schostak M, F. Zengerling F, Schumacher U, Loidl W, Meran J. Tailored ImmunoTherapy Approach with Nivolumab in advanced Transitional Cell Carcinoma (TITAN-TCC) Abstract ASCO-GU 2021   nicht relevant
50. Großek A, Elter T, Oberste M, Wolf F, Joisten N, Harting P, Walzik D, Rosenberger F, Kiesl D, Wahl P, Bloch W, Zimmer P. Feasibility and suitability of a graded exercise test in patients with aggressive hemato-oncological disease. Support Care Cancer. 2021 Aug;29(8):4859-4866. doi: 10.1007/s00520-021-06035-w. Epub 2021 Feb 5.  PMID: 33544247
51. Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. Eur J Cancer. 2021 Oct;156:202-216. doi: 10.1016/j.ejca.2021.06.049. Epub 2021 Sep 8. PMID: 34509059.
52. Hajda J, Leuchs B, Angelova AL, Frehtman V, Rommelaere J, Mertens M, Pilz M, Kieser M, Krebs O, Dahm M, Huber B, Engeland CE, Mavratzas A, Hohmann N, Schreiber J, Jäger D, Halama N, Sedlaczek O, Gaida MM, Daniel V, Springfeld C, Ungerechts G. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2021 Oct 15;27(20):5546-5556 doi: 10.1158/1078-0432.CCR-21-1020. PMID: 34426438   63107
53. Harbeck N, Schneeweiss A, Thuss-Patience P, Miller K, Garbe C, Griesinger F, Eberhardt WEE, Klussmann JP, Wollenberg B, Grimm MO, Zander T, Lüftner D. Neoadjuvant and adjuvant end-points in health technology assessment in oncology. Eur J Cancer. 2021 Apr;147:40-50. doi: 10.1016/j.ejca.2021.01.006. Epub 2021 Feb 19.   63105
54. Haussmann A, Ungar N, Tsiouris A, Depenbusch J, Sieverding M, Wiskemann J, Steindorf K. Physical activity counseling to cancer patients: How are patients addressed and who benefits most? Patient Educ Couns. 2021 Dec;104(12):2999-3007. doi: 10.1016/j.pec.2021.04.019. 63106
55. Hecht A, Meyer JA, Jann JC, Sockel K, Giagounidis A, Götze KS, Letsch A, Haase D, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Thol F, Büsche G, Schuler E, Nowak V, Obländer J, Fey S, Müller N, Metzgeroth G, Hofmann WK, Germing U, Nolte F, Reinwald M, Nowak D. Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Ann Hematol. 2021 Jun;100(6):1463-1471. doi: 10.1007/s00277-021-04492-1. Epub 2021 Apr 27.
56. Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021 Apr 16;14(1):63. doi: 10.1186/s13045-021-01075-5
57. Heij LR, Tan X, Kather JN, Niehues JM, Sivakumar S, Heussen N, van der Kroft G, Damink SWMO, Lang S, Aberle MR, Luedde T, Gaisa NT, Bednarsch J, Liu DHW, Cleutjens JPM, Modest DP, Neumann UP, Wiltberger GJ. Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. J Clin Med. 2021 Jan 30;10(3):490. doi: 10.3390/jcm10030490. PMID: 33573277; PMCID: PMC7866811.
58. Heilig CE, Horak P, Kreutzfeldt S, Teleanu V, Mock A, Renner M, Bhatti IA, Hutter B, Hüllein J, Fröhlich M, Uhrig S, Süße H, Heiligenthal L, Ochsenreither S, Illert AL, Vogel A, Desuki A, Heinemann V, Heidegger S, Bitzer M, Scheytt M, Brors B, Hübschmann D, Baretton G, Stenzinger A, Steindorf K, Benner A, Jäger D, Heining C, Glimm H, Fröhling S, Schlenk RF. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. ESMO Open. 2021 Nov 19;6(6):100310. doi: 10.1016/j.esmoop.2021.100310.   63115
59. Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler LA, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23.  63118
60. Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hutter B, Ishaque N, Hirsch S, Gieldon L, Stenzinger A, Springfeld C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröhling S, Sinn HP, Jäger D, Thewes V, Zapatka M, Lichter P, Schneeweiss A. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precis Oncol. 2021 Apr 22;5:PO.20.00248. doi: 10.1200/PO.20.00248. eCollection 2021.   63119
61. Hoefflin R, Harlander S, Schäfer S, Metzger P, Kuo F, Schönenberger D, Adlesic M, Peighambari A, Seidel P, Chen CY, Consenza-Contreras M, Jud A, Lahrmann B, Grabe N, Heide D, Uhl FM, Chan TA, Duyster J, Zeiser R, Schell C, Heikenwalder M, Schilling O, Hakimi AA, Boerries M, Frew IJ. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 2020 Aug 17;11(1):4111. doi: 10.1038/s41467-020-17873-3.  63120
62. Höhn J, Hekler A, Krieghoff-Henning E, Kather JN, Utikal JS, Meier F, Gellrich FF, Hauschild A, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Heppt M, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Maron RC, Schmitt M, Jutzi T, Fröhling S, Lipka DB, Brinker TJ. Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. J Med Internet Res. 2021 Jul 2;23(7):e20708. doi: 10.2196/20708. PMID:34255646; PMCID: PMC8285747.
63. Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, Frohlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Mohrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgauer M, Ruhnke L, Lassmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfutze K, Georg C, Meissburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schrock E, Hubschmann D, Weichert W, Glimm H, Frohling S. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 2021 Nov;11(11):2780-2795. doi: 10.1158/2159-8290.CD-21-0126.   63122
64. Howard FM, Dolezal J, Kochanny S, Schulte J, Chen H, Heij L, Huo D, Nanda R, Olopade OI, Kather JN, Cipriani N, Grossman RL, Pearson AT. The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 Jul 20;12(1):4423. doi: 10.1038/s41467-021-24698-1.   63123
65. Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Pasotuxizumab, a BiTE ® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Pdf vorh
66. Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart M. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treat Rev. 2021 Sep;99:102229. doi: 10.1016/j.ctrv.2021.102229. Epub 2021 May 20.
67. Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 2021 Sep 1;16(9):e0257142. doi: 10.1371/journal.pone.0257142. eCollection 2021.
68. Jaramillo S, Schlenk RF. Post-Induction Treatment for Acute Myeloid Leukemia: Something Change? Curr Oncol Rep. 2021 Jul 16;23(9):109. doi: 10.1007/s11912-021-01092-0.
69. Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, Rank A, Behringer D, Teichmann L, Görner M, Trappe RU, Röllig C, Krause S, Hanoun M, Hopfer O, Held G, Buske S, Fransecky L, Kayser S, Schliemann C, Schaefer-Eckart K, Al-Fareh Y, Schubert J, Geer T, Kaufmann M, Brecht A, Niemann D, Kieser M, Bornhäuser M, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Schlenk RF. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials. 2021 Nov 3;22(1):765. doi: 10.1186/s13063-021-05703-w.
70. Jungkunz M, Köngeter A, Mehlis K, Winkler EC, Schickhardt C. Secondary Use of Clinical Data in Data-Gathering, Non-Interventional Research or Learning Activities: Definition, Types, and a Framework for Risk Assessment. J Med Internet Res. 2021 Jun 8;23(6):e26631. doi: 10.2196/26631.
71. Kacew AJ, Strohbehn GW, Saulsberry L, Laiteerapong N, Cipriani NA, Kather JN, Pearson AT. Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer Genotyping. Front Oncol. 2021 Jun 8;11:630953. doi:10.3389/fonc.2021.630953. PMID: 34168975; PMCID: PMC8217761.
72. Kayser S, Kramer M, Martínez-Cuadrón D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Ráčil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stölzel F, Ho AD, Thiede C, Stone RM, Röllig C, Montesinos P, Schlenk RF, Levis MJ. Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2021 Aug 5. doi: 10.3324/haematol.2021.278645. Online ahead of print.
73. Kayser S, Schlenk RF, Lebon D, Carre M, Götze KS, Stölzel F, Berceanu A, Schäfer-Eckart K, Peterlin P, Hicheri Y, Rahme R, Raffoux E, Chermat F, Krause SW, Aulitzky WE, Rigaudeau S, Noppeney R, Berthon C, Görner M, Jost E, Carassou P, Keller U, Orvain C, Braun T, Saillard C, Arar A, Kunzmann V, Wemeau M, De Wit M, Niemann D, Bonmati C, Schwänen C, Abraham J, Aljijakli A, Haiat S, Krämer A, Reichle A, Gnadler M, Willekens C, Spiekermann K, Hiddemann W, Müller-Tidow C, Thiede C, Röllig C, Serve H, Bornhäuser M, Baldus CD, Lengfelder E, Fenaux P, Platzbecker U, Adès L. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study. Haematologica . 2021 Dec 1;106(12):3100-3106. doi: 10.3324/haematol.2021.278722. doi: 10.3324/haematol.2021.278722.
74. Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, Estey EH, Shaw CM, Ráčil Z, Mayer J, Zak P, Baer MR, Brunner AM, Szotkowski T, Cetkovsky P, Grimwade D, Walter RB, Burnett AK, Ho AD, Ehninger G, Müller-Tidow C, Platzbecker U, Thiede C, Röllig C, Schulz A, Warsow G, Brors B, Esteve J, Russell NH, Schlenk RF, Levis MJ. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. Br J Haematol. 2021 Mar;192(5):832-842. doi: 10.1111/bjh.17336. Epub 2021 Feb 2.
75. Keller A, Pixberg C, Hassel J. Multiple alopecic patches in the hairy scalp area of a 28-year-old female patient. J Dtsch Dermatol Ges. 2021 Aug;19(8):1222-1224. doi: 10.1111/ddg.14333
76. Kiehl L, Kuntz S, Höhn J, Jutzi T, Krieghoff-Henning E, Kather JN, Holland-Letz T, Kopp-Schneider A, Chang-Claude J, Brobeil A, von Kalle C, Fröhling S, Alwers E, Brenner H, Hoffmeister M, Brinker TJ. Deep learning can predict lymph node status directly from histology in colorectal cancer. Eur J Cancer. 2021 Nov;157:464-473. doi: 10.1016/j.ejca.2021.08.039. Epub 2021 Oct 11. PMID: 34649117.
77. Klupp F, Kahlert C, Franz C, Halama N, Schleussner N, Wirsik NM, Warth A, Schmidt T, Ulrich AB. Granulin: An Invasive and Survival-Determining Marker in Colorectal Cancer Patients. Int J Mol Sci. 2021 Jun 16;22(12):6436. doi: 10.3390/ijms22126436.
78. Koeppel M, Mathis K, Schmitz KH, Wiskemann J. Muscle hypertrophy in cancer patients and survivors via strength training. A meta-analysis and meta-regression. Crit Rev Oncol Hematol. 2021 Jul;163:103371. doi: 10.1016/j.critrevonc.2021.103371. Epub 2021 May 29.
79. Koeppel M, Körbi C, Winkels RM, Schmitz KH, Wiskemann J. Relationship Between Cancer Related Fatigue, Physical Activity Related Health Competence, and Leisure Time Physical Activity in Cancer Patients and Survivors. Front Sports Act Living. 2021 Aug 5;3:687365. doi: 10.3389/fspor.2021.687365. eCollection 2021.
80. Koeppel M, Mathis K, Schmitz KH, Wiskemann J. Muscle Hypertrophy in Cancer Patients and Survivors via Strength Training. A Meta-Analysis and Meta-Regression. Crit Rev Oncol Hematol . 2021 Jul;163:103371. doi: 10.1016/j.critrevonc.2021.103371. Epub 2021 May 29
81. Koerber SA, Finck R, Dendl K, Uhl M, Lindner T, Kratochwil C, Röhrich M, Rathke H, Ungerechts G, Adeberg S, Herfarth K, Jaeger D, Debus J, Haberkorn U, Giesel FL. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3918-3924. doi: 10.1007/s00259-021-05374-4. Epub 2021 May 21.
82. Koerber SA, Boesch J, Kratochwil C, Schlampp I, Ristau J, Winter E, Zschaebitz S, Hofer L, Herfarth K, Kopka K, Holland-Letz T, Jaeger D, Hohenfellner M, Haberkorn U, Debus J, Giesel FL.Cancers (Basel). 2021 Mar 25;13(7):1508. doi: 10.3390/cancers13071508. PMID: 33805971 Free PMC article.
83. Kontermann RE, Ungerechts G, Nettelbeck DM. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs. 2021 Jan-Dec;13(1):1982447. doi: 10.1080/19420862.2021.1982447.
84. Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, van Poelgeest MIE, Mustafa DAM, van der Burg SH. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2021 Oct;9(10):e003671. doi: 10.1136/jitc-2021-003671.
85. Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, Mier W, Jäger D, Lindner T, Haberkorn U. [153 Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3011-3013. doi: 10.1007/s00259-021-05273-8. Epub 2021 Mar 17.
86. Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F, Choyke PL, Haberkorn U, Giesel FL, Morgenstern A. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):54-63.

87. doi: 10.1007/s00259-021-05474-1.

88. Krause J, Grabsch HI, Kloor M, Jendrusch M, Echle A, Buelow RD, Boor P, Luedde T, Brinker TJ, Trautwein C, Pearson AT, Quirke P, Jenniskens J, Offermans K, van den Brandt PA, Kather JN. Deep learning detects genetic alterations in cancer histology generated by adversarial networks. J Pathol. 2021 May;254(1):70-79. doi: 10.1002/path.5638. Epub 2021 Mar 16. PMID: 33565124.
89. Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021 Oct 20;39(30):3318-3327. doi: 10.1200/JCO.20.02724.
90. Krug S, Kegel T, Gress TM, Rinke A, Apostolidis L, Jann H, König A, Hörsch D, Schrader J, Ettrich TJ, Richter M, Steighardt J, Michl P.Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial. BMC Cancer. 2021 Nov 12;21(1):1206. doi: 10.1186/s12885-021-08900-7.
91. Kuendgen A, Nomdedeu M, Tuechler  H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 Mar;35(3):835-849.. doi: 10.1038/s41375-020-0917-7. PMID: 32595214  pdf vorh
92. Kuntz S, Krieghoff-Henning E, Kather JN, Jutzi T, Höhn J, Kiehl L, Hekler A, Alwers E, von Kalle C, Fröhling S, Utikal JS, Brenner H, Hoffmeister M, Brinker TJ. Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. Eur J Cancer. 2021 Sep;155:200-215. doi: 10.1016/j.ejca.2021.07.012. Epub 2021 Aug 11. PMID: 34391053.
93. Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 Sep;35(9):2539-2551. doi: 10.1038/s41375-021-01179-4. Epub 2021 Mar 2.
94. Laryionava K, Hauke D, Heußner P, Hiddemann W, Winkler EC. "Often Relatives are the Key […]" -Family Involvement in Treatment Decision Making in Patients with Advanced Cancer Near the End of Life. 2021 May;26(5):e831-e837. doi: 10.1002/onco.13557.
95. Laryionava K, Winkler EC. Dealing with Family Conflicts in Decision-making in End-of-Life Care of Advanced Cancer Patients. Curr Oncol Rep. 2021 Aug 27;23(11):124. doi: 10.1007/s11912-021-01122-x
96. Li J, Pohl L, Schüler J, Korzeniewski N, Reimold P, Kaczorowski A, Hou W, Zschäbitz S, Nientiedt C, Jäger D, Hohenfellner M, Duensing A, Duensing S. Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines. 2021 May 31;9(6):627. doi: 10.3390/biomedicines9060627
97. Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, Friedmann-Bette B, Bondong M, Bohus M, Wiskemann J. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior transplantation. Support Care Cancer. 2021 Jan;29(1):359-367. doi: 10.1007/s00520-020-05485-y.  Epub 2020 May 4
98. Lindner T, Altmann A, Giesel F, Kratochwil C, Kleist C, Krämer S, Mier W, Cardinale J, Kauczor HU, Jäger D, Debus J, Haberkorn U. 18 F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem. 2021 Aug 21;6(1):26. doi: 10.1186/s41181-021-00144-x.
99. Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301.
100. Lüftner D, Hartkopf AD, Lux MP, Overkamp F, Tesch H, Titzmann A, Pöschke P, Wallwiener M, Müller V, Beckmann MW, Belleville E, Janni W, Fehm TN, Kolberg HC, Ettl J, Wallwiener D, Schneeweiss A, Brucker SY, Fasching PA. Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. Breast Care (Basel). 2021 Apr;16(2):108-114. doi: 10.1159/000515701. Epub 2021 Mar 16.
101. Mehlis K. Finanzielle „Nebenwirkungen“ einer Krebserkrankung, Editorial. Im Fokus Onkologie 2021; 24 (2)
102. Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd. 2021 Apr;81(4):469-480. doi: 10.1055/a-1397-7170. Epub 2021 Apr 14.
103. Machiraju D, Wiecken M, Lang N, Hülsmeyer I, Roth J, Schank TE, Eurich R, Halama N, Enk A, Hassel JC. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncoimmunology. 2021 May 25;10(1):1926762. doi: 10.1080/2162402X.2021.1926762.
104. Marmé F, Solbach C, Michel L, Schneeweiss A, Blohmer JU, Huober J, Fasching PA, Jackisch C, Nekljudova V, Link T, Rhiem K, Rey J, Denkert C, Hanusch C, Tesch H, Lederer B, Loibl S, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021 Aug;153:203-212. doi: 10.1016/j.ejca.2021.05.027. Epub 2021 Jun 26.
105. Maron RC, Schlager JG, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Heppt MV, Berking C, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Krieghoff-Henning E, Hekler A, Fröhling S, Lipka DB, Kather JN, Brinker TJ. A benchmark for neural network robustness in skin cancer classification. Eur J Cancer. 2021 Sep;155:191-199. doi:10.1016/j.ejca.2021.06.047. Epub 2021 Aug 11. PMID: 34388516.
106. Maron RC, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hauschild A, French LE, Schlaak M, Ghoreschi K, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Hekler A, Krieghoff-Henning E, Kather JN, Fröhling S, Lipka DB, Brinker TJ. Robustness of convolutional neural networks in recognition of pigmented skin lesions. Eur J Cancer. 2021 Mar;145:81-91. doi: 10.1016/j.ejca.2020.11.020. Epub 2021 Jan 7. PMID: 33423009.
107. Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kröcher A, Kreutzfeldt S, Gress TM, Rinke A. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. Front Endocrinol (Lausanne). 2021 Oct 6;12:709256. doi: 10.3389/fendo.2021.709256. eCollection 2021.
108. Meyer-Schwickerath C, Morawietz C, Baumann F, Huber G, Wiskemann J. Physical activity counseling in cancer patients: Efficacy of behavior change counseling interventions on physical activity - a systematic review.
109. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
110. Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2.
111. Mock A, Plath M, Moratin J, Tapken MJ, Jäger D, Krauss J, Fröhling S, Hess J, Zaoui K. EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers. Front Oncol. 2021 Jun 11;11:678966. doi: 10.3389/fonc.2021.678966. eCollection 2021.
112. Mock-Ohnesorge J, Mock A, Hackert T, Fröhling S, Schenz J, Poschet G, Jäger D, Büchler MW, Uhle F, Weigand MA.Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery. Oncotarget. 2021 May 11;12(10):996-1010. doi: 10.18632/oncotarget.27956. eCollection 2021 May 11.
113. Möbus V, Lück HJ, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke EM, Wachsmann G, Forstbauer H, Untch M, Marmé F, Blohmer JU, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn BV, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S; GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer. 2021 Oct;156:138-148. doi: 10.1016/j.ejca.2021.07.033. Epub 2021 Aug 24.
114. Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fröhling S, Jäger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C. Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Front Oncol. 2021 Jul 29;11:712944. doi: 10.3389/fonc.2021.712944. eCollection 2021.
115. Morigny P, Kaltenecker D, Zuber J, Machado J, Mehr L, Tsokanos FF, Kuzi H, Hermann CD, Voelkl M, Monogarov G, Springfeld C, Laurent V, Engelmann B, Friess, H, Zörnig I, Krüger A, Krijgsveld J, Prokopchuk O, Fisker Schmidt S, Rohm M, Herzig S, Berriel Diaz M. Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy. J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1333-1351. doi: 10.1002/jcsm.12758. Epub 2021 Aug 23. PMID: 34427055; PMCID: PMC8517355.
116. Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, Augustinsson A, Auvinen PK, Beane Freeman LE, Becher H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Brenner H, Briceno I, Brucker SY, Camp NJ, Campa D, Canzian F, Castelao JE, Chanock SJ, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Egan KM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Giles GG, Grip M, Guénel P, Haiman CA, Håkansson N, Hall P, Hamann U, Han SN, Hart SN, Hartman M, Heyworth JS, Hoppe R, Hopper JL, Hunter DJ, Ito H, Jager A, Jakimovska M, Jakubowska A, Janni W, Kaaks R, Kang D, Kapoor PM, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Lacey JV, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Mariapun S, Matsuo K, Mavroudis D, Milne RL, Muranen TA, Newman WG, Noh DY, Nordestgaard BG, Obi N, Olshan AF, Olsson H, Park-Simon TW, Petridis C, Pharoah PDP, Plaseska-Karanfilska D, Presneau N, Rashid MU, Rennert G, Rennert HS, Rhenius V, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schwentner L, Scott C, Shah M, Shen CY, Shu XO, Southey MC, Stram DO, Tamimi RM, Tapper W, Tollenaar RAEM, Tomlinson I, Torres D, Troester MA, Truong T, Vachon CM, Wang Q, Wang SS, Williams JA, Winqvist R, Wolk A, Wu AH, Yoo KY, Yu JC, Zheng W, Ziogas A, Yang XR, Eliassen AH, Holmes MD, García-Closas M, Teo SH, Schmidt MK, Chang-Claude J; ABCTB Investigators; NBCS Collaborators. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):623-642. doi: 10.1158/1055-9965.EPI-20-0924. Epub 2021 Jan 26.
117. Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brüning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL; NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Dörk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, García-Sáenz JA, Giles GG, Grip M, Guénel P, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubiński J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, García-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res. 2021 Aug 18;23(1):86. doi: 10.1186/s13058-021-01450-7.
118. Müller J, Weiler M, Schneeweiss A, Haag GM, Steindorf K, Wick W, Wiskemann J. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. Br J Cancer. 2021 Sep;125(7):955-965. doi: 10.1038/s41416-021-01471-1.
119. Müller J, Kreutz C, Ringhof S, Koeppel M, Kleindienst N, Sam G, Schneeweiss A, Wiskemann J, Weiler M. Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control. Sci Rep. 2021 Jan 27;11(1):2398. doi: 10.1038/s41598-021-81902-4.
120. Müller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch HR, Sommer-Joos AK, Schneeweiss A. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study. Breast. 2021 Dec;60:70-77. doi: 10.1016/j.breast.2021.08.014. Epub 2021 Aug 27.
121. Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T; DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021 Dec;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25.
122. Muti HS, Heij LR, Keller G, Kohlruss M, Langer R, Dislich B, Cheong JH, Kim YW, Kim H, Kook MC, Cunningham D, Allum WH, Langley RE, Nankivell MG, Quirke P, Hayden JD, West NP, Irvine AJ, Yoshikawa T, Oshima T, Huss R, Grosser B, Roviello F, d'Ignazio A, Quaas A, Alakus H, Tan X, Pearson AT, Luedde T, Ebert MP, Jäger D, Trautwein C, Gaisa NT, Grabsch HI, Kather JN. Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. Lancet Digit Health. 2021 Oct;3(10):e654-e664. doi: 10.1016/S2589-7500(21)00133-3. Epub 2021 Aug 17.
123. Narchi J, Winkler EC. Nipping Diseases in the Bud? Ethical and Social Considerations of the Concept of ‘Disease Interception’. Public Health Ethics. 2021 Mar 15;14(1):100-108. doi: 10.1093/phe/phaa036. eCollection 2021 Apr
124. Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, Eberle J, Ehrhardt A, Engeland CE, Fechner H, Geletneky K, Goepfert K, Holm PS, Kochanek S, Kreppel F, Krutzke L, Kühnel F, Lang KS, Marchini A, Moehler M, Mühlebach MD, Naumann U, Nawroth R, Nüesch J, Rommelaere J, Lauer UM, Ungerechts G. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses. 2021 Jul 21;13(8):1420. doi: 10.3390/v13081420.
125. Neuendorff NR, Frenzel LP, Leuschner F, Fremd C. Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy.
     J Geriatr Oncol. 2021 Apr;12(3):479-482. doi: 10.1016/j.jgo.2020.09.006. PMID: 32978103
126. Nientiedt C, Duensing A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing S. PARP inhibition in prostate cancer. Genes Chromosomes Cancer. 2021 May;60(5):344-351. doi: 10.1002/gcc.22903. PMID: 33084183 Review.
127. Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26.
128. Noble R, Burri D, Le Sueur C, Lemant J, Viossat Y, Kather JN, Beerenwinkel N. Spatial structure governs the mode of tumour evolution. Nat Ecol Evol. 2021 Dec 23. doi: 10.1038/s41559-021-01615-9. Epub ahead of print. PMID: 34949822.
129. O'Shaughnessy J, Emens LA, Chui SY, Wang W, Russell K, Lin SW, Flores Avile C, Luhn P, Schneeweiss A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Curr Oncol. 2021 Jul 17;28(4):2741-2752. doi: 10.3390/curroncol28040239.
130. Pal A, Schneider J, Schlüter K, Steindorf K, Wiskemann J, Rosenberger F, Zimmer P. Different endurance exercises modulate NK cell cytotoxic and inhibiting receptors. Eur J Appl Physiol. 2021 Dec;121(12):3379-3387. doi: 10.1007/s00421-021-04735-z.
131. Pal A, Zimmer P, Clauss D, Schmidt ME, Ulrich CM, Wiskemann J, Steindorf K. Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients. Int J Sports Med. 2021 Jan;42(1):33-40. doi: 10.1055/a-1186-1009.
132. Pauge S, Surmann B, Mehlis K, Zueger A, Richter L, Menold N, Greiner W, Winkler EC. Patient-Reported Financial Distress in Cancer: A Systematic Review of Risk Factors in Universal Healthcare Systems. Cancers (Basel) 2021 Oct 7;13(19):5015. doi: 10.3390/cancers13195015.
133. Pietrobon V, Cesano A, Marincola F, Kather JN. Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. Front Immunol. 2021 Jan 27;11:604967. doi: 10.3389/fimmu.2020.604967. PMID: 33584676; PMCID:PMC7873485.
134. Röhrich M, Naumann P, Giesel FL, Choyke P, Staudinger F, Wefers A, Liew DP, Kratochwil C, Rathke H, Liermann J, Herfarth K, Jäger D, Debus J, Haberkorn UA, Lang M, Koerber SA. Impact of 68 Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021 Jun 1;62(6):779-786. doi: 10.2967/jnumed.120.253062.
135. Roider T, Wang X, Hüttl K, Müller-Tidow C, Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. Int J Cancer. 2021 Jan 1;148(1):150-160. doi: 10.1002/ijc.33202. Epub 2020 Aug 15.
136. Rosenberger F, Schneider J, Schlueter K, Paratte JL, Wiskemann J. Vertebral fracture during one repetition maximum testing in a breast cancer survivor: A case report. Medicine (Baltimore). 2021 May 21;100(20):e25705. doi: 10.1097/MD.0000000000025705. PMID: 34011028
137. Rosenberger F, Sprave T, Clauss D, Hoffmann P, Welzel T, Debus J, Rief H, Wiskemann J. Spinal Stabilization Exercises for Cancer Patients with Spinal Metastases of High Fracture Risk: Feasibility of the DISPO-II Training Program. Cancers (Basel). 2021 Jan 8;13(2):201. doi: 10.3390/cancers13020201.
138. Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Duc AN, Viale G, Molinero L, Emens LA. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 Jun 7;113(12):1733-43. doi: 10.1093/jnci/djab108.
139. Sauer C, Krauß J, Jäger D, Zschäbitz S, Haag GM, Sauer S, Kiermeier S, Friederich HC, Maatouk I. eHealth intervention to manage symptoms for patients with cancer on immunotherapy (SOFIA): a study protocol for a randomised controlled external pilot trial. BMJ Open. 2021 Jul 19;11(7):e047277. doi: 10.1136/bmjopen-2020-047277.
140. Scharhag-Rosenberger F, Sprave T, Clauss D, Hoffmann P, Welzel T, Debus J, Rief H, Wiskemann J. Spinal Stabilization Exercises for Cancer Patients with Spinal Metastases of High Fracture Risk: Feasibility of the DISPO-II Training Program. Cancers (Basel) . 2021 Jan 8;13(2):201. doi: 10.3390/cancers13020201
141. Scharhag-Rosenberger F, Schneider J, Schlüter K, Paratte JL, Wiskemann J. Vertebral fracture during one 1-RM testing in a breast cancer survivor: a case repot. Medicine (Baltimore).

142. 2021 May 21;100(20):e25705. doi: 10.1097/MD.0000000000025705

143. Schildmann J, Winkler EC. Assistierte Selbsttötung bei Krebspatient(innen): Regelungsbedarf und Ermessensspielraum. Mitgliederrundschreiben DGHO, 1-2021
144. Schildmann J, Junghanss C, Oldenburg M, Schuler U, Trümper L, Wörmann B, Winkler EC. Role and responsibility of oncologists in assisted suicide. Practice and views among members of the German Society of Haematology and Medical Oncology. ESMO Open. 2021 Dec;6(6):100329. doi: 10.1016/j.esmoop.2021.100329. Epub 2021 Dec 9
145. Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 Jun 3;137(22):3093-3104. doi: 10.1182/blood.2020007626.
146. Schmitt M, Maron RC, Hekler A, Stenzinger A, Hauschild A, Weichenthal M, Tiemann M, Krahl D, Kutzner H, Utikal JS, Haferkamp S, Kather JN, Klauschen F, Krieghoff-Henning E, Fröhling S, von Kalle C, Brinker TJ. Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. J Med Internet Res. 2021 Feb 2;23(2):e23436. doi:10.2196/23436. PMID: 33528370; PMCID: PMC7886613.
147. Schnabel E, Knoll M, Schwager C, Warta R, Mock A, Campos B, König L, Jungk C, Wick W, Unterberg A, Debus J, Herold-Mende C, Abdollahi A. Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. Int J Mol Sci. 2021 Mar 15;22(6):2960. doi: 10.3390/ijms22062960.
148. Schneeweiss A, Fasching PA, Fehm T, Gerber B, Jackisch C, Loibl S, Schmidt M, Stickeler E, Wöckel A, Janni W, Müller V; AGO Kommission Mamma. AGO Algorithms for the Treatment of Breast Cancer: Update 2021. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1101-1111. doi: 10.1055/a-1519-7089. Epub 2021 Oct 6.
149. Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17.
150. Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast. 2021 Feb;55:138-139. doi: 10.1016/j.breast.2020.12.007. Epub 2021 Jan 5.
151. Schneider L, Laiouar-Pedari S, Kuntz S, Krieghoff-Henning E, Hekler A, Kather

152. JN, Gaiser T, Fröhling S, Brinker TJ. Integration of deep learning-based image

     analysis and genomic data in cancer pathology: A systematic review. Eur J

     Cancer. 2022 Jan;160:80-91. doi: 10.1016/j.ejca.2021.10.007. Epub 2021 Nov 19.

     PMID: 34810047.

153. Seydel F, Delecluse S, Zeier M, Holland-Letz T, Haag GM, Berger AK, Grün BC, Bougatf N, Hohenfellner M, Duensing S, Jäger D, Zschäbitz S. Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort StudyCancers (Basel). 2021 Apr 1;13(7):1623. doi: 10.3390/cancers13071623.
154. Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos JP, Jäger D, Siveke J, Springfeld C. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Genes Chromosomes Cancer. 2021 May;60(5):373-384. doi: 10.1002/gcc.22932. PMID: 33341987 Review.
155. Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C, Ungerechts G. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Mol Ther Oncolytics. 2021 May 5;21:340-355. doi: 10.1016/j.omto.2021.04.015. eCollection 2021 Jun 25.
156. Sinn BV, Loibl S, Hanusch CA, Zahm DM, Sinn HP, Untch M, Weber K, Karn T, Becker C, Marmé F, Schmitt WD, Müller V, Schem C, Treue D, Stickeler E, Klauschen F, Burchardi N, Furlanetto J, van Mackelenbergh M, Fasching PA, Schneeweiss A, Denkert C. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clin Cancer Res. 2021 May 1;27(9):2584-2591. doi: 10.1158/1078-0432.CCR-20-3113. Epub 2021 Feb 16.
157. Spitz M, Jungkunz M, Schickhardt C, Cornelius K (2021): Rechtlicher Rahmen für eine privilegierte Nutzung klinischer Daten zu Forschungszwecken, Medizinrecht, 39:499-504. https://doi.org/10.1007/s00350-021-5898-7
158. Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M. Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. Geburtshilfe Frauenheilkd. 2021 May;81(5):526-538. doi: 10.1055/a-1464-0953. Epub 2021 May 3.
159. Strobel SB, Machiraju D, Hülsmeyer I, Becker JC, Paschen A, Jäger D, Wels WS, Bachmann M, Hassel JC. Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. Life (Basel). 2021 Mar 24;11(4):269. doi: 10.3390/life11040269.
160. Sauer C, Krauß J, Jäger D, Zschäbitz S, Haag GM, Walle T, Sauer S, Kiermeier S, Friederich HC, Maatouk I. Sauer C, Krauß J, Jäger D, Zschäbitz S, Haag GM, Walle T, Sauer S, Kiermeier S, Friederich HC, Maatouk I. BMJ Open. 2021 Jul 19;11(7):e047277. doi: 10.1136/bmjopen-2020-047277.
161. Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungelius JU, Baumann M, Mangasarian A, Halama N. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. J Immunother Cancer. 2021 Oct;9(10):e002505. doi: 10.1136/jitc-2021-002505.
162. Surmann B, Lingnau R, Witte J, Walther J, Mehlis K, Winkler EC, Greiner W. Individuelle finanzielle Belastungen infolge einer Krebserkrankungaus der Perspektive von Sozialdiensten in Deutschland. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2021 May; 162:16-23
163. Tan X, Sivakumar S, Bednarsch J, Wiltberger G, Kather JN, Niehues J, de Vos-Geelen J, Valkenburg-van Iersel L, Kintsler S, Roeth A, Hao G, Lang S, Coolsen ME, den Dulk M, Aberle MR, Koolen J, Gaisa NT, Olde Damink SWM, Neumann UP, Heij LR. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Oncogene. 2021 Feb;40(5):899-908. doi:10.1038/s41388-020-01578-4. Epub 2020 Dec 7. PMID: 33288884; PMCID: PMC7862068.
164. Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik VI, Schlenk RF, Paschka P, Weber D, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Ramachandran D, Benner A, Ganser A, Döhner H, Heuser M, Döhner K, Thol F. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica. 2021 Nov 1;106(11):2986-2989. doi: 10.3324/haematol.2021.278894.
165. Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N.AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.  Breast Care (Basel). 2021 Jun;16(3):228-235. doi: 10.1159/000516420. Epub 2021 May 27.
166. Tiwari-Heckler S, Rauber C, Longhi MS, Zörnig I, Schnitzler P, Jäger D, Giese T, Merle U. Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness. Open Forum Infect Dis. 2021 Jan 18;8(3):ofab019. doi: 10.1093/ofid/ofab019. eCollection 2021 Mar.
167. Tönnies J, Hartmann M, Jäger D, Bleyel C, Becker N, Friederich HC, Haun MW. Aggressiveness of Care at the End-of-Life in Cancer Patients and Its Association With Psychosocial Functioning in Bereaved Caregivers. Front Oncol. 2021 Jun 4;11:673147. doi: 10.3389/fonc.2021.673147. eCollection 2021.
168. Tóth M, Wehling L, Thiess L, Rose F, Schmitt J, Weiler SME, Sticht C, De La Torre C, Rausch M, Albrecht T, Grabe N, Duwe L, Andersen JB, Köhler BC, Springfeld C, Mehrabi A, Kulu Y, Schirmacher P, Roessler S, Goeppert B, Breuhahn K. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer. 2021 Oct 6;21(1):1079. doi: 10.1186/s12885-021-08794-5. PMID: 34615513; PMCID: PMC8496054.
169. Tsiouris A, Ungar N, Gabrian M, Haussmann A, Steindorf K, Wiskemann J, Sieverding M. What is the Image of the "Typical Cancer Patient"? The View of Physicians. Am J Mens Health. 2021 Mar-Apr;15(2):1557988320988480. doi: 10.1177/1557988320988480.
170. Untch M, Fasching PA, Brucker SY, Budach W, Denkert C, Haidinger R, Huober J, Jackisch C, Janni W, Kolberg-Liedtke C, Krug D, Kühn T, Loibl S, Lüftner D, Müller V, Schneeweiss A, Thill M, Harbeck N, Thomssen C.Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd. 2021 Jun;81(6):637-653. doi: 10.1055/a-1483-2782. Epub 2021 May 19.
171. Veinalde R, Pidelaserra-Martí G, Moulin C, Jeworowski LM, Küther L, Buchholz CJ, Jäger D, Ungerechts G, Engeland CE. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory. Mol Ther Oncolytics. 2021 Nov 29;24:43-58. doi: 10.1016/j.omto.2021.11.020. eCollection 2022 Mar 17.
172. Vears DF, Minion JT, Roberts SJ, Cummings J, Machirori M, Blell M, Budin-Ljøsne I, Cowley L, Dyke SOM, Gaff C, Green RC, Hall A, Johns AL, Knoppers BM, Mulrine S, Patch C, Winkler E, Murtagh MJ. Return of individual research results from genomic research: A systematic review of stakeholder perspectives. PLoS One. 2021 Nov 8;16(11):e0258646. doi: 10.1371/journal.pone.0258646. eCollection 2021.
173. Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer HU, Fasching PA, Weber KE, Albig C, Heinrichs C, Marmé F, Hartmann A, Hanusch C, Schmitt WD, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn BV, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer. 2021 May;148:159-170. doi: 10.1016/j.ejca.2021.02.020. Epub 2021 Mar 18.
174. Walther J, Mehlis K. Finanzielle Belastungen von Krebspatient*innen: Perspektive des Sozialdienstes und empirische Daten einer Pilotstudie am NCT Heidelberg. Krebs im Focus. 2021;13:34-36.
175. Warwas KM, Meyer M, Gonçalves M, Moldenhauer G, Bulbuc N, Knabe S, Luckner-Minden C, Ziegelmeier C, Heussel CP, Zörnig I, Jäger D, Momburg F. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Front Immunol. 2021 Aug 16;12:719116. doi: 10.3389/fimmu.2021.719116. eCollection 2021.
176. Wehling C, Dill MT, Olkus A, Springfeld C, Chang DH, Naumann P, Longerich T, Kratochwil C, Mehrabi A, Merle U, Pfeiffenberger J, Rupp C, Weiss KH, Mieth M. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. J Cancer Res Clin Oncol. 2021 Aug;147(8):2471-2481. doi: 10.1007/s00432-021-03528-3. Epub 2021 Feb 4. PMID: 33537908; PMCID: PMC8236446.
177. Weller S, Hart NH, Bolam KA, Mansfield S, Santa Mina D, Winters-Stone KM, Campbell A, Rosenberger F, Wiskemann J, Quist M, Cormie P, Goulart J, Campbell KL. Exercise for individuals with bone metastases: A systematic review. Crit Rev Oncol Hematol. 2021 Aug 3:103433. doi: 10.1016/j.critrevonc.2021.103433.
178. Wentzensen N, Lahrmann B, Clarke MA, Kinney W, Tokugawa D, Poitras N, Locke A, Bartels L, Krauthoff A, Walker J, Zuna R, Grewal KK, Goldhoff PE, Kingery JD, Castle PE, Schiffman M, Lorey TS, Grabe N. Accuracy and Efficiency of Deep-Learning-Based Automation of Dual Stain Cytology in Cervical Cancer Screening. J Natl Cancer Inst. 2021 Jan 4;113(1):72-79. doi: 10.1093/jnci/djaa066.
179. Werner J, Kronberg RM, Stachura P, Ostermann PN, Müller L, Schaal H, Bhatia S, Kather JN, Borkhardt A, Pandyra AA, Lang KS, Lang PA. Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses. 2021 Apr 2;13(4):610. doi: 10.3390/v13040610. PMID: 33918368; PMCID: PMC8066066.
180. Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol. 2021 Nov 5;9:743908. doi: 10.3389/fcell.2021.743908. PMID: 34805152; PMCID: PMC8603393.
181. Xydia M, Rahbari R, Ruggiero E, Macaulay I, Tarabichi M, Lohmayer R, Wilkening S, Michels T, Brown D, Vanuytven S, Mastitskaya S, Laidlaw S, Grabe N, Pritsch M, Fronza R, Hexel K, Schmitt S, Müller-Steinhardt M, Halama N, Domschke C, Schmidt M, von Kalle C, Schütz F, Voet T, Beckhove P. Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients. Nat Commun. 2021 Feb 18;12(1):1119. doi: 10.1038/s41467-021-21297-y. PMID: 33602930
182. Yu T, Cao J, Alaa Eddine M, Moustafa M, Mock A, Erkut C, Abdollahi A, Warta R, Unterberg A, Herold-Mende C, Jungwirth G. Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers (Basel). 2021 Nov 24;13(23):5898. doi: 10.3390/cancers13235898.
183. Stellungnahme der Zentralen Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer (u.a. mit Winkler EC). Entscheidungsunterstützung ärztlicher Tätigkeit durch Künstliche Intelligenz. Deutsches Ärzteblatt, Jg. 118 | Heft 33–34 | 23. August 2021, 1-13, doi: 10.3238/arztebl.zeko_sn_cdss_2021
184. Neoptolemos JP, Springfeld C, Hackert T. A Review of Pancreatic Cancer. JAMA. 2021 Dec 21;326(23):2436. doi: 10.1001/jama.2021.20065
185. Springfeld C, Bailey P, Hackert T, Neoptolemos JP. Perioperative immunotherapy for pancreatic cancer is on its way. Hepatobiliary Surg Nutr. 2021 Aug;10(4):534-537. doi: 10.21037/hbsn-21-238.

1. Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 May;31(5):582-589. doi: 10.1016/j.annonc.2020.02.003. Epub 2020 Feb 20.
2. Albrecht T, Rausch M, Roessler S, Geissler V, Albrecht M, Halske C, Seifert C, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil-Warth A, Busch E, Köhler B, Rupp C, Weiss KH, Springfeld C, Röcken C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Arch. 2020 Jun;476(6):871-880. doi: 10.1007/s00428-019-02706-6. Epub 2019 Dec 14. PMID: 31838585
3. Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grüllich C, Quach C, Carroll S, Ding B, Zhu QC, Piault-Louis E, Schiff C, Escudier B. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 Jun 1;26(11):2506-2514. doi: 10.1158/1078-0432.CCR-19-2838. Epub 2020 Mar 3. PMID: 32127394
4. Avancini A, Trestini I, Tregnago D, Wiskemann J, Lanza M, Milella M, Pilotto S.Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa071. doi: 10.1093/jncics/pkaa071. eCollection 2020 Dec. PMID: 33385107
5. Berger AK, Allgäuer M, Apostolidis L, Schulze-Schleithoff AE, Merle U, Jäger D, Haag GM. Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis. World J Gastrointest Oncol. 2020 Nov 15;12(11):1288-1295. doi: 10.4251/wjgo.v12.i11.1288. PMID: 33250961
6. Berger AK, Mughal SS, Allgäuer M, Springfeld C, Hackert T, Weber TF, Naumann P, Hutter B, Horak P, Jahn A, Schröck E, Haag GM, Apostolidis L, Jäger D, Stenzinger A, Fröhling S, Glimm H, Heining C. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology. 2020 Apr;20(3):425-432. doi: 10.1016/j.pan.2020.02.017. Epub 2020 Feb 29
7. Berghoff AS, Breckwoldt MO, Riedemann L, Karimian-Jazi K, Loew S, Schlieter F, Furtner J, Cinci M, Thomas M, Strowitzki MJ, Marmé F, Michel LL, Schmidt T, Jäger D, Bendszus M, Preusser M, Wick W, Winkler F. Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. Neurooncol Adv. 2020 Mar 16;2(1):vdaa038. doi: 10.1093/noajnl/vdaa038. eCollection 2020 Jan-Dec.
8. Bolkestein M, Wong JKL, Thewes V, Körber V, Hlevnjak M, Elgaafary S, Schulze M, Kommoss FKF, Sinn HP, Anzeneder T, Hirsch S, Devens F, Schröter P, Höfer T, Schneeweiss A, Lichter P, Zapatka M, Ernst A. Chromothripsis in Human Breast Cancer. Cancer Res. 2020 Nov 15;80(22):4918-4931. doi: 10.1158/0008-5472.CAN-20-1920. Epub 2020 Sep 24.
9. Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, Schmidt P, Harbottle RP. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci Adv. 2021 Apr 14;7(16):eabf1333. doi: 10.1126/sciadv.abf1333. Print 2021 Apr.
10. Busch E, Kreutzfeldt S, Agaimy A, Mechtersheimer G, Horak P, Brors B, Hutter B, Fröhlich M, Uhrig S, Mayer P, Schröck E, Stenzinger A, Glimm H, Jäger D, Springfeld C, Fröhling S, Zschäbitz S. Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud. 2020 Aug; 6(4): a005553. doi: 10.1101/mcs.a005553. Print 2020 Aug
11. Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, Osen W, Eichmüller SB, Jäger D, Ungerechts G, Engeland CE. Measles Vaccines Designed for Enhanced CD8 + T Cell Activation. Viruses. 2020 Feb 21;12(2):242. doi: 10.3390/v12020242.
12. Busch E, Woydack L, Jäger D, Zschäbitz S. Individualisierte Behandlungsalgorithmen durch zielgerichtete Substanzen. Der Klinikarzt. 2020; 49(11): 446-450 DOI: 10.1055/a-1278-5795
13. Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, Heining C, Schlenk RF, Cheema P, Jones MR, Drilon A, Trombetta D, Muscarella LA, Tolba K, Gounant V, Cseh A, Solca F, Laskin JJ, Renouf DJ. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. Oncologist. 2021 Jan;26(1):7-16. doi: 10.1634/theoncologist.2020-0379. Epub 2020 Sep 23. PMID: 32852072
14. Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020 Mar;34(3):914-918. doi: 10.1038/s41375-019-0589-3. Epub 2019 Oct 14.PMID: 31611624  
15. Conte P*, Schneeweiss A*, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2020 Jul 1;126(13):3132-3139. doi: 10.1002/cncr.32873. Epub 2020 Apr 14.
16. de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, Bauersachs J, Bertero E, Coats AJS, Čelutkienė J, Chioncel O, Dodion P, Eschenhagen T, Farmakis D, Bayes-Genis A, Jäger D, Jankowska EA, Kitsis RN, Konety SH, Larkin J, Lehmann L, Lenihan DJ, Maack C, Moslehi JJ, Müller OJ, Nowak-Sliwinska P, Piepoli MF, Ponikowski P, Pudil R, Rainer PP, Ruschitzka F, Sawyer D, Seferovic PM, Suter T, Thum T, van der Meer P, Van Laake LW, von Haehling S, Heymans S, Lyon AR, Backs J. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029. Online ahead of print. PMID: 33094495
17. de Gregorio A, Häberle L, Fasching PA, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl TWP, Bauer E, de Gregorio N, Deniz M, Fink V, Bekes I, Andergassen U, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Lato K, Beckmann MW, Rack B, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. 2020 Oct 23;22(1):111. doi: 10.1186/s13058-020-01348-w.
18. Depenbusch J, Haussmann A, Tsiouris A, Schmidt L, Wiskemann J, Ungar N, Sieverding M, Steindorf K. The association between physicians' exercise counseling and physical activity in patients with cancer: Which roles do patients' satisfaction and previous physical activity levels play? Psychooncology. 2020 Nov;29(11):1856-1863. doi: 10.1002/pon.5506. Epub 2020 Sep 14. PMID: 32779261
19. Deutsch TM, Riethdorf S, Fremd C, Feisst M, Nees J, Fischer C, Hartkopf AD, Pantel K, Trumpp A, Schütz F, Schneeweiss A, Wallwiener M.  HER2-targeted therapy influences CTC status in metastatic breast cancer. Breast Cancer Res Treat. 2020 Jul;182(1):127-136. doi: 10.1007/s10549-020-05687-2. Epub 2020 May 20.PMID: 32436146
20. Deutsch TM, Stefanovic S, Feisst M, Fischer C, Riedel F, Fremd C, Domschke C, Pantel K, Hartkopf AD, Sutterlin M, Brucker SY, Schneeweiss A, Wallwiener M. Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. Cancers (Basel). 2020 Apr 24;12(4):1055. doi: 10.3390/cancers12041055. PMID: 32344685
21. Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, Müller V, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Diel I, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Moebus V, Mundhenke C, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Witzel I, Wöckel A, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel). 2020 Jun;15(3):294-309. doi: 10.1159/000508736. Epub 2020 Jun 10.
22. Echle A, Grabsch HI, Quirke P, van den Brandt PA, West NP, Hutchins GGA, Heij LR, Tan X, Richman SD, Krause J, Alwers E, Jenniskens J, Offermans K, Gray R, Brenner H, Chang-Claude J, Trautwein C, Pearson AT, Boor P, Luedde T, Gaisa NT, Hoffmeister M, Kather JN. Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology. 2020 Oct;159(4):1406-1416.e11. doi: 10.1053/j.gastro.2020.06.021. Epub 2020 Jun 17. PMID: 32562722
23. Edelmann D, Habermehl C, Schlenk RF, Benner A.  Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls.  Biom J. 2020 Mar;62(2):311-329. doi: 10.1002/bimj.201800390. Epub 2019 Sep 25. PMID: 31553076 tions based on stratification or using historical controls.
24. Engelmann L, Thierauf J, Koerich Laureano N, Stark HJ, Prigge ES, Horn D, Freier K, Grabe N, Rong C, Federspil P, Zaoui K, Plinkert PK, Rotter N, von Knebel Doeberitz M, Hess J, Affolter A.  Organotypic Co-Cultures as a Novel 3D Model for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Aug 18;12(8):2330. doi: 10.3390/cancers12082330. PMID: 32824777
25. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Tibiletti MG, Greene MH, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylkäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French JD, Edwards SL, Antoniou AC, Chenevix-Trench G, Simard J, Easton DF, Kraft P, Dunning AM. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1. Epub 2020 Jan 7.
26. Forster T, Köhler C, El Shafie R, Weykamp F, König L, Arians N, Adeberg S, Michel L, Smetanay K, Golatta M, Sohn C, Heil J, Schneeweiss A, Debus J, Hörner-Rieber J. Adjuvant Radiation Therapy for Male Breast Cancer-A Rare Indication? Cancers (Basel). 2020 Dec 4;12(12):3645. doi: 10.3390/cancers12123645.
27. Fresnais M, Roth A, Foerster KI, Jäger D, Pfister SM, Haefeli WE, Burhenne J, Longuespée R. Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS Assay. Cancers (Basel). 2020 Jul 14;12(7):1897. doi: 10.3390/cancers12071897.
28. Fresnais M, Yildirim E, Karabulut S, Jäger D, Zörnig I, Benzel J, Pajtler KW, Pfister SM, Burhenne J, Haefeli WE, Longuespée R. Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives Molecules. 2021 Feb 26;26(5):1281. doi: 10.3390/molecules26051281. PMID: 33652935 Free PMC article.
29. Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, Barthelemy V, Klein E, Bougnaud S, Keunen O, Wantz M, Michelucci A, Neirinckx V, Muller A, Kaoma T, Nazarov PV, Azuaje F, De Falco A, Flies B, Richart L, Poovathingal S, Arns T, Grzyb K, Mock A, Herold-Mende C, Steino A, Brown D, May P, Miletic H, Malta TM, Noushmehr H, Kwon YJ, Jahn W, Klink B, Tanner G, Stead LF, Mittelbronn M, Skupin A, Hertel F, Bjerkvig R, Niclou SP. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol. 2020 Dec;140(6):919-949. doi: 10.1007/s00401-020-02226-7. Epub 2020 Oct 3. PMID: 33009951
30. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23. PMID: 31873309.
31. Grapp M, Rosenberger F, Hemlein E, Klein E, Friederich H-C, Maatouk I. Acceptability and feasibility of a guided biopsychosocial online intervention for cancer patients undergoing chemotherapy. J Cancer Educ. 2020; Online ahead of print
32. Halama N, Haberkorn U. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. Semin Nucl Med. 2020 Sep;50(5):389-398. doi: 10.1053/j.semnuclmed.2020.06.003. Epub 2020 Jul 8. PMID: 32768003
33. Haussmann A, Ungar N, Tsiouris A, Sieverding M, Wiskemann J, Steindorf K. The Influence of Cancer Patient Characteristics on the Recommendation of Physical Activity by Healthcare Professionals. Int J Behav Med. 2020 Feb;27(1):65-78. doi: 10.1007/s12529-019-09833-z. PMID: 31823182
34. Heger P, Probst P, Wiskemann J, Steindorf K, Diener MK, Mihaljevic AL. A Systematic Review and Meta-analysis of Physical Exercise Prehabilitation in Major Abdominal Surgery (PROSPERO 2017 CRD42017080366). J Gastrointest Surg. 2020 Jun;24(6):1375-1385. doi: 10.1007/s11605-019-04287-w. Epub 2019 Jun 21. PMID: 31228083
35. Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford). 2020 Feb;22(2):224-232. doi: 10.1016/j.hpb.2019.06.012. Epub 2019 Jul 30. PMID: 31375338
36. Heilig CE, Horak P, Lipka DB, Mock A, Uhrig S, Kreutzfeldt S, Richter S, Gieldon L, Fröhlich M, Hutter B, Hübschmann D, Teleanu V, Schmier JW, Philipzen J, Beuthien-Baumann B, Schröck E, von Deimling A, Bauer S, Heining C, Mechtersheimer G, Stenzinger A, Brors B, Wardelmann E, Glimm H, Hartmann W, Fröhling S. Germline SDHB-inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes Cancer. 2020 Oct;59(10):601-608. doi: 10.1002/gcc.22876. Epub 2020 Jun 26. PMID: 32501622
37. Heitmann JS, Walz JS, Pflügler M, Kauer J, Schlenk RF, Jung G, Salih HR. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. BMJ Open. 2020 Oct 16;10(10):e039639. doi: 10.1136/bmjopen-2020-039639. PMID: 33067297 ü
38. Himbert C, Klossner N, Coletta AM, Barnes CA, Wiskemann J, LaStayo PC, Varghese TK Jr, Ulrich CM. Exercise and lung cancer surgery: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2020 Dec;156:103086. doi: 10.1016/j.critrevonc.2020.103086. Epub 2020 Sep 13. PMID: 33038630
39. Hoefflin R, Harlander S, Schäfer S, Metzger P, Kuo F, Schönenberger D, Adlesic M, Peighambari A, Seidel P, Chen CY, Consenza-Contreras M, Jud A, Lahrmann B, Grabe N, Heide D, Uhl FM, Chan TA, Duyster J, Zeiser R, Schell C, Heikenwalder M, Schilling O, Hakimi AA, Boerries M, Frew IJ.  HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 2020 Aug 17;11(1):4111. doi: 10.1038/s41467-020-17873-3. PMID: 32807776
40. Huebner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Ruebner M, Untch M, Fasching PA, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer. 2020 Nov 11;20(1):1091. doi: 10.1186/s12885-020-07546-1.
41. Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Pasotuxizumab, a BiTE ® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. PMID: 33172323
42. Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W, Ettl J, Belleville E, Thill M, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Tesch H, Fehm TN, Lüftner D, Schütz F, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1105-1114. doi: 10.1055/a-1270-7208. Epub 2020 Nov 6.
43. Ihrig A, Richter J, Grüllich C, Apostolidis L, Horak P, Villalobos M, Grapp M, Friederich HC, Maatouk I.  Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol. 2020 Dec;146(12):3189-3198. doi: 10.1007/s00432-020-03336-1. Epub 2020 Aug 19. PMID: 32813113
44. Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, Corbacioglu A, Herzig J, Weber D, Schrade A, Götze K, Schröder T, Lübbert M, Wellnitz D, Koller E, Schlenk RF, Gaidzik VI, Paschka P, Rücker FG, Heuser M, Thol F, Ganser A, Benner A, Döhner H, Bullinger L, Döhner K. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020 Dec 22;4(24):6342-6352. doi: 10.1182/bloodadvances.2020002673. PMID: 33351131
45. Jansen L, Holleczek B, Kraywinkel K, Weberpals J, Schröder CC, Eberle A, Emrich K, Kajüter H, Katalinic A, Kieschke J, Nennecke A, Sirri E, Heil J, Schneeweiss A, Brenner H. Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States. Cancers (Basel). 2020 Aug 26;12(9):2419. doi: 10.3390/cancers12092419.
46. Janssen M, Schäkel U, Fokou CD, Krisam J, Jacek Stermann J, Kriegsmann K, Haberbosch I, Novotny JP, Weber S, Vehreschild M, Bornhäuser M, Bullinger L, Schmitt M, Liebregts T, Dreger P, Lorenz H-M, Plaszczyca A, Bartenschlager R, Müller B, Kräusslich H-G, Halama N, Jäger D, Schlenk RF, Leo A, Meuer S, Weigand MA, Motsch J, Merle U, Denkinger CM, Müller-Tidow C. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21: 828. Published online 2020 Oct 6. doi: 10.1186/s13063-020-04735-y.
47. Jensen P, Carlet M, Schlenk RF, Weber A, Kress J, Brunner I, Słabicki M, Grill G, Weisemann S, Cheng YY, Jeremias I, Scholl C, Fröhling S. Requirement for LIM kinases in acute myeloid leukemia. Leukemia. 2020 Dec;34(12):3173-3185. doi: 10.1038/s41375-020-0943-5. Epub 2020 Jun 26. PMID: 32591645
48. Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, Theis F, Rücker FG, Teleanu MV, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer KT, Lübbert M, Wattad M, Götze KS, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk RF, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020 Dec 24;136(26):3041-3050. doi: 10.1182/blood.2020005998. PMID: 33367545  
49. Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, Becker C, Blohmer JU, Marmé F, Schmitt WD, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching PA, Jackisch C, Untch M, Schneeweiss A, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015. Epub 2020 May 24.
50. Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A,. Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica  2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.
51. Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Adès L, Montesinos P.  Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia. 2020 Sep;34(9):2333-2341. doi: 10.1038/s41375-020-0758-4. Epub 2020 Feb 19.PMID: 32076120  
52. Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, Kirchner M, Charoentong P, Volk N, Haag J, Wirtz R, Oskarsson T, Schulz A, Heil J, Schneeweiss A, Winter H, Sinn P.  Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer. JCO Precis Oncol. 2020 Jul 24;4:PO.19.00337. doi: 10.1200/PO.19.00337. eCollection 2020.PMID: 32923902
53. Klupp F, Schuler S, Kahlert C, Halama N, Franz C, Mayer P, Schmidt T, Ulrich A. Evaluation of the inflammatory markers CCL8, CXCL5, and LIF in patients with anastomotic leakage after colorectal cancer surgery. Int J Colorectal Dis. 2020; 35(7): 1221–1230. Published online 2020 Apr 19. doi: 10.1007/s00384-020-03582-2
54. Köppel M, Bannasch M, Huber G, Wiskemann J. Erfassung von Funktionseinschränkungen bei Patienten mit chemotherapieinduzierter Polyneuropathie. B&G 2020;36:112-118. Doi: 10.1055/a-1152-3847
55. Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, Rathke H, Winter E, Lindner T, Syed M, Bhatti IA, Herfarth K, Choyke PL, Jäger D, Haberkorn U, Debus J, Giesel FL. The Role of 68 Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. J Nucl Med. 2020 Sep;61(9):1331-1336. doi: 10.2967/jnumed.119.237016. Epub 2020 Feb 14.
56. Kowalski C, Albert US, Baumann W, Carl EG, Ernstmann N, Hermes-Moll K, Fallenberg EM, Feick G, Feiten S, Härter M, Heidt V, Heuser C, Hübner J, Joos S, Katalinic A, Kempkens Ö, Kerek-Bodden H, Klinkhammer-Schalke M, Koller M, Langer T, Lehner B, Lux MP, Maatouk I, Pfaff H, Ratsch B, Schach S, Scholl I, Skoetz N, Voltz R, Wiskemann J, Inwald E. DNVF Memorandum Health Services Research in Oncology. Gesundheitswesen. 2020 Sep;82(8-09):e108-e121. doi: 10.1055/a-1191-3759. Epub 2020 Aug 28. PMID: 32858754
57. Kreutz C, Müller J, Schmidt, ME, Steindorf, K. Comparison of subjectively and objectively assessed sleep problems in breast cancer patients starting neoadjuvant chemotherapy. Support Care Cancer. 2021 Feb;29(2):1015-1023. doi: 10.1007/s00520-020-05580-0. Epub 2020 Jun 19
58. Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020 Apr;34(4):1182-1186. doi: 10.1038/s41375-019-0645-z. Epub 2019 Dec 3. PMID: 31796915
59. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2020 Jun 29. doi: 10.1038/s41375-020-0917-7. Online ahead of print. PMID: 32595214  
60. Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Lux MP, Hartkopf AD. Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):e289. doi: 10.1055/a-1306-7231. Epub 2020 Nov 25.
61. Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1134-1142. doi: 10.1055/a-1286-2917. Epub 2020 Nov 6.
62. Laryionava K, Hauke D, Heußner P, Hiddemann W, Winkler EC. "Often Relatives are the Key […]" -Family Involvement in Treatment Decision Making in Patients with Advanced Cancer Near the End of Life. Oncologist. 2020 Oct 10. doi: 10.1002/onco.13557. Online ahead of print.
63. Laskin J, Liu SV, Tolba K, Heining C, Schlenk RF, Cheema P, Cadranel J, Jones MR, Drilon A, Cseh A, Gyorffy S, Solca F, Duruisseaux M. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol. 2020 Dec;31(12):1693-1703. doi: 10.1016/j.annonc.2020.08.2335. Epub 2020 Sep 9. PMID: 32916265
64. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.
65. Leber MF, Hoyler B, Prien S, Neault S, Engeland CE, Förster JM, Bossow S, Springfeld C, von Kalle C, Jäger D, Bell JC, Ungerechts G. Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations. J Gen Virol. 2020 Apr;101(4):399-409. doi: 10.1099/jgv.0.001395. Epub 2020 Feb 13. PMID: 32053093
66. Leber MF, Neault S, Jirovec E, Barkley R, Said A, Bell JC, Ungerechts G. Engineering and combining oncolytic measles virus for cancer therapy. Cytokine Growth Factor Rev. 2020 Dec;56:39-48. doi: 10.1016/j.cytogfr.2020.07.005. Epub 2020 Jul 3. PMID: 32718830
67. Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, Friedmann-Bette B, Bondong A, Bohus M, Wiskemann J. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation. Support Care Cancer. 2021 Jan;29(1):359-367. doi: 10.1007/s00520-020-05485-y. Epub 2020 May 4. PMID: 32367227
68. Liu J, Prager-van der Smissen WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Augustinsson A, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bernstein L, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Brauch H, Brenner H, Briceno I, Brucker SY, Brüning T, Burwinkel B, Cai Q, Cai H, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Choi JY, Christiaens M, Clarke CL; NBCS Collaborators, Couch FJ, Czene K, Daly MB, Devilee P, Dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haiman CA, Håkansson N, Hall P, Harrington PA, Hart SN, Hartman M, Hillemanns P, Hopper JL, Hou MF, Hunter DJ, Huo D; ABCTB Investigators, Ito H, Iwasaki M, Jakimovska M, Jakubowska A, John EM, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kraft P, Kristensen VN, Kurian AW, Le Marchand L, Li J, Lindblom A, Lophatananon A, Luben RN, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Mariapun S, Matsuo K, Maurer T, Mavroudis D, Meindl A, Menon U, Milne RL, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Offit K, Olopade OI, Olson JE, Olsson H, Orr N, Park SK, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Romero A, Ruebner M, Saloustros E, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Shen CY, Shu XO, Simard J, Sohn C, Southey MC, Spinelli JJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Torres D, Truong T, Untch M, Vachon CM, van Asperen CJ, Wolk A, Yamaji T, Zheng W, Ziogas A, Ziv E, Torres-Mejía G, Dörk T, Swerdlow AJ, Hamann U, Schmidt MK, Dunning AM, Pharoah PDP, Easton DF, Hooning MJ, Martens JWM, Hollestelle A. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 Jun 16;10(1):9688. doi: 10.1038/s41598-020-65665-y.
69. Loeffler MA, Hu J, Kirchner M, Wei X, Xiao Y, Albrecht T, De La Torre C, Sticht C, Banales JM, Vogel MN, Pathil-Warth A, Mehrabi A, Hoffmann K, Rupp C, Köhler B, Springfeld C, Schirmacher P, Ji J, Roessler S, Goeppert B. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis.
    J Pathol. 2020 Nov;252(3):239-251. doi: 10.1002/path.5514. Epub 2020 Sep 15. PMID: 32710569
70. Lüftner D, Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lux MP. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd. 2020 Apr;80(4):391-398. doi: 10.1055/a-1111-8775. Epub 2020 Apr 21.
71. Mahalingam D, Patel MR, Sachdev JC, Lowell L. Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Völkel D, Youssef A, de Jong FA, Tsimberidou AM. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020 Sep; 86(9): 1836–1848. Published online 2020 Apr 12. doi: 10.1111/bcp.14289
72. Mama SK, Bhuiyan N, Foo W, Segel JE, Bluethmann SM, Winkels RM, Wiskemann J, Calo WA, Lengerich EJ, Schmitz KH. Rural-urban differences in meeting physical activity recommendations and health status in cancer survivors in central Pennsylvania. Support Care Cancer. 2020 Oct;28(10):5013-5022. doi: 10.1007/s00520-020-05342-y. Epub 2020 Feb 8. PMID: 32036469
73. Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261.
74. Mavratzas A, Seitz J, Smetanay K, Schneeweiss A, Jäger D, Fremd C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol. 2020 Jan;16(3):4439-4453. doi: 10.2217/fon-2019-0468. Epub 2019 Dec 12.
75. McNamara MG, Goyal L, Doherty M, Springfeld C, Cosgrove D, Sjoquist KM, Park JO, Verdaguer H, Braconi C, Ross PJ, Gramont A, Zalcberg JR, Palmer DH, Valle JW, Knox JJ. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncol. 2020 Jun;16(16):1069-1081. doi: 10.2217/fon-2020-0247. Epub 2020 May 6. PMID: 32374623
76. Mehlis K, Bierwirth E, Laryionava K, Mumm F, Heussner P, Winkler EC. Late decisions about treatment limitation in patients with cancer: empirical analysis of end-of-life practices in a haematology and oncology unit at a German university hospital. ESMO Open. 2020 Oct;5(5):e000950. doi: 10.1136/esmoopen-2020-000950.
77. Mehlis K, Surmann B, Winkler EC. Financial impact of cancer and socioethical implications. Der Onkologe 2020;26: 425–430
78. Mehlis K, Witte J, Surmann B, Kudlich M, Apostolidis L, Walther J, Jäger D, Greiner W, Winkler EC. The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients. BMC Cancer. 2020 Jun 5;20(1):529. doi: 10.1186/s12885-020-07028-4.
79. Mehlis K, Woydack L, Winkler EC. [Ethical frameworks as a corrective in daily clinical practice? : Reflection on the significance of organizational ethics in tackling the challenges of economization in the medical system]. Med Klin Intensivmed Notfmed. 2020 Jun;115(5):367-371. doi: 10.1007/s00063-019-0587-2. Epub 2019 May 10. PMID: 31076797
80. Michel LL, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel). 2020 Oct 17;12(10):3021. doi: 10.3390/cancers12103021.
81. Michel LL, von Au A, Mavratzas A, Smetanay K, Schütz F, Schneeweiss A. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer. Target Oncol. 2020 Aug;15(4):415-428. doi: 10.1007/s11523-020-00730-0.
82. Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4.
83. Moraleda RR, Xiong W, Valous NA, Halama N. Segmentation of biomedical images based on a computational topology framework. Semin Immunol. 2020 Apr;48:101432. doi: 10.1016/j.smim.2020.101432. Epub 2020 Dec 2. PMID: 33277153
84. Morigny P, Kaltenecker D, Zuber J, Machado J, Mehr L, Tsokanos FF, Kuzi H, Hermann CD, Voelkl M, Monogarov G, Springfeld C, Laurent V, Engelmann B, Friess H, Zörnig I, Krüger A, Krijgsveld J, Prokopchuk O, Fisker Schmidt S, Rohm M, Herzig S, Berriel Diaz M. J Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy. Cachexia Sarcopenia Muscle.2021 Oct;12(5):1333-1351. doi: 10.1002/jcsm.12758. Epub 2021 Aug 23.
85. Müller J, Ringhof S, Vollmer M, Jäger LB, Stein T, Weiler M, Wiskemann J. Out of balance - Postural control in cancer patients before and after neurotoxic chemotherapy. Gait Posture. 2020 Mar;77:156-163. doi: 10.1016/j.gaitpost.2020.01.012. Epub 2020 Jan 15. PMID: 32036320
86. Neuendorff NR, Frenzel LP, Leuschner F, Fremd C. Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy.
    J Geriatr Oncol. 2020 Sep 22:S1879-4068(20)30433-1. doi: 10.1016/j.jgo.2020.09.006. Online ahead of print. PMID: 32978103
87. Neumeyer S, Hua X, Seibold P, Jansen L, Benner A, Burwinkel B, Halama N, Berndt SI, Phipps AI, Sakoda LC, Schoen RE, Slattery ML, Chan AT, Gala M, Joshi AD, Ogino S, Song M, Herpel E, Bläker H, Kloor M, Scherer D, Ulrich A, Ulrich CM, Win AK, Figueiredo JC, Hopper JL, Macrae F, Milne RL, Giles GG, Buchanan DD, Peters U, Hoffmeister M, Brenner H, Newcomb PA, Chang-Claude J. Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2719-2728. doi: 10.1158/1055-9965.EPI-20-0714. Epub 2020 Oct 2. PMID: 33008876
88. Nientiedt C, Duensing A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing S. PARP inhibition in prostate cancer. Genes Chromosomes Cancer. 2020 Oct 21. doi: 10.1002/gcc.22903. Online ahead of print. PMID: 33084183 Review.
89. Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, Volckmar AL, Leichsenring J, Neumann O, Kirchner M, Hoveida S, Lantwin P, Kaltenecker K, Dieffenbacher S, Gasch C, Hofer L, Franke D, Tosev G, Görtz M, Schütz V, Radtke JP, Nyarangi-Dix J, Hatiboglu G, Simpfendörfer T, Schönberg G, Isaac S, Teber D, Koerber SA, Christofi G, Czink E, Kreuter R, Apostolidis L, Kratochwil C, Giesel F, Haberkorn U, Debus J, Sültmann H, Zschäbitz S, Jäger D, Duensing A, Schirmacher P, Grüllich C, Hohenfellner M, Stenzinger A, Duensing S. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol. 2020 Jul;38(7):637.e17-637.e27. doi: 10.1016/j.urolonc.2020.03.001. Epub 2020 Apr 10.
90. Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2020 Feb;146(2):449-455. doi: 10.1007/s00432-019-03071-2. Epub 2019 Dec 14.PMID: 31838576
91. Pal A, Zimmer P, Clauss D, Schmidt ME, Ulrich CM, Wiskemann J, Steindorf K. Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients. Int J Sports Med. 2021 Jan;42(1):33-40. doi: 10.1055/a-1186-1009. Epub 2020 Jul 24. PMID: 32707579
92. Pein M, Insua-Rodríguez J, Hongu T, Riedel A, Meier J, Wiedmann L, Decker K, Essers MAG, Sinn HP, Spaich S, Sütterlin M, Schneeweiss A, Trumpp A, Oskarsson T. Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nat Commun. 2020 Mar 20;11(1):1494. doi: 10.1038/s41467-020-15188-x.
93. Pflügler S, Svinka J, Scharf I, Crncec I, Filipits M, Charoentong P, Tschurtschenthaler M, Kenner L, Awad M, Stift J, Schernthanner M, Bischl R, Herndler-Brandstetter D, Glitzner E, Moll HP, Casanova E, Timelthaler G, Sibilia M, Gnant M, Lax S, Thaler J, Müller M, Strobl B, Mohr T, Kaser A, Trajanoski Z, Heller G, Eferl R.  IDO1 + Paneth cells promote immune escape of colorectal cancer. Commun Biol. 2020 May 22;3(1):252. doi: 10.1038/s42003-020-0989-y.PMID: 32444775
94. Pidelaserra-Martí G, Engeland CE. Mechanisms of measles virus oncolytic immunotherapy. Cytokine Growth Factor Rev. 2020 Dec;56:28-38. doi: 10.1016/j.cytogfr.2020.07.009. Epub 2020 Jul 3. PMID: 32660751
95. Pocha K, Mock A, Rapp C, Dettling S, Warta R, Geisenberger C, Jungk C, Martins LR, Grabe N, Reuss D, Debus J, von Deimling A, Abdollahi A, Unterberg A, Herold-Mende CC. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. Clin Cancer Res. 2020 May 1;26(9):2231-2243. doi: 10.1158/1078-0432.CCR-19-2184. Epub 2020 Jan 17. PMID: 31953311
96. Pohlmann S, Kunz A, Ose D, Winkler EC, Brandner A, Poss-Doering R, Szecsenyi J, Wensing M. Digitalizing Health Services by Implementing a Personal Electronic Health Record in Germany: Qualitative Analysis of Fundamental Prerequisites From the Perspective of Selected Experts.
    J Med Internet Res. 2020 Jan 29;22(1):e15102. doi: 10.2196/15102. PMID: 32012060
97. Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020 May 1;6(5):744-748. doi: 10.1001/jamaoncol.2020.0007.
98. Ran T, Eichmüller SB, Schmidt P, Schlander M. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer. 2020 Dec 15;147(12):3438-3445. doi: 10.1002/ijc.33156. Epub 2020 Jul 6. PMID: 32535920
99. Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, Olszanski AJ, Jäger D, Lakhani N, Ryan DP, Rasmussen E, Juan G, Wong H, Soman N, Smit MD, Nagorsen D, Papadopoulos KP. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer. 2020 Oct;8(2):e001006. doi: 10.1136/jitc-2020-001006. PMID: 33046621
100. Riedel F, Hoffmann AS, Moderow M, Heublein S, Deutsch TM, Golatta M, Wallwiener M, Schneeweiss A, Heil J, Hennigs A. Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer. 2020 Dec 1;147(11):3049-3058. doi: 10.1002/ijc.33122. Epub 2020 Jun 13.
101. Rippinger N, Fischer C, Haun MW, Rhiem K, Grill S, Kiechle M, Cremer FW, Kast K, Nguyen HP, Ditsch N, Kratz CP, Vogel J, Speiser D, Hettmer S, Glimm H, Fröhling S, Jäger D, Seitz S, Hahne A, Maatouk I, Sutter C, Schmutzler RK, Dikow N, Schott S. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer. 2020 Sep 1;126(17):4032-4041. doi: 10.1002/cncr.33004. Epub 2020 Jun 18.
102. Röhrich M, Naumann P, Giesel FL, Choyke P, Staudinger F, Wefers A, Liew DP, Kratochwil C, Rathke H, Liermann J, Herfarth K, Jäger D, Debus J, Haberkorn UA, Lang M, Koerber SA. Impact of 68 Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2020 Oct 23:jnumed.120.253062. doi: 10.2967/jnumed.120.253062. Online ahead of print. PMID: 33097632
103. Roider T, Wang X, Hüttl K, Müller-Tidow C, Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S.  The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. Int J Cancer. 2021 Jan 1;148(1):150-160. doi: 10.1002/ijc.33202. Epub 2020 Aug 15. PMID: 32638373
104. Rosenberger F, Sprave T, Clauss D, Hoffmann P, Welzel T, Debus J, Rief H, Wiskemann J. Spinal Stabilization Exercises for Cancer Patients with Spinal Metastases of High Fracture Risk: Feasibility of the DISPO-II Training Program. Cancers (Basel). 2021 Jan 8;13(2):201. doi: 10.3390/cancers13020201.
105. Rüger AM, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé F, Lübbe K, Sinn B, Karn T, Stickeler E, Müller V, Schem C, Denkert C, Fasching PA, Nekljudova V, Garfias-Macedo T, Hasenfuß G, Haverkamp W, Loibl S, von Haehling S. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. J Am Heart Assoc. 2020 Dec;9(23):e018143. doi: 10.1161/JAHA.120.018143. Epub 2020 Nov 16.
106. Scherr AL, Jassowicz A, Pató A, Elssner C, Ismail L, Schmitt N, Hoffmeister P, Neukirch L, Gdynia G, Goeppert B, Schulze-Bergkamen H, Jäger D, Köhler BC. Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells. Int J Mol Sci. 2020 Feb 7;21(3):1099. doi: 10.3390/ijms21031099.
107. Scherr AL, Mock A, Gdynia G, Schmitt N, Heilig CE, Korell F, Rhadakrishnan P, Hoffmeister P, Metzeler KH, Schulze-Osthoff K, Illert AL, Boerries M, Trojan J, Waidmann O, Falkenhorst J, Siveke J, Jost PJ, Bitzer M, Malek NP, Vecchione L, Jelas I, Brors B, Glimm H, Stenzinger A, Grekova SP, Gehrig T, Schulze-Bergkamen H, Jäger D, Schirmacher P, Heikenwalder M, Goeppert B, Schneider M, Fröhling S, Köhler BC. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death Dis. 2020 Oct 17;11(10):875. doi: 10.1038/s41419-020-03092-7. PMID: 33070156
108. Schickhardt C, Fleischer H, Winkler EC. Do patients and research subjects have a right to receive their genomic raw data? An ethical and legal analysis. BMC Med Ethics. 2020 Jan 16;21(1):7. doi: 10.1186/s12910-020-0446-y.
109. Schickhardt C, Horak P, Fröhling S, Winkler EC. The molecular tumor board. Ethical challenges and recommendations for practice. Der Onkologe 2020;26:431-437
110. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
111. Schneeweiss A, Bauerfeind I, Fehm T, Janni W, Thomssen C, Witzel I, Wöckel A, Müller V. Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Breast Care (Basel). 2020 Dec;15(6):608-618. doi: 10.1159/000511925.
112. Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29.
113. Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Huober J, Thill M, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lüftner D, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd. 2020 Mar;80(3):277-287. doi: 10.1055/a-1111-2431. Epub 2020 Mar 4.
114. Schneider J, Schlüter K, Sprave T, Wiskemann J, Rosenberger F. Exercise intensity prescription in cancer survivors: ventilatory and lactate thresholds are useful submaximal alternatives to VO _2peak. Support Care Cancer. 2020 Nov;28(11):5521-5528. doi: 10.1007/s00520-020-05407-y. Epub 2020 Mar 16. PMID: 32173766
115. Schneider J, Schlüter K, Wiskemann J, Rosenberger F. Do we underestimate maximal oxygen uptake in cancer survivors? Findings from a supramaximal verification test. Appl Physiol Nutr Metab. 2020 May;45(5):486-492. doi: 10.1139/apnm-2019-0560. Epub 2019 Oct 11. PMID: 31604021
116. Schöpf B, Weissensteiner H, Schäfer G, Fazzini F, Charoentong P, Naschberger A, Rupp B, Fendt L, Bukur V, Giese I, Sorn P, Sant'Anna-Silva AC, Iglesias-Gonzalez J, Sahin U, Kronenberg F, Gnaiger E, Klocker H. OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation. Nat Commun. 2020 Mar 20;11(1):1487. doi: 10.1038/s41467-020-15237-5.PMID: 32198407 
117. Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos JP, Jäger D, Siveke J, Springfeld C. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Online ahead of print. PMID: 33341987 Review.
118. Sisic L, Blank S, Nienhüser H, Haag GM, Jäger D, Bruckner T, Ott K, Schmidt T, Ulrich A. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surg Oncol. 2020 Jun;33:177-188. doi: 10.1016/j.suronc.2017.06.001. Epub 2017 Jun 29. PMID: 28684226
119. Springfeld C, Hackert T, Jäger D, Büchler MW, Neoptolemos JP. Neoadjuvant and adjuvant treatment of pancreatic cancer. Chirurg. 2020 Aug;91(8):636-641. doi: 10.1007/s00104-020-01169-9. PMID: 32300820 Review
120. Stefanovic S, Deutsch TM, Riethdorf S, Fischer C, Hartkopf A, Sinn P, Feisst M, Pantel K, Golatta M, Brucker SY, Sütterlin M, Schneeweiss A, Wallwiener M. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. Int J Mol Sci. 2020 Mar 21;21(6):2161. doi: 10.3390/ijms21062161.
121. Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Kohler M, Hofmann J, Bankovic S, Vassilev K, Sütterlin M, Schneeweiss A, Wallwiener M. Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. Diagnostics (Basel). 2020 Jun 4;10(6):369. doi: 10.3390/diagnostics10060369.
122. Steindorf K, Depenbusch J, Haussmann A, Tsiouris A, Schmidt L, Hermann S, Sieverding M, Wiskemann J, Ungar N. Change patterns and determinants of physical activity differ between breast, prostate, and colorectal cancer patients. Support Care Cancer. 2020 Jul;28(7):3207-3218. doi: 10.1007/s00520-019-05097-1. Epub 2019 Nov 13. PMID: 31720802
123. Strobel O, Lorenz P, Hinz U, Gaida M, König AK, Hank T, Niesen W, Kaiser J, Al-Saeedi M, Bergmann F, Springfeld C, Berchtold C, Diener MK, Schneider M, Mehrabi A, Müller-Stich BP, Hackert T, Jäger D, Büchler MW. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Ann Surg. 2020 Jul 7. doi: 10.1097/SLA.0000000000004147. Online ahead of print. PMID: 32649469
124. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
125. Talla SB, Rempel E, Endris V, Jenzer M, Allgäuer M, Schwab C, Kazdal D, Stögbauer F, Volckmar AL, Kocsmar I, Neumann O, Schirmacher P, Zschäbitz S, Duensing S, Budczies J, Stenzinger A, Kirchner M. Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing. Genes Chromosomes Cancer. 2020 Jul;59(7):406-416. doi: 10.1002/gcc.22843. Epub 2020 Apr 17. PMID: 32212351
126. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk RF, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020 Jul;26(7):992-994. doi: 10.1038/s41591-020-0969-2. PMID: 32632195
127. Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
128. Valous NA, Moraleda RR, Jäger D, Zörnig I, Halama N. Interrogating the microenvironmental landscape of tumors with computational image analysis approaches. Semin Immunol. 2020 Apr;48:101411. doi: 10.1016/j.smim.2020.101411. Epub 2020 Nov 6. PMID: 33168423 Review.
129. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 May;26(5):665-671. doi: 10.1038/s41591-020-0874-8. Epub 2020 Apr 16. PMID: 32405058 Review.
130. van Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, VAN Beurden M, Oldenburg HS, Sonke GS, VAN Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, VAN Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-DE Leeuw IM, Brug J, May AM, Buffart LM. Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. Med Sci Sports Exerc. 2020 Feb;52(2):303-314. doi: 10.1249/MSS.0000000000002154. PMID: 31524827
131. Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020 Apr;146(4):1033-1050. doi: 10.1007/s00432-020-03135-8. Epub 2020 Feb 27. PMID: 32107625
132. Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 Oct 13;4(19):4945-4954. doi: 10.1182/bloodadvances.2020002904. PMID: 33049054  
133. Walle T, Erdal E, Mühlsteffen L, Singh HM, Gnutzmann E, Grün B, Hofmann H, Ivanova A, Köhler BC, Korell F, Mavratzas A, Mock A, Pixberg C, Schult D, Starke H, Steinebrunner N, Woydack L, Schneeweiss A, Dietrich M, Jäger D, Krisam J, Kather JN, Winkler EC. Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trial. ESMO Open. 2020 Nov;5(6):e000912. doi: 10.1136/esmoopen-2020-000912.
134. Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, Fremd C, Grischke EM, Sinn P, Brucker SY, Schneeweiss A, Hartkopf AD, Wallwiener M. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug;183(1):137-144. doi: 10.1007/s10549-020-05746-8. Epub 2020 Jul 1.
135. Weber TF, Spurny M, Hasse FC, Sedlaczek O, Haag GM, Springfeld C, Mokry T, Jäger D, Kauczor HU, Berger AK. Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients. Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients. Insights Imaging. 2020 Sep 29;11(1):106. doi: 10.1186/s13244-020-00907-1. PMID: 32990824
136. Weis A, Pohlmann S, Poss-Doering R, Strauss B, Ullrich C, Hofmann H, Ose D, Winkler EC, Szecsenyi J, Wensing M. Caregivers' role in using a personal electronic health record: a qualitative study of cancer patients and caregivers in Germany. BMC Med Inform Decis Mak. 2020 Jul 13;20(1):158. doi: 10.1186/s12911-020-01172-4. PMID: 32660600
137. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC; Tumor Neoantigen Selection Alliance, Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell. 2020 Oct 29;183(3):818-834.e13. doi: 10.1016/j.cell.2020.09.015. Epub 2020 Oct 9. PMID: 33038342
138. Wentzensen N, Lahrmann B, Clarke MA, Kinney W, Tokugawa D, Poitras N, Locke A, Bartels L, Krauthoff A, Walker J, Zuna R, Grewal KK, Goldhoff PE, Kingery JD, Castle PE, Schiffman M, Lorey TS, Grabe N.  Accuracy and Efficiency of Deep-Learning-Based Automation of Dual Stain Cytology in Cervical Cancer Screening. J Natl Cancer Inst. 2021 Jan 4;113(1):72-79. doi: 10.1093/jnci/djaa066. PMID: 32584382
139. Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer JU, Seiler S, Denkert C, Tesch H, Jackisch C, Gerber B, Schneeweiss A, Link T, Krug D, Huober J, Rhiem K, Kühn T, Vladimirova V, Nekljudova V, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020 May;130:92-101. doi: 10.1016/j.ejca.2020.02.015. Epub 2020 Mar 13.
140. Weykamp F, El Shafie RA, König L, Seidensaal K, Forster T, Arians N, Regnery S, Hoegen P, Deutsch TM, Schneeweiss A, Debus J, Hörner-Rieber J. Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool. Front Oncol. 2020 Sep 2;10:1557. doi: 10.3389/fonc.2020.01557. eCollection 2020.
141. Weykamp F, König L, Seidensaal K, Forster T, Hoegen P, Akbaba S, Mende S, Welte SE, Deutsch TM, Schneeweiss A, Debus J, Hörner-Rieber J. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. Front Oncol. 2020 Jun 26;10:987. doi: 10.3389/fonc.2020.00987. eCollection 2020.
142. Winkler EC, Knoppers BM. Ethical challenges of precision cancer medicine. Semin Cancer Biol. 2020 Oct 9:S1044-579X(20)30201-7. doi: 10.1016/j.semcancer.2020.09.009. Online ahead of print.
143. Wiskemann J, Köppel M, Voland A, Wegener A, Rosenberger F, Biazeck B, Jäger E, Graf K. Implementation von Sport- und Bewegungstherapie in die onkologische Routineversorgung. TumorDiagnostik & Therapie. 2020;41:306-310. DOI: 10.1055/a-1132-1176
144. Wochner R, Clauss D, Nattenmüller J, Tjaden C, Bruckner T, Kauczor HU, Hackert T, Wiskemann J, Steindorf K. Impact of progressive resistance training on CT quantified muscle and adipose tissue compartments in pancreatic cancer patients. PLoS One. 2020 Nov 30;15(11):e0242785. doi: 10.1371/journal.pone.0242785. eCollection 2020. PMID: 33253318
145. Xia L, Xu Z, Zhou X, Bergmann F, Grabe N, Büchler MW, Neoptolemos JP, Hackert T, Kroemer G, Fortunato F.  Impaired autophagy increases susceptibility to endotoxin-induced chronic pancreatitis. Cell Death Dis. 2020 Oct 21;11(10):889. doi: 10.1038/s41419-020-03050-3. PMID: 33087696
146. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blanco A, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Bondavalli D, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brucker SY, Brüning T, Burwinkel B, Buys SS, Byers H, Caldés T, Caligo MA, Calvello M, Campa D, Castelao JE, Chang-Claude J, Chanock SJ, Christiaens M, Christiansen H, Chung WK, Claes KBM, Clarke CL, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Diez O, Domchek SM, Dörk T, Dwek M, Eccles DM, Ekici AB, Evans DG, Fasching PA, Figueroa J, Foretova L, Fostira F, Friedman E, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Häberle L, Hahnen E, Haiman CA, Hake CR, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huebner H, Hulick PJ, Imyanitov EN; kConFab Investigators; ABCTB Investigators, Isaacs C, Izatt L, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khan S, Khusnutdinova E, Kitahara CM, Ko YD, Konstantopoulou I, Koppert LB, Koutros S, Kristensen VN, Laenkholm AV, Lambrechts D, Larsson SC, Laurent-Puig P, Lazaro C, Lazarova E, Lejbkowicz F, Leslie G, Lesueur F, Lindblom A, Lissowska J, Lo WY, Loud JT, Lubinski J, Lukomska A, MacInnis RJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matricardi L, McGuffog L, McLean C, Mebirouk N, Meindl A, Menon U, Miller A, Mingazheva E, Montagna M, Mulligan AM, Mulot C, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen FC, Nikitina-Zake L, Nodora J, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Papi L, Papp J, Park-Simon TW, Parsons MT, Peissel B, Peixoto A, Peshkin B, Peterlongo P, Peto J, Phillips KA, Piedmonte M, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Prokofyeva D, Rack B, Radice P, Ramus SJ, Rantala J, Rashid MU, Rennert G, Rennert HS, Risch HA, Romero A, Rookus MA, Rübner M, Rüdiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Scheuner MT, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Senter L, Sharma P, Sherman ME, Shu XO, Singer CF, Smichkoska S, Soucy P, Southey MC, Spinelli JJ, Stone J, Stoppa-Lyonnet D; EMBRACE Study; GEMO Study Collaborators, Swerdlow AJ, Szabo CI, Tamimi RM, Tapper WJ, Taylor JA, Teixeira MR, Terry M, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van den Ouweland AMW, van der Kolk LE, van Veen EM, vanRensburg EJ, Vega A, Wappenschmidt B, Weinberg CR, Weitzel JN, Wildiers H, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zheng W, Zorn KK, Milne RL, Kraft P, Simard J, Pharoah PDP, Michailidou K, Antoniou AC, Schmidt MK, Chenevix-Trench G, Easton DF, Chatterjee N, García-Closas M. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020 Jun;52(6):572-581. doi: 10.1038/s41588-020-0609-2. Epub 2020 May 18.
147. Zschäbitz S, Niegisch G. Second-line treatment of metastatic urothelial carcinoma: Update immuno-oncology. Urologe A. 2020 Jul;59(7):804-809. doi: 10.1007/s00120-020-01236-3.
148. Zschäbitz S, Ivanyi P, Delecluse S. Revolution in der Systemtherapie des metastasierten Nierenzellkarzinoms. Der Nephrologe. 2020;15:12-19.

1. Aghamaliyev U, Gaitantzi H, Thomas M, Simon-Keller K, Gaiser T, Marx A, Yagublu V, Araos J, Cai C, Valous NA, Halama N, Kiesslich T, Ebert M, Grützmann R, Rückert F, Breitkopf-Heinlein K. Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells. Eur Surg Res. 2019;60(1-2):1-12. doi: 10.1159/000494734. Epub 2019 Jan 16.
2. Akbaba S, Ahmed D, Mock A, Held T, Bahadir S, Lang K, Syed M, Hoerner-Rieber J, Forster T, Federspil P, Herfarth K, Plinkert P, Debus J, Adeberg S. Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience.
3. Akbaba S, Heusel A, Mock A, Held T, Lang K, Hoerner-Rieber J, Forster T, Katayama S, Kargus S, Rieken S, Plinkert P, Herfarth K, Debus J, Adeberg S. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience. Oral Oncol. 2019 Oct;97:115-123. doi: 10.1016/j.oraloncology.2019.08.018. Epub 2019 Sep 5.
4. Akbaba S, Mock A, Hoerner-Rieber J, Held T, Katayama S, Forster T, Freudlsperger C, Rieken S, Herfarth K, Plinkert P, Debus J, Adeberg S. Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck. Front Oncol. 2019 Aug 13;9:755. doi: 10.3389/fonc.2019.00755. eCollection 2019.
5. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
6. Albrecht J, Baumann F, Wiskemann J. Erfassung der Versorgungsmerkmale von Krebsnachsorge-Sportgruppen in Nord- und Südbaden [Evaluation of cancer rehabilitation groups in North- and South Baden]. LZS (accepted June 06th, 2019)
7. Albrecht T, Rausch M, Roessler S, Geissler V, Albrecht M, Halske C, Seifert C, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil-Warth A, Busch E, Köhler B, Rupp C, Weiss KH, Springfeld C, Röcken C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Arch. 2019 Dec 14. doi: 10.1007/s00428-019-02706-6. [Epub ahead of print]
8. Albrecht T, Rausch M, Rössler S, Albrecht M, Braun JD, Geissler V, Mehrabi A, Vogel MN, Pathil-Warth A, Mechtersheimer G, Renner M, Rupp C, Weiss KH, Busch E, Köhler B, Springfeld C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer. 2019 Dec 5;19(1):1191. doi: 10.1186/s12885-019-6320-y.
9. Ann Surg Oncol. 2019 Nov;26(12):3892-3901. doi: 10.1245/s10434-019-07635-x. Epub 2019 Jul 26.
10. Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. eCollection 2019 Jan 1.
11. Aprupe L, Litjens G, Brinker TJ, van der Laak J, Grabe N. Robust and accurate quantification of biomarkers of immune cells in lung cancer micro-environment using deep convolutional neural networks. PeerJ. 2019 Apr 10;7:e6335. doi: 10.7717/peerj.6335. eCollection 2019.
12. Arians N, Kieser M, Benner L, Rochet N, Schröder L, Katayama S, Herfarth K, Schubert K, Schneeweiss A, Sohn C, Lindel K, Debus J. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. Radiat Oncol. 2019 Oct 21;14(1):179. doi: 10.1186/s13014-019-1381-2.
13. Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.
14. Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyler B, Poth T, Jäger D, Ungerechts G, Engeland CE. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists. Viruses. 2019 Oct 3;11(10). pii: E914. doi: 10.3390/v11100914.
15. Bernard P, Savard J. Steindorf K, Sweegers MG, Courneya K, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten WH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM. Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses. J Psychosom Res. 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23.
16. Campbell KL, Winters-Stone K, Wiskemann J, May A, Schwartz A, Courneya KS, Zucker D, Matthews C, Ligibel J, Gerber L, Morris S, Patel A, Hue T, Perna F, Schmitz K (2019). Exercise Guidelines for Cancer Survivors: Consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
17. Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020 Mar;34(3):914-918. doi: 10.1038/s41375-019-0589-3. Epub 2019 Oct 14.
18. Clauss D, Quirmbach F, Wiskemann J, Rosenberger F. Adverse Events beim Training mit onkologischen Patienten: Wie sicher ist das Training außerhalb klinischer Studien? [Adverse events in exercise oncology: How safe is training outside of clinical trials?]. Bewegungstherapie und Gesundheitssport 2019, 35: 194–201
19. Das K, Eisel D, Vormehr M, Müller-Decker K, Hommertgen A, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, Osen W, Eichmüller SB. A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. BMC Cancer. 2019 Sep 13;19(1):914. doi: 10.1186/s12885-019-6102-6.
20. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16.
21. DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 Oct;85:106197. doi: 10.1016/j.leukres.2019.106197. Epub 2019 Aug 1.
22. Edelmann D, Habermehl C, Schlenk RF, Benner A. Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls. Biom J. 2020 Mar;62(2):311-329. doi: 10.1002/bimj.201800390. Epub 2019 Sep 25.
23. Ehrenberg KR, Gao J, Oppel F, Frank S, Kang N, Dieter SM, Herbst F, Möhrmann L, Dubash TD, Schulz ER, Strakerjahn H, Giessler KM, Weber S, Oberlack A, Rief EM, Strobel O, Bergmann F, Lasitschka F, Weitz J, Glimm H, Ball CR. Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. Cells. 2019 Feb 10;8(2). pii: E142. doi: 10.3390/cells8020142.
24. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.
25. Farzanegi P, Asadi M, Abdi A, Etemadian M, Amani, M, Amrollah V, Shahri, F, Gholami V, Abdi Z, Moradi L, Ghorbani S, Fallah Z, Wiskemann J, Azarbayjani MA. Swimming exercise in combination with garlic extract administration as a therapy against doxorubicin-induced hepatic, heart and renal toxicity to rats. https://www.tandfonline.com/doi/abs/10.1080/15569543.2018.1559194?journalCode=itxr20
26. Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15.
27. Fasching PA, Schneeweiss A, Kolberg HC, Ettl J, Fehm TN, Overkamp F, Lüftner D. Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Curr Opin Obstet Gynecol. 2019 Feb;31(1):67-75. doi: 10.1097/GCO.0000000000000510.
28. Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda NFDCC, Trajanoski Z. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6.
29. Forster T, Akbaba S, Schmitt D, Krug D, El Shafie R, Oelmann-Avendano J, Lindel K, König L, Arians N, Bernhardt D, Marmé F, Schneeweiss A, Heil J, Sohn C, Debus J, Hörner-Rieber J. Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation. J Contemp Brachytherapy. 2019 Aug;11(4):312-319. doi: 10.5114/jcb.2019.87001. Epub 2019 Aug 29.
30. Forster T, Huettner FJ, Springfeld C, Loehr M, Kalkum E, Hackbusch M, Hackert T, Diener MK, Probst P. Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology. 2020;98(1):53-60. doi: 10.1159/000502844. Epub 2019 Oct 2.
31. Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A. Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care (Basel). 2019 Mar;14(1):53-59. doi: 10.1159/000492580. Epub 2018 Nov 14.
32. Fremd C, Jaeger D, Schneeweiss A. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
33. Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching PA, Gerber B, Bauerfeind I, Nitz U, Lück HJ, Hanusch C, Thomssen C, Untch M, Nekljudova V, Mehta K, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer. 2019 Nov;26(6):826-834. doi: 10.1007/s12282-019-00990-3. Epub 2019 Jun 28.
34. Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic J, Marienfeld RB, Möller P, Völkel G, Kraus JM, Kestler HA, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Doescher J, Hoffmann TK, Pawlita M, Butt J, Waterboer T, Laban S. Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. Int J Cancer. 2019 Dec 15;145(12):3436-3444. doi: 10.1002/ijc.32623. Epub 2019 Aug 26.
35. Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfeld C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Sci Rep. 2019 Mar 13;9(1):4338. doi: 10.1038/s41598-019-40487-9.
36. Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol. 2019 May 8;14(1):36. doi: 10.1186/s13000-019-0813-5.
37. Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer. 2019 Jan;120(1):109-114. doi: 10.1038/s41416-018-0199-2. Epub 2018 Oct 31.
38. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23.
39. Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
40. Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer. 2019 Apr 1;144(7):1697-1703. doi: 10.1002/ijc.32030. Epub 2019 Jan 4.
41. Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb.
42. Halama N. Machine learning for tissue diagnostics in oncology: brave new world. Br J Cancer. 2019 Sep;121(6):431-433. doi: 10.1038/s41416-019-0535-1. Epub 2019 Aug 9.
43. Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D. Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
44. Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267. doi: 10.1055/a-0842-6614. Epub 2019 Mar 12.
45. Haussmann A, Ungar N, Tsiouris A, Sieverding M, Wiskemann J*, Steindorf K*. The influence of cancer patient characteristics on the recommendation of physical activity by healthcare professionals. Int J Behav Med. 2020 Feb;27(1):65-78. doi: 10.1007/s12529-019-09833-z.
46. Heger P, Probst P, Wiskemann J, Steindorf K, Diener MK, Mihaljevic A. A Systematic Review and Meta-analysis of Physical Exercise Prehabilitation in Major Abdominal Surgery (PROSPERO 2017 CRD42017080366). J Gastrointest Surg. 2019 Jun 21. doi: 10.1007/s11605-019-04287-w. [Epub ahead of print]
47. Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford). HPB (Oxford). 2020 Feb;22(2):224-232. doi: 10.1016/j.hpb.2019.06.012. Epub 2019 Jul 30.
48. Heidbuechel JPW, Engeland CE. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J Vis Exp. 2019 Jan 7;(143). doi: 10.3791/58651.
49. Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat. 2019 Jan;173(2):429-438. doi: 10.1007/s10549-018-5009-2. Epub 2018 Oct 12.
50. Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica. 2019 Feb;104(2):e63-e64. doi: 0.3324/haematol.2018.199794. Epub 2018 Aug 31.
51. Idler I, Schickhardt C, Cornelius K, Winkler E. "» Stellungnahme zur Herausgabe genomischer Rohdaten an Patient_innen und Studienteilnehmende« Marsilius-Kolleg, Heidelberg, 2019.
52. Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076.
53. Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J. Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
54. Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.
55. Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
56. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. Recent Advances targeting CCR5 for Cancer and its Role in Immuno-Oncology. Cancer Res. 2019 Oct 1;79(19):4801-4807. doi: 10.1158/0008-5472.CAN-19-1167. Epub 2019 Jul 10. Review.
57. Kather JN, Halama N. Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br J Cancer. 2019 Apr;120(9):871-882. doi: 10.1038/s41416-019-0441-6. Epub 2019 Apr 2. Review.
58. Kather JN, Krisam J, Charoentong P, Luedde T, Herpel E, Weis CA, Gaiser T, Marx A, Valous NA, Ferber D, Jansen L, Reyes-Aldasoro CC, Zörnig I, Jäger D, Brenner H, Chang-Claude J, Hoffmeister M, Halama N. Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. PLoS Med. 2019 Jan 24;16(1):e1002730. doi: 10.1371/journal.pmed.1002730. eCollection 2019 Jan.
59. Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, Trautwein C, Luedde T. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019 Jul;25(7):1054-1056. doi: 10.1038/s41591-019-0462-y. Epub 2019 Jun 3.
60. Kaufmann J, Wentzensen N, Brinker TJ, Grabe N. Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget. 2019 Apr 2;10(26):2515-2529. doi: 10.18632/oncotarget.26808. eCollection 2019 Apr 2.
61. Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfeld C, Schirmacher P, Penzel R, Endris V, Stenzinger A. RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers (Basel). 2019 Sep 5;11(9). pii: E1309. doi: 10.3390/cancers11091309.
62. Klafke N, Mahler C, von Hagens C, Uhlmann L, Bentner M, Schneeweiss A, Mueller A, Szecsenyi J, Joos S. The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial. Cancer Med. 2019 Jul;8(8):3666-3676. doi: 10.1002/cam4.2196. Epub 2019 May 21.
63. Kolberg HC, Schneeweiss A, Fehm TN, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux MP, Janni W, Hartkopf AD, Taran FA, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching PA, Brucker SY. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482. doi: 10.1055/a-0887-0861. Epub 2019 May 21
64. Köppel M, Wiskemann J, Huber G, Eckert K. Körperliches Training vor Krebsoperationen am Gastrointestinaltrakt. link.springer.com/content/pdf/10.1007/s11377-019-0377-7
65. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. ⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.
66. Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer. 2019 Jan 15;19(1):72. doi: 10.1186/s12885-018-5254-0.
67. Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer JU, Costa SD, Denkert C, Ditsch N, Gerber B, Hanusch C, Heil J, Hilfrich J, Huober JB, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Loibl S.
68. Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019 Dec 3. doi: 10.1038/s41375-019-0645-z. [Epub ahead of print]
69. Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm DM, Blohmer JU, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S. evelopment of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res. 2019 May 10;21(1):60. doi: 10.1186/s13058-019-1144-x.
70. Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende CC, Dyckhoff G, Boscolo-Rizzo P, Ezić J, Marienfeld R, Möller P, Kraus JM, Völkel G, Kestler HA, Brunner C, Schuler PJ, Wigand MC, Theodoraki MN, Doescher J, Hoffmann TK, Pawlita M, Waterboer T, Butt J. Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019 Dec 15;25(24):7405-7412. doi: 10.1158/1078-0432.CCR-19-1490. Epub 2019 Aug 23.
71. Liebers R, Jäger D. Surgical wound immunotherapy. Nat Nanotechnol. 2019 Jan;14(1):7-8. doi: 10.1038/s41565-018-0328-3.
72. Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.
73. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.
74. Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17.
75. Matthies LM, Taran FA, Keilmann L, Schneeweiss A, Simoes E, Hartkopf AD, Sokolov AN, Walter CB, Sickenberger N, Wallwiener S, Feisst M, Gass P, Lux MP, Schuetz F, Fasching PA, Sohn C, Brucker SY, Graf J, Wallwiener M. An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for easuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study. J Med Internet Res. 2019 Jan 22;21(1):e10004. doi: 10.2196/10004.
76. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.
77. Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. Breast. 2019 Jun;45:22-28. doi: 10.1016/j.breast.2019.02.002. Epub 2019 Feb 13.
78. Mavratzas A, Seitz J, Smetanay K, Schneeweiss A, Jäger D, Fremd C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol. 2020 Jan;16(3):4439-4453. doi: 10.2217/fon-2019-0468. Epub 2019 Dec 12.
79. Mehlis K, Woydack L, Winkler EC. [Ethical frameworks as a corrective in daily clinical practice? : Reflection on the significance of organizational ethics in tackling the challenges of economization in the medical system]. Med Klin Intensivmed Notfmed. 2019 May 10. doi: 10.1007/s00063-019-0587-2. [Epub ahead of print]
80. Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F. Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score. Breast Cancer Res Treat. 2019 Sep;177(2):437-446. doi: 10.1007/s10549-019-05314-9. Epub 2019 Jun 24.
81. Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F. Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. PLoS One. 2019 Jan 31;14(1):e0211337. doi: 10.1371/journal.pone.0211337. eCollection 2019.
82. Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger D, Schlenk R, Glimm H, Fröhling S, Horak P; DKTK MASTER Network. Community-driven development of a modified progression-free survival ratio for precision oncology. 2019 Nov 13;4(6):e000583. doi: 10.1136/esmoopen-2019-000583. eCollection 2019.
83. Mock A, Zschäbitz S, Kirsten R, Scheffler M, Wolf B, Herold-Mende C, Kramer R, Busch E, Jenzer M, Jäger D, Grüllich C. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunol Immunother. 2019 Dec;68(12):2005-2014. doi: 10.1007/s00262-019-02428-3. Epub 2019 Nov 7.
84. Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.
85. Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2020 Feb;146(2):449-455. doi: 10.1007/s00432-019-03071-2. Epub 2019 Dec 14.
86. Pal A, Zimmer P, Schmidt ME, Hummels M, Ulrich CM, Wiskemann J, Steindorf K. No Evidence for Effect of Exercise on Transcriptome of NK Cells in Breast Cancer Patients Undergoing Adjuvant Therapy: Results From a Pilot Study. Front Physiol. 2019 Jul 25;10:959. doi: 10.3389/fphys.2019.00959. eCollection 2019.
87. Pfuderer PL, Ballhausen A, Seidler F, Stark HJ, Grabe N, Frayling IM, Ager A, von Knebel Doeberitz M, Kloor M, Ahadova A. High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer. Br J Cancer. 2019 Aug;121(5):395-404. doi: 10.1038/s41416-019-0514-6. Epub 2019 Jul 30.
88. Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, Roesch S, Mock A, Sahm F, Schmidt M, Jungwirth G, Zweckberger K, Lamszus K, Gousias K, Kessler AF, Grabe N, Loehr M, Ketter R, Urbschat S, Senft C, Westphal M, Abdollahi A, Debus J, von Deimling A, Unterberg A, Simon M, Herold-Mende CC. Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. Clin Cancer Res. 2019 Sep 1;25(17):5260-5270. doi: 10.1158/1078-0432.CCR-19-0389. Epub 2019 Jun 21.
89. Reul J, Frisch J, Engeland CE, Thalheimer FB, Hartmann J, Ungerechts G, Buchholz CJ. Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Front Oncol. 2019 Feb 14;9:52. doi: 10.3389/fonc.2019.00052. eCollection 2019.
90. Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open. 2019 Aug 20;9(8):e028696. doi: 10.1136/bmjopen-2018-028696. Erratum in: BMJ Open. 2019 Sep 19;9(9):e028696corr1.
91. Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.
92. Ruppert M, Korkmaz-Icöz S, Li S, Brlecic P, Németh BT, Oláh A, Horváth EM, Veres G, Pleger S, Grabe N, Merkely B, Karck M, Radovits T, Szabó G. Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy. Front Physiol. 2019 Jan 8;9:1869. doi: 10.3389/fphys.2018.01869. eCollection 2018.
93. Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Review.
94. Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SL, Kortekaas KE, de Vos van Steenwijk PJ, van Poelgeest MIE, Welters MJP, van der Burg SH. The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. Clin Cancer Res. 2019 Jan 1;25(1):240-252. doi: 10.1158/1078-0432.CCR-18-1749. Epub 2018 Sep 17.
95. Schlenk RF, Jaramillo S, Müller-Tidow C. What's new in consolidation therapy in AML? Semin Hematol. 2019 Apr;56(2):96-101. doi: 10.1053/j.seminhematol.2018.08.005. Epub 2018 Aug 29.
96. Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.
97. Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H. Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.
98. Schlüter K, Schneider J, Sprave T, Wiskemann J, Rosenberger F. Feasibility of two high-intensity interval training protocols in cancer survivors. Med Sci Sports Exerc. 2019 Dec;51(12):2443-2450. doi: 10.1249/MSS.0000000000002081.
99. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
100. Schmidt M, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019 Jul;28(4):e13051. doi: 10.1111/ecc.13051. Epub 2019 Apr 29.
101. Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ. Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
102. Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel). 2019 Dec 10;11(12). pii: E1987. doi: 10.3390/cancers11121987.
103. Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5.
104. Schneider J*, Schlüter K*, Wiskemann J, Rosenberger F. Do we underestimate VO2max in cancer survivors? Findings from a supramaximal verification test. Appl Physiol Nutr Metab. 2019 Oct 11. doi: 10.1139/apnm-2019-0560. [Epub ahead of print]
105. Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
106. Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J, Sohn C, Jaeger D, Schneeweiss A, Marmé F. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):135-143. doi: 10.1007/s10549-018-4983-8. Epub 2018 Sep 25.
107. Sprave T, Scharhag-Rosenberger F, Verma V, Förster R, Bruckner T, Schlampp I, Bostel T, Welzel T, Akbaba S, Rackwitz T, Nicolay NH, Grosu AL, Wiskemann J, Debus J, Rief H. Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Trial. Cancers (Basel). 2019 Nov 11;11(11). pii: E1771. doi: 10.3390/cancers11111771.
108. Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. doi: 10.1016/j.lpm.2019.02.025. Epub 2019 Mar 15. Review.
109. Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Schuetz F, Sohn C, Bohlmann MK, Sütterlin M, Schneeweiss A, Wallwiener M. Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers (Basel). 2019 Mar 11;11(3). pii: E342. doi: 10.3390/cancers11030342.
110. Steindorf K, Clauss D, Tjaden C, Hackert T, Schneider L, Ulrich CM, Wiskemann J. Quality of Life, Fatigue, and Sleep Problems in Pancreatic Cancer Patients - A Randomized Trial on the Effects of Exercise. Dtsch Arztebl Int. 2019 Jul 8;116(27-28):471-478. doi: 10.3238/arztebl.2019.0471.
111. Steindorf K, Depenbusch J, Haussmann A, Tsiouris A, Schmidt L, Herrmann S, Sieverding M, Wiskemann J*, Ungar N*. Change patterns and determinants of physical activity differ between breast, prostate and colorectal cancer patients. Support Care Cancer. 2019 Nov 22. doi: 10.1007/s00520-019-05097-1. [Epub ahead of print]
112. Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28.
113. Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019.
114. Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2019 Aug 1;30(8):1404. doi: 10.1093/annonc/mdy538.
115. Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM. Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.
116. Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30.
117. Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152.
118. Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, deGregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C. Response to Di Cosimo, Torri, and Porcu. J Natl Cancer Inst. 2019 Nov 1;111(11):1234-1235. doi: 10.1093/jnci/djz095. No abstract available.
119. Tsingos E, Höckendorf B, Sütterlin T, Kirchmaier S, Grabe N, Centanin L, Wittbrodt J. Retinal stem cells modulate proliferative parameters to coordinate post-embryonic morphogenesis in the eye of fish. Elife. 2019 Mar 26;8. pii: e42646. doi: 10.7554/eLife.42646.
120. Ungar N, Rupprecht FS, Steindorf K, Wiskemann J, Sieverding M. Worse or even better than expected? Outcome expectancies and behavioral experiences in the context of physical activity among cancer patients. J Health Psychol. 2019 Mar 11:1359105319832345. doi: 10.1177/1359105319832345. [Epub ahead of print]
121. Ungar N, Schmidt L, Gabrian M, Haussmann A, Tsiouris A, Sieverding M, Steindorf K*, Wiskemann J*. Which self-management strategies do health care professionals recommend to their cancer patients? An experimental investigation of patient age and treatment phas. J Behav Med. 2019 Apr;42(2):342-352. doi: 10.1007/s10865-018-9980-1. Epub 2018 Oct 23. *shared last authorship
122. Ungar N, Tsiouris A, Haussmann A, Herbolsheimer F, Steindorf K, Wiskemann J, Sieverding M. To rest or not to rest-Health care professionals' attitude toward recommending physical activity to their cancer patients. Psychooncology. 2019 Apr;28(4):784-791. doi: 10.1002/pon.5020. Epub 2019 Feb 20.
123. Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019 Sep 1;37(25):2226-2234. doi: 10.1200/JCO.18.01842. Epub 2019 May 13.
124. Untch M, Schneeweiss A, Krug D, Kühn T, Loibl S. Post-Neoadjuvant Therapy. Breast Care (Basel). 2019 Dec;14(6):409-413. doi: 10.1159/000504661. Epub 2019 Nov 27.
125. Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14.
126. Vallet S, Fan F, Malvestiti S, Pecherstorfer M, Sattler M, Schneeweiss A, Schulze-Bergkamen H, Opferman JT, Cardone MH, Jäger D, Podar K. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Res Treat. 2019 Feb;173(3):585-596. doi: 10.1007/s10549-018-5022-5. Epub 2018 Oct 29.
127. van Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, May AM, Buffart LM. Moderators of effects of exercise on cancer-related fatigue: meta-analysis of individual patient data.
128. von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). Phytomedicine. 2019 Feb 15;54:140-148. doi: 10.1016/j.phymed.2018.09.178. Epub 2018 Sep 17.
129. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
130. Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN. Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.
131. Wiskemann J*, Clauss D*, Tjaden C, Hackert T, Schneider L, Ulrich CM, Steindorf K. Progressive Resistance Training to Impact Physical Fitness and Body Weight in Pancreatic Cancer Patients. Pancreas. 2019 Feb;48(2):257-266. doi: 10.1097/MPA.0000000000001221. *shared first authorship.
132. Wiskemann J, Köppel M, Biazeck B. Sport und Bewegung nach Krebstherapie – OnkoAktiv als ein Beispiel. https://link.springer.com/article/10.1007/s11377-019-0376-8
133. Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, Winkler EC. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications
134. Yuan B, Schafferer S, Tang Q, Scheffler M, Nees J, Heil J, Schott S, Golatta M, Wallwiener M, Sohn C, Koal T, Wolf B, Schneeweiss A, Burwinkel B. A plasma metabolite panel as biomarkers for early primary breast cancer detection. Int J Cancer. 2019 Jun 1;144(11):2833-2842. doi: 10.1002/ijc.31996. Epub 2019 Jan 4.
135. Zimmer P, Schmidt M, Berdel B, Wiskemann J, Kellner KH, Debus J, Ulrich CM, Opitz A, Steindorf K. Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy. Front Oncol. 2019 Sep 25;9:962. doi: 10.3389/fonc.2019.00962. eCollection 2019.

1.    Adler D, Kriegsmann M, Sinn P, Schneeweiss A, Almansour H, Lehner B, Akbar M. Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies. Orthopade. 2018 Jul;47(7):594-603. doi: 10.1007/s00132-018-3540-9. German.

2.    Al-Saeedi M, Steinebrunner N, Kudsi H, Halama N, Mogler C, Büchler MW, Krammer PH, Schemmer P, Müller M. Neutralization of CD95 ligand protects theliver against ischemia-reperfusion injury and prevents acute liver failure. Cell Death Dis. 2018 Jan 26;9(2):132. doi: 10.1038/s41419-017-0150-0. PubMed PMID: 29374146; PubMed Central PMCID: PMC5833836.

3.    Alunni-Fabbroni M, Majunke L, Trapp EK, Tzschaschel M, Mahner S, Fasching PA, Fehm T, Schneeweiss A, Beck T, Lorenz R, Friedl TWP, Janni W, Rack B; SUCCESS Study Group. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. BMC Cancer. 2018 Feb 6;18(1):141. doi: 10.1186/s12885-018-4020-7.

4.    Apostolidis L, Nientiedt C, Winkler ERC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik C, Distler FA, Grüllich C. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget, 2019, Vol. 10, (No. 1), pp: 17-29.

5.    Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, Jäger D, Schirmacher P, Stremmel W, Schulze-Bergkamen H, Springfeld C, Weiss KH. Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointest Tumors. 2018 Sep;5(1-2):38-46. doi: 10.1159/000487635. Epub 2018 Apr 11. PubMed PMID: 30574480; PubMed Central PMCID: PMC6288626.

6.    Bärtsch, MA., Kriegsmann, K., Pavel, P., Bruckner, T., Hundemer, M., Kriegsmann, M., Ho, AD., Goldschmidt, H., Wuchter, P. Platelet count before peripheral blood stem cell mobilization is associated with the need for plerixafor but not with the collection result. Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.

7.    Baertsch, MA:, Hillengass, J., Blocka, J., Schönland, S., Hegenbart, U., Goldschmidt, H., Raab, MS. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. Hematol Oncol. 2018 Feb;36(1):210-216. doi: 10.1002/hon.2462. Epub 2017 Jul 7.

8.    Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group. Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. Breast Cancer Res Treat. 2018 Oct;171(3):571-580. doi: 10.1007/s10549-018-4856-1. Epub 2018 Jun 21.

9.    Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V. Does exercise have a preventive effect on a secondary lymphedema in breast cancer patients following medical treatment? - A systematic review. Breast Care (Basel). 2018 Oct;13(5):380-385. doi: 10.1159/000487428. Epub 2018 May 3.

10.    Berger AK, Lücke St, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2. PMID: 29961759

11.    Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer. 2018 Mar;21(2):303-314. doi: 10.1007/s10120-017-0746-1. Epub 2017 Jul 6. PMID: 28685209.

12.    Bringhen, S., Milan, A., Ferri, C., Wäsch, R., Gay, F., Larocca, A., Salvini, M., Terpos, E., Goldschmidt, H., Cavo, M., Petrucci, MT., Ludwig, H., Auner, HW., Caers, J., Gramatzki, M., Boccadoro, M., Einsele, H., Sonneveld, P., Engelhardt, M. Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26.

13.    Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T., Robert, N., Requirand, G., Boireau, S., Müller-Tidow, C., Veyrune JL., Vincent, L., Bouhya, S., Goldschmidt, H., Vanderkerken, K., Hose, D., Klein, B., DeBruyne, E., Moreaux, J. DNMTi/HDACi combined epigenetic targeted treatment induces reporgramming of myeloma cells in the direction of normal plasma cells. Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

14.    Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC,  Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Brug J, Courneya KS. Targeting exercise interventions to patients with cancer in need: results from an individual patient data meta-analysis. J Natl Cancer Inst. 2018 Nov 1;110(11):1190-1200. doi: 10.1093/jnci/djy161.

15.    Caers, J., Garderet, L., Kortüm, KM., O'Dwyer, ME., van de Donk, NWCJ., Binder, M., Dold, SM., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, MA., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., Goldschmidt, H., Sonneveld, P., Delforge, M., Auner, HW., Terpos, E., Engelhardt, M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

16.    Campo, C., da Silva Filho, M.I., Weinhold, N., Mahmoudpour, S.H., Goldschmidt, H., Hemminki, K., Merz, M., Försti, A. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients. Hematol Oncol. 2018 Feb;36(1):232-237. doi: 10.1002/hon.2391. Epub 2017 Mar 20.

17.    Cao X, Tang Q, Holland-Letz T, Gündert M, Cuk K, Schott S, Heil J, Golatta M, Sohn C, Schneeweiss A, Burwinkel B. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. Int J Mol Sci. 2018 Mar 19;19(3). pii: E900. doi: 10.3390/ijms19030900.

18.    Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16.

19.    Colombo M, Lòpez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, Tudini E, Foglia C, Mondini P, Manoukian S, Behar R, Garcia EBG, Meindl A, Montagna M, Niederacher D, Schmidt AY, Varesco L, Wappenschmidt B, Bolla MK, Dennis J, Michailidou K, Wang Q, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadel A, Benitez J, Boeckx B, Bogdanova NV, Bojesen SE, Bonanni B, Brauch H, Brenner H, Burwinkel B, Chang-Claude J, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Eriksson M, Fasching PA, Figueroa J, Fletcher O, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hauke J, Hollestelle A, Hopper JL, Jakubowska A, Jung A, Kosma VM, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Mannermaa A, Margolin S, Miao H, Milne RL, Neuhausen SL, Nevanlinna H, Olson JE, Peterlongo P, Peto J, Pylkäs K, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, See MH, Southey MC, Swerdlow A, Teo SH, Toland AE, Tomlinson I, Truong T, van Asperen CJ, van den Ouweland AMW, van der Kolk LE, Winqvist R, Yannoukakos D, Zheng W; kConFab/AOCS Investigators, Dunning AM, Easton DF, Henderson A, Hogervorst FBL, Izatt L, Offitt K, Side LE, van Rensburg EJ, Embrace S, Hebon S, McGuffog L, Antoniou AC, Chenevix-Trench G, Spurdle AB, Goldgar DE, Hoya M, Radice P. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat. 2018 May;39(5):729-741. doi: 10.1002/humu.23411. Epub 2018 Apr 6.

20.    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.

21.    Dieffenbacher S, Zschäbitz St, Hofer L, Hatiboglu G, Hou W, Hohenfellner M, Duensing St, Sültmann H, Pahernik S, Grüllich C. Prospective, single center trial of next generation sequencing analysis in metastatic renal cell cancer: The MORE-TRIAL. Future Science 14 March 2018.

22.    Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15.

23.    Fasching PA, Schneeweiss A, Kolberg HC, Ettl J, Fehm TN, Overkamp F, Lüftner D. Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Curr Opin Obstet Gynecol. 2019 Feb;31(1):67-75. doi: 10.1097/GCO.0000000000000510.

24.    Fremd C, Jaeger D, Schneeweiss A. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. Expert Rev Anticancer Ther. 2018 Oct 23:1-14. doi: 10.1080/14737140.2019.1537785. [Epub ahead of print].

25.    Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L, Erber R, Hein A, Jud SM, Lux MP, Hack CC, Hartmann A, Kolberg HC, Ettl J, Lüftner D, Jackisch C, Beckmann MW, Janni W, Schneeweiss A, Fasching PA, Nabieva N. Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. Geburtshilfe Frauenheilkd. 2018 Jul;78(7):707-714. doi: 10.1055/a-0642-9462. Epub 2018 Jul 25.

26.    Gay, F., Engelhardt, M., Terpos, E., Wäsch, R., Giaccone, L., Auner, HW., Caers, J.,  Gramatzki, M., van de Donk, N., Oliva, S., Zamagni, E., Garderet, L., Straka, C., Hajek, R., Ludwig, H., Einsele, H., Dimopoulos, M., Boccadoro, M., Kröger, N., Cavo, M., Goldschmidt, H., Bruno, B., Sonneveld, P. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7.

27.    Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

28.    Goldschmidt, H., Lokhorst, HM., Mai, EK., van der Holt, B., Blau, IW., Zweegman, S., Weisel, KC., Vellenga, E., Pfreundschuh, M., Kersten, MJ., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, MS., Broijl, A., Lindemann, HW., Bos, GMJ., Brossart, P., van Marwijk Kooy, M., Ypma, P., Duehrsen, U., Schaafsma, RM., Bertsch, U., Hielscher, T., Jarari, L., Salwender, HJ., Sonneveld, P. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

29.    Goldschmidt, H. Multiples Myelom (MM, Plasmozytom), in: Honecker, F., Claßen, J., Preiß, J., Dornoff, W. Onkologie 2018/19. Interdisziplinäre Empfehlungen zur Therapie. Zuckschwerdt Verlag 19. Auflage 52-58.

30.    Goldschmidt, H., (Plasmazellneoplasie) in: Karl-Anton Kreuzer: Referenz Hämatologie. Verlag Georg Thieme 2018, 438-442.

31.    Grüllich C. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Small Molecules in Oncology, pp 67-75. 2 August 2018.

32.    Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018 Feb;90:122-129. doi: 10.1016/j.ejca.2017.12.001. Epub 2018 Jan 5. PubMed PMID: 29306769.

33.    Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb.

34.    Halama N. Macrophage repolarisation therapy in colorectal cancer. ESMO Open. 2018 Aug 3;3(5):e000426. doi: 10.1136/esmoopen-2018-000426. eCollection 2018. PubMed PMID: 30116595; PubMed Central PMCID: PMC6088340.

35.    Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast. 2018 Feb;37:42-51. doi: 10.1016/j.breast.2017.10.002. Epub 2017 Oct 26.

36.    Haussmann A, Ungar N, Gabrian M, Tsiouris A, Sieverding M, Wiskemann J, Steindorf K. Are healthcare professionals being left in the lurch? The role of structural barriers and information resources to promote physical activity to cancer patients. Support Care Cancer. 2018 Dec;26(12):4087-4096. doi: 10.1007/s00520-018-4279-x. Epub 2018 Jun 23.

37.    Haussmann A, Gabrian M, Ungar N, Jooß S, Wiskemann, J, Sieverding M, Steindorf K. What hinders health care professionals in promoting physical activity towards cancer patients? The influencing role of concerns, patient characteristics and structural factors. Eur J Cancer Care (Engl). 2018 Jul;27(4):e12853. doi: 10.1111/ecc.12853. Epub 2018 May 9.

38.    Hecksteden A, Pitsch W, Rosenberger F, Meyer T. Repeated testing for the assessment of individual response to exercise training. Journal of Applied Physiology, 124(6):1567-1579, 2018.

39.    Heger U, Sisic L, Nienhüser H, Blank S, Hinz U, Haag GM, Ott K, Ulrich A, Büchler MW, Schmidt T. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas. Ann Surg Oncol. 2018 Aug;25(8):2418-2427. doi: 10.1245/s10434-018-6541-3. Epub 2018 May 31. PMID: 29855828

40.    Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K,Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub2018 May 25. PubMed PMID: 29802158.

41.    Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat. 2019 Jan;173(2):429-438. doi: 10.1007/s10549-018-5009-2. Epub 2018 Oct 12.

42.    Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076.

43.    Insua-Rodríguez J, Pein M, Hongu T, Meier J, Descot A, Lowy CM, De Braekeleer E, Sinn HP, Spaich S, Sütterlin M, Schneeweiss A, Oskarsson T. Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Mol Med. 2018 Oct;10(10). pii: e9003. doi: 10.15252/emmm.201809003.

44.    Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.

45.    Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, OhDY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi:10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. PubMed PMID: 29182496; PubMed CentralPMCID: PMC6075847.

46.    Kather JN, Berghoff AS, Ferber D, Suarez-Carmona M, Reyes-Aldasoro CC, Valous NA, Rojas-Moraleda R, Jäger D, Halama N. Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. Oncoimmunology. 2018 Mar 29;7(7):e1444412. doi: 10.1080/2162402X.2018.1444412. eCollection 2018.  PubMed PMID: 29900054; PubMed Central PMCID: PMC5993505.

47.    Kather JN, Charoentong P, Suarez-Carmona M, Herpel E, Klupp F, Ulrich A, Schneider M, Zoernig I, Luedde T, Jaeger D, Poleszczuk J, Halama N. High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer. Cancer Res. 2018 Sep 1;78(17):5155-5163. doi: 10.1158/0008-5472.CAN-18-1126. Epub 2018 Jul 2.

48.    Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, Schott S, Zörnig I, Utikal J, Marx A, Gaiser T, Brenner H, Chang-Claude J, Hoffmeister M, Jäger D, Halama N. Topography of cancer-associated immune cells in human solid tumors. Elife. 2018 Sep 4;7. pii: e36967. doi: 10.7554/eLife.36967.

49.    Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol. 2018 Oct;52(Pt 2):189-197. doi: 10.1016/j.semcancer.2018.02.010. Epub 2018 Mar 1. Review. PubMed PMID: 29501787.

50.    Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing St. Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, Volume 8, Article number: 16708 (2018).

51.    Köhler BC, Goeppert B, Waldburger N, Schlamp K, Sauer P, Jäger D, Weiss KH, Macher-Göppinger S, Schulze-Bergkamen H, Schirmacher P, Springfeld C. An undifferentiated carcinoma at Klatskin-position with long-term complete remissionafter chemotherapy. Oncotarget. 2018 Apr 24;9(31):22230-22235. doi:10.18632/oncotarget.25125. eCollection 2018 Apr 24. PubMed PMID: 29774134; PubMedCentral PMCID: PMC5955137.

52.    Kriegsmann, K., Dittrich, T., Neuber, B., Awwad MHS., Hegenbart, U., Goldschmidt, H., Hillengass, J., Hose, D., Seckinger, A., Müller-Tidow, C., Ho, AD., Schönland, S., Hundemer, M. Quantification of Number of CD38 Sites on Bone Marrow Plasma Cells in Patients with Light Chain Amyloidosis and Smoldering Multiple Myeloma. Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.

53.    Kriegsmann, K., Kriegsmann, M., Cremer, M., Schmitt, M., Dreger, P., Goldschmidt, H., Müller-Tidow, C., Hundemer, M. Cell-based Immunotherapy approaches for multiple myeloma. Br J Cancer. 2019 Jan;120(1):38-44. doi: 10.1038/s41416-018-0346-9. Epub 2018 Dec 6. Review.

54.    Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux MP. Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? Cancer Manag Res. 2018 Nov 8;10:5423-5431. doi: 10.2147/CMAR.S177240. eCollection 2018.

55.    Larocca, A., Dold, SM., Zweegman, S., Terpos, E., Wäsch, R., D'Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., Ludwig, H., Straka, C., Bringhen, S., Auner, HW., Caers, J., Gramatzki, M., Offidani, M., Dimopoulos, MA., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25.

56.    Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfeld C, Jäger D, von Kalle C, Ungerechts G. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites. Mol TherOncolytics. 2018 Apr 12;9:30-40. doi: 10.1016/j.omto.2018.04.002. eCollection 2018 Jun 29. PubMed PMID: 29988512; PubMed Central PMCID: PMC6026446.

57.    Lehners, N., Ellert, E., Xu, J., Hillengass, J., Leichsenring, J., Stenzinger, A., Goldschmidt, H., Andrulis, M., Raab MS. Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders. 2018. Leuk Lymphoma. 2018 Nov;59(11):2660-2669. doi: 10.1080/10428194.2018.1443450. Epub 2018 Apr 4.

58.    Lehners, N., Becker, N., Benner, A., Pritsch, M., Löpprich, M., Mai, EK.,  Hillengass, J., Goldschmidt, H., Raab, MS. Analysis of long-term  survival in multiple myeloma after first-line autologous stem cell transplantation:  impact of  clinical risk factors and sustained response. Cancer Med. 2018 Feb;7(2):307-316. doi: 10.1002/cam4.1283. Epub 2017 Dec 28.

59.    Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018 Dec 1;29(12):2341-2347. doi: 10.1093/annonc/mdy460.

60.    Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet- Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, MA.,  San-Miguel, JF., Terpos, E., Zweegman, S., Garderet, L., Mateos, MV., Cook, G.,  Leleu, X., Goldschmidt, H., Jackson, G., Kaiser, M., Weisel, K., van de Donk,  NWCJ., Waage, A., Beksac, M., Mellqvist, UH., Engelhardt, M., Caers, J.,  Driessen, C., Sonneveld, P. Prevention and management of adverse events of  Novel agents in multiple myeloma: A consensus of the European myeloma  network. Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

61.    Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Schneeweiss A, Brucker SY. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel). 2018 Dec 21;11(1). pii: E10. doi: 10.3390/cancers11010010.

62.    Maatouk, I., Goldschmidt, H., Hillengaß, J. Multiples Myelom und seine Vorstufen. Der Onkologe, Vol. 24, 625-631.

63.    Mackelenbergh MT van, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2018 Jan;167(1):59-71. doi: 10.1007/s10549-017-4480-5. Epub 2017 Sep 5.

64.    Mateos, MV., Goldschmidt, H., San-Miguel, J., Mikhael, J., DeCosta, L., Zhou, L., Obreja, M., Blaedel, J., Szabo, Z., Leleu, X. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy:  A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15

65.    Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.

66.    Mehlis K, Bierwirth E, Laryionava K, Mumm FH, Hiddemann W, Heußner P, Winkler EC (2018). „High prevalence of moral distress reported by oncologists and oncology nurses in end-of-life decision making” Psychooncology. 2018 Dec;27(12):2733-2739. doi: 10.1002/pon.4868.

67.    Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi  S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I. Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018. PubMed PMID: 29872552; PubMed Central PMCID: PMC5980408.

68.    Minckwitz G von, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, Di Giovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. KATHERINE Investigators.N N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.

69.    Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C; AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018 Jan 1;29(1):178-185. doi: 10.1093/annonc/mdx690.

70.    Moisan A, Michielin F, Jacob W, Kronenberg S, Wilson S, Avignon B, Gérard R, Benmansour F, McIntyre C, Meneses-Lorente G, Hasmann M, Schneeweiss A, Weisser M, Adessi C. Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Mol Cancer Ther. 2018 Jul;17(7):1464-1474. doi: 10.1158/1535-7163.MCT-17-1268. Epub 2018 Apr 13.

71.    Montfoort N van, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell 175 (7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29

72.    Mosebach, J., Shah, S., Delorme, S., Hielscher, T., Goldschmidt, H., Schlemmer, HP., Schönland, SO., Hegenbart, U., Hillengass, J. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica. Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7.

73.    Müller V, Nabieva N, Häberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lüftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Wallwiener M. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast. 2018 Feb;37:154-160. doi: 10.1016/j.breast.2017.08.008. Epub 2017 Dec 10.

74.    Müller V, Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Hadji P, Tesch H, Ettl J, Lüftner D, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Schneeweiss A, Overkamp F. Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1119-1128. doi: 10.1055/a-0715-2899. Epub 2018 Nov 26.

75.    Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewitz B, Trumpp A,Eils R, Werner J, Friess H, Esposito I, Klöppel G, Ceyhan GO, Jesinghaus M, Denkert C, Bahra M, Stenzinger A, Sprick MR, Jäger D, Springfeld C, Weichert W. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers HepatocyteNuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and TreatmentResponse. Clin Cancer Res. 2018 Jan 15;24(2):351-359. doi:10.1158/1078-0432.CCR-17-2180. Epub 2017 Nov 3. PubMed PMID: 29101303.

76.    Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Glück S, Crane R, Li H, Luo X. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). Contemp Clin Trials. 2018 Aug;71:194-198. doi: 10.1016/j.cct.2018.06.016. Epub 2018 Jun 26.

77.    Palm V, Sheng R, Mayer P, Weiss KH, Springfeld C, Mehrabi A, Longerich T, Berger AK, Kauczor HU, Weber TF. Imaging features of fibrolamellar hepatocellularcarcinoma in gadoxetic acid-enhanced MRI. Cancer Imaging. 2018 Mar 1;18(1):9.doi: 10.1186/s40644-018-0143-y. PubMed PMID: 29490696; PubMed Central PMCID:PMC5831838.

78.    Papageorgiou IE, Valous NA, Lahrmann B, Janova H, Klaft ZJ, Koch A, Schneider UC, Vajkoczy P, Heppner FL, Grabe N, Halama N, Heinemann U, Kann O. Astrocytic glutamine synthetase is expressed in the neuronal somatic layers and down-regulated proportionally to neuronal loss in the human epileptic hippocampus. Glia. 2018 May;66(5):920-933. doi: 10.1002/glia.23292. Epub 2018 Jan 19. PubMed PMID: 29350438.

79.    Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing St. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urologic Oncology Volume 36, Issue 8, August 2018, Pages 365.e15-365.e26.

80.    Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, Rezai M, Dohnal K, Tesch H, Hansmann ML, Salat C, Beer M, Schneeweiss A, Sinn P, Bankfalvi A, Darb-Esfahani S, von Minckwitz G, Sinn BV, Kronenwett R, Weber K, Denkert C, Loibl S. Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol. 2018 Apr;31(4):607-615. doi: 10.1038/modpathol.2017.171. Epub 2017 Dec 22.

81.    Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, Hillengass J, Halama N, Neuber B, Müller-Tidow C, Goldschmidt H, Hundemer M. IL-10 inducible CD8(+) regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20. PubMed PMID: 30128739.

82.    Quandt, J, Schlude C, Bartoschek, M, Will, M, Cid-Arregui, A, Wiemann, S, Momburg, F, and Beckhove, P. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018 Sep 21;7(12):e1500671. doi: 10.1080/2162402X.2018.1500671. eCollection 2018.

83.    Rölle, A., Meyer, M., Calderazzo, S., Jäger, D., and Momburg, F. Distinct HLA-E peptide complexes modify antibody-driven effector functions of adaptive NK cells. Cell Rep. 24: 1967-1976, 2018.

84.    Rölle A, Jäger D, Momburg F. HLA-E peptide repertoire and dimorphism-centerpieces in the adaptive NK cell puzzle? Front. Immunol. 9: 2410, 2018.

85.    Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SL, Kortekaas KE, de Vos van Steenwijk PJ, van Poelgeest MIE, Welters MJP, van der Burg SH. The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1749.

86.    Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

87.    Schmidt ME, Wiskemann J, Schneeweiss A, Potthoff K, Ulrich CM, Steindorf K. Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. Int J Cancer. 2018 Mar 15;142(6):1148-1157. doi: 10.1002/ijc.31138. Epub 2017 Nov 13.

88.    Schmidt ME, Wiskemann J, Johnson T, Habermann N, Schneeweiss A, Steindorf K. L-Thyroxine intake as a potential risk factor for the development of fatigue in breast cancer patients undergoing chemotherapy. Support Care Cancer. 2018 Aug;26(8):2561-2569. doi: 10.1007/s00520-018-4095-3. Epub 2018 Feb 14.

89.    Schmidt M, Wiskemann J, Steindorf K. Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res. 2018 Aug;27(8):2077-2086. doi: 10.1007/s11136-018-1866-8. Epub 2018 May 8.

90.    Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H,Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boostvaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients withadvanced pancreatic cancer. Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi:10.1080/2162402X.2017.1303584. eCollection 2018. PubMed PMID: 29632710; PubMedCentral PMCID: PMC5889207.

91.    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018 Jan;89:27-35. doi: 10.1016/j.ejca.2017.10.021. Epub 2017 Dec 8.

92.    Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

93.    Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

94.    Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5.

95.    Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W, Friedl TWP; SUCCESS Study Group. Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. Oncol Res Treat. 2018;41(3):93-98. doi: 10.1159/000485566. Epub 2018 Feb 27.

96.    Seufert R, Sedlacek L, Kahl B, Hogardt M, Hamprecht A, Haase G, Gunzer F, Haas A, Grauling-Halama S, MacKenzie CR, Essig A, Stehling F, Sutharsan S, Dittmer S, Killengray D, Schmidt D, Eskandarian N, Steinmann E, Buer J, Hagen F, Meis JF, Rath PM, Steinmann J. Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany. J Antimicrob Chemother. 2018 Aug 1;73(8):2047-2053. doi: 10.1093/jac/dky147.

97.    Siegel, DS., Dimopoulos, MA., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., San-Miguel, J., Obreja, M., Blaedel, J., Stewart, AK. Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.

98.    Sisic L, Strowitzki MJ, Blank S, Nienhueser H, Dorr S, Haag GM, Jäger D, Ott K, Büchler MW, Ulrich A, Schmidt T. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric Cancer. 2018 May;21(3):552-568. doi: 10.1007/s10120-017-0751-4. Epub 2017 Jul 24. PMID: 28741059

99.    Sisic L, Blank S, Nienhüser H, Dorr S, Haag GM, Jäger D, Bruckner T, Müller-Stich BP, Ott K, Büchler MW, Ulrich A, Schmidt T. Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment. Eur J Surg Oncol. 2018 Oct;44(10):1646-1656. doi: 10.1016/j.ejso.2018.06.030. Epub 2018 Jul 7. PMID: 30082176

100.    Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J, Sohn C, Jaeger D, Schneeweiss A, Marmé F. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2018 Sep 25. doi: 10.1007/s10549-018-4983-8. [Epub ahead of print]

101.    Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors. Clin Cancer Res. 2018 May 1;24(9):2128-2137. doi: 10.1158/1078-0432.CCR-17-2651. Epub 2018 Feb 6.

102.    Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

103.    Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2018 Jul 1;29(7):1607. doi: 10.1093/annonc/mdx802. No abstract available.

104.    Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvão DA, Garrod R, Griffith KA, von Harten WH, Hayes S, Herrero-Roman F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke GS, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chinapaw MJ, Buffart LM. Moderators of the exercise effects on physical fitness in patients with cancer: a meta-analysis of individual patient data. Br J Sports Med. 2018 Sep 4. pii: bjsports-2018-099191. doi: 10.1136/bjsports-2018-099191. [Epub ahead of print]

105.    Taran FA, Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Fasching PA, Fehm TN, Schütz F. Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):237-245. doi: 10.1055/s-0044-101613. Epub 2018 Mar 21.

106.    Terpos, E., Suzan, F., Goldschmidt, H. Going the Distance:  Are we losing patients along the multiple myeloma treatment pathway? Crit Rev Oncol Hematol. 2018 Jun;126:19-23. Doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29.

107.    Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30.

108.    Titz C, Hummler S, Schmidt M, Thomas M, Steins M, Wiskemann J. Exercise Behavior and Physical Fitness in Patients with Advanced Lung Cancer. Support Care Cancer. 2018 Aug;26(8):2725-2736. doi: 10.1007/s00520-018-4105-5. Epub 2018 Feb 26.

109.    Toberer F, Enk A, Hartschuh W, Grüllich C. Testicular chorio-carcinoma with cutaneous metastasis in a 19-year-old man. Journal of Cutaneous Pathology. J Cutan Pathol. 2018 Jul;45(7):535-538. doi: 10.1111/cup.13261. Epub 2018 May 16..

110.    Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2018 Oct 11. doi: 10.1093/jnci/djy152. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152. [Epub ahead of print].

111.    Tsiouris A, Ungar N, Gabrian M, Haussmann A, Sieverding M, Steindorf K, Wiskemann, J. Health-care professionals’ perception of contraindications for physical activity during cancer treatment. Front. Oncol. 8:98. doi: 10.3389/fonc.2018.00098

112.    Ungar N, Schmidt L, Gabrian M, Haussmann A, Tsiouris A, Sieverding M, Steindorf K*, Wiskemann J. Which self-management strategies do health care professionals recommend to their cancer patients? An experimental investigation of patient age and treatment phas. J Behav Med. 2019 Apr;42(2):342-352. doi: 10.1007/s10865-018-9980-1. Epub 2018 Oct 23.

113.    Vallet S, Fan F, Malvestiti S, Pecherstorfer M, Sattler M, Schneeweiss A, Schulze-Bergkamen H, Opferman JT, Cardone MH, Jäger D, Podar K. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Res Treat. 2019 Feb;173(3):585-596. doi: 10.1007/s10549-018-5022-5. Epub 2018 Oct 29.

114.    Valous NA, Xiong W, Halama N, Zörnig I, Cantre D, Wang Z, Nicolai B, Verboven P, Rojas Moraleda R. Multilacunarity as a spatial multiscale multi-mass morphometric of change in the meso-architecture of plant parenchyma tissue. Chaos. 2018 Sep;28(9):093110. doi: 10.1063/1.5047021. PubMed PMID: 30278622.

115.    Vulpen JK van, Schmidt ME, Velthuis MJ, Wiskemann J, Schneeweiss A, Vermeulen RCH, Habermann N, Ulrich CM, Peeters PHM, van der Wall E, May AM, Steindorf K. Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy. Breast Cancer Res Treat. 2018 Apr;168(2):421-431. doi: 10.1007/s10549-017-4608-7. Epub 2017 Dec 12.

116.    Waldenfels G von, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, Kümmel S, von Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018 Feb 26;9(20):15168-15179. doi: 10.18632/oncotarget.24586. eCollection 2018 Mar 16.

117.    Walker, BA., Mavrommatis, K., Wardell, CP., Ashby, TC., Bauer, M., Davies, FE., Rosenthal, A., Wang, H., Qu, P., Hoering, A., Samur, M., Towfic, F., Ortiz, M., Flynt, E., Yu, Z., Yang, Z., Rozelle, D., Obenauer, J., Trotter, M., Auclair, D., Keats, J., Bolli, N., Fulciniti, M., Szalat, R., Moreau, P., Durie, B., Stewart, AK., Goldschmidt, H., Raab, MS., Einsele, H., Sonneveld, P., San Miguel, J., Lonial, S., Jackson, GH., Anderson, KC., Avet-Loiseau, H., Munshi, N., Thakurta, A., Morgan, GJ. Identification of novel mutational drivers reveals oncogene dependenices in multiple myeloma. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8.

118.    Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S. Genomic features of renal cell carcinoma with venous tumor thrombus. Scientific Reports volume 8, 10 May 2018.

119.    Weber, D., Knaak, S., Hettrich, K., Andrulis, M,. Momburg, F., Quade, M., Gelinsky, M., and Schwartz-Albiez, R. Influence of regioselectively sulfated cellulose on in vitro vascularization of biomimetic bone matrices. Biomacromolecules 19: 4228-4238, 2018.

120.    Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer. Clin Cancer Res. 2018 Feb 1;24(3):634-647. doi: 10.1158/1078-0432.CCR-17-2140. Epub 2017 Oct 10.

121.    Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann PU, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching PA, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M. . Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd. 2018 Oct;78(10):927-948. doi: 10.1055/a-0646-4522. Epub 2018 Oct 19.

122.    Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, Jírů-Hillmann S, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching P, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1056-1088. doi: 10.1055/a-0646-4630. Epub 2018 Nov 26.

123.    Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Schneeweiss A, Kolberg HC. Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1110-1118. doi: 10.1055/a-0715-2821. Epub 2018 Nov 26.

124.    Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng TD, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghoussaini M, Giles GG, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo WY, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, Mavroudis D, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott CG, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar RAEM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E; kConFab/AOCS Investigators, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018 Jul;50(7):968-978. doi: 10.1038/s41588-018-0132-x. Epub 2018 Jun 18.

125.    Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.

126.    Yuan B, Schafferer S, Tang Q, Scheffler M, Nees J, Heil J, Schott S, Golatta M, Wallwiener M, Sohn C, Koal T, Wolf B, Schneeweiss A, Burwinkel B. A plasma metabolite panel as biomarkers for early primary breast cancer detection. Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31996. Volume144, Issue11 1 June 2019 Pages 2833-2842 [Epub ahead of print].

127.    Zschäbitz St, Distler FA, Krieger B, Wuchter P, Schäfer-Eckart K, Jenzer M, Hohenfellner M, Dreger P, Haag GM, Jäger D, Pahernik S, Grüllich C. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. Oncotarget, 2018, Vol. 9, (No. 32), pp: 22537-22545.

128.    Zschäbitz St, Grüllich C. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. Small Molecules in Oncology, 211; pp 187-98. 2 August 2018.

1. Alaterre, E., S. Raimbault, H. Goldschmidt, S. Bouhya, G. Requirand, N. Robert, S. Boireau, A. Seckinger, D. Hose, B. Klein, and J. Moreaux. 2017. 'CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma', Oncotarget, 8: 98931-44.
2. Apostolidis, L., D. Schwarz, A. Xia, M. Weiler, A. Heckel, T. Godel, S. Heiland, H. P. Schlemmer, D. Jäger, M. Bendszus, and P. Baumer. 2017. 'Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy', PLoS One, 12: e1-e15.
3. Baertsch, M. A., and H. Goldschmidt. 2017. '[Multiple myeloma : What has been confirmed in therapy?]', Internist (Berl), 58: 1250-57.
4. Baertsch, M. A., J. Hillengass, J. Blocka, S. Schonland, U. Hegenbart, H. Goldschmidt, and M. S. Raab. 2017. 'Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice', Hematol Oncol.
5. Baertsch, M. A., J. Schlenzka, K. Lisenko, J. Krzykalla, N. Becker, K. Weisel, R. Noppeney, H. Martin, H. W. Lindemann, M. Haenel, A. Nogai, C. Scheid, H. Salwender, R. Fenk, U. Graeven, P. Reimer, M. Schmidt-Hieber, M. Goerner, I. G. H. Schmidt-Wolf, S. Klein, A. D. Ho, H. Goldschmidt, and P. Wuchter. 2017. 'Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE', European Journal of Haematology, 99: 42-50.
6. Baudendistel, I., E. C. Winkler, M. Kamradt, S. Brophy, G. Langst, F. Eckrich, O. Heinze, B. Bergh, J. Szecsenyi, and D. Ose. 2017. 'Cross-sectoral cancer care: views from patients and health care professionals regarding a personal electronic health record', European Journal of Cancer Care, 26: e1-e11.
7. Baumann, F. T., A. Hasenburg, P. Jahn, M. Leitzmann, A. Mumm, B. Schulte-Frei, and J. Wiskemann. 2017. 'Excercise is medicine in oncology. On the way to becoming a standard pillar in the treatment of cancer patients', Onkologe, 23: 1021-30.
8. Beer, T. M., E. D. Kwon, C. G. Drake, K. Fizazi, C. Logothetis, G. Gravis, V. Ganju, J. Polikoff, F. Saad, P. Humanski, J. M. Piulats, P. Gonzalez Mella, S. S. Ng, D. Jaeger, F. X. Parnis, F. A. Franke, J. Puente, R. Carvajal, L. Sengelov, M. B. McHenry, A. Varma, A. J. van den Eertwegh, and W. Gerritsen. 2017. 'Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer', J Clin Oncol, 35: 40-47.
9. Berger, A. K., G. M. Haag, M. Ehmann, A. Byl, D. Jäger, and C. Springfeld. 2017. 'Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient', BMC Gastroenterol, 17: 143.
10. Berger, A. K., H. M. Singh, W. Werft, A. Muckenhuber, M. R. Sprick, A. Trumpp, W. Weichert, D. Jäger, and C. Springfeld. 2017. 'High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study', Pancreatology, 17: 629-34.
11. Berthel, A., I. Zoernig, N. A. Valous, C. Kahlert, F. Klupp, A. Ulrich, J. Weitz, D. Jaeger, and N. Halama. 2017. 'Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival', Oncoimmunology, 6: e1-e10.
12. Blank, S., T. Schmidt, P. Heger, M. J. Strowitzki, L. Sisic, U. Heger, H. Nienhueser, G. M. Haag, T. Bruckner, A. L. Mihaljevic, K. Ott, M. W. Büchler, and A. Ulrich. 2017. 'Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?', Gastric Cancer, 21: 303-14.
13. Breitkopf-Heinlein, K., C. Meyer, C. König, H. Gaitantzi, A. Addante, M. Thomas, E. Wiercinska, C. Cai, Q. Li, F. Wan, C. Hellerbrand, N. A. Valous, M. Hahnel, C. Ehlting, J. G. Bode, S. Müller-Bohl, U. Klingmüller, J. Altenoder, I. Ilkavets, M. J. Goumans, L. J. Hawinkels, S. J. Lee, M. Wieland, C. Mogler, M. P. Ebert, B. Herrera, H. Augustin, A. Sanchez, S. Dooley, and P. Ten Dijke. 2017. 'BMP-9 interferes with liver regeneration and promotes liver fibrosis', Gut, 66: 939-54.
14. Buffart, L. M., J. Kalter, M. G. Sweegers, K. S. Courneya, R. U. Newton, N. K. Aaronson, P. B. Jacobsen, A. M. May, D. A. Galvao, M. J. Chinapaw, K. Steindorf, M. L. Irwin, M. M. Stuiver, S. Hayes, K. A. Griffith, A. Lucia, I. Mesters, E. van Weert, H. Knoop, M. M. Goedendorp, N. Mutrie, A. J. Daley, A. McConnachie, M. Bohus, L. Thorsen, K. H. Schulz, C. E. Short, E. L. James, R. C. Plotnikoff, G. Arbane, M. E. Schmidt, K. Potthoff, M. van Beurden, H. S. Oldenburg, G. S. Sonke, W. H. van Harten, R. Garrod, K. H. Schmitz, K. M. Winters-Stone, M. J. Velthuis, D. R. Taaffe, W. van Mechelen, M. J. Kersten, F. Nollet, J. Wenzel, J. Wiskemann, I. M. Verdonck-de Leeuw, and J. Brug. 2017. 'Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs', Cancer Treatment Reviews, 52: 91-104.
15. Butt, J., S. Werner, M. Willhauck-Fleckenstein, A. Michel, T. Waterboer, I. Zörnig, A. Boleij, S. Dramsi, H. Brenner, and M. Pawlita. 2017. 'Serology of Streptococcus gallolyticus subspecies gallolyticus and its association with colorectal cancer and precursors', International Journal of Cancer, 141: 897-904.
16. Campo, C., M. I. da Silva Filho, N. Weinhold, S. H. Mahmoudpour, H. Goldschmidt, K. Hemminki, M. Merz, and A. Försti. 2017. 'Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients', Hematol Oncol.
17. Campo, C., M. I. D. Filho, N. Weinhold, H. Goldschmidt, K. Hemminki, M. Merz, and A. Försti. 2017. 'Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci', Neurochemical Research, 42: 925-31.
18. Cavo, M., E. Terpos, C. Nanni, P. Moreau, S. Lentzsch, S. Zweegman, J. Hillengass, M. Engelhardt, S. Z. Usmani, D. H. Vesole, J. San-Miguel, S. K. Kumar, P. G. Richardson, J. R. Mikhael, F. L. da Costa, M. A. Dimopoulos, C. Zingaretti, N. Abildgaard, H. Goldschmidt, R. Z. Orlowski, W. J. Chng, H. Einsele, S. Lonial, B. Barlogie, K. C. Anderson, S. V. Rajkumar, B. G. M. Durie, and E. Zamagni. 2017. 'Role of F-18-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group', Lancet Oncology, 18: e206-e17.
19. Chen, X., C. Bernemann, Y. Tolkach, M. Heller, C. Nientiedt, M. Falkenstein, E. Herpel, M. Jenzer, C. Grüllich, D. Jäger, H. Sultmann, A. Duensing, S. Perner, M. V. Cronauer, C. Stephan, J. Debus, A. J. Schrader, G. Kristiansen, M. Hohenfellner, and S. Duensing. 2017. 'Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy', Urol Oncol.
20. Chng, W. J., H. Goldschmidt, M. A. Dimopoulos, P. Moreau, D. Joshua, A. Palumbo, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosinol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, H. H. Gillenwater, N. Mohamed, S. Feng, S. Aggarwal, and R. Hajek. 2017. 'Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR', Leukemia, 31: 1368-74.
21. Chudasama, P., M. Renner, M. Straub, S. S. Mughal, B. Hutter, Z. Kosaloglu, R. Schwessinger, M. Scheffler, I. Alldinger, S. Schimmack, T. Persigehl, C. Kobe, D. Jäger, C. von Kalle, P. Schirmacher, M. K. Beckhaus, S. Wolf, C. Heining, S. Gröschel, J. Wolf, B. Brors, W. Weichert, H. Glimm, C. Scholl, G. Mechtersheimer, K. Specht, and S. Fröhling. 2017. 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma', Clinical Cancer Research, 23: 962-73.
22. Clauss, D., C. Tjaden, T. Hackert, L. Schneider, C. M. Ulrich, J. Wiskemann, and K. Steindorf. 2017. 'Cardiorespiratory fitness and muscle strength in pancreatic cancer patients', Supportive Care in Cancer, 25: 2797-807.
23. Czink, E., M. Kloor, B. Goeppert, S. Fröhling, S. Uhrig, T. F. Weber, J. Meinel, C. Sutter, K. H. Weiss, P. Schirmacher, M. V. K. Doeberitz, D. Jäger, and C. Springfeld. 2017. 'Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer', Cold Spring Harb Mol Case Stud, 3.
24. da Silva Filho, M. I., A. Försti, N. Weinhold, I. Meziane, C. Campo, S. Huhn, J. Nickel, P. Hoffmann, M. M. Nöthen, K. H. Jöckel, S. Landi, J. S. Mitchell, D. Johnson, G. J. Morgan, R. Houlston, H. Goldschmidt, A. Jauch, P. Milani, G. Merlini, D. Rowcieno, P. Hawkins, U. Hegenbart, G. Palladini, A. Wechalekar, S. O. Schönland, and K. Hemminki. 2017. 'Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma', Leukemia, 31: 1735-42.
25. Dieter, S. M., C. Heining, A. Agaimy, D. Huebschmann, D. Bonekamp, B. Hutter, K. R. Ehrenberg, M. Fröhlich, M. Schlesner, C. Scholl, H. P. Schlemmer, S. Wolf, A. Mavratzas, C. S. Jung, S. Gröschel, C. von Kalle, R. Eils, B. Brors, R. Penzel, M. Kriegsmann, D. E. Reuss, P. Schirmacher, A. Stenzinger, P. A. Federspil, W. Weichert, H. Glimm, and S. Fröhling. 2017. 'Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma', Annals of Oncology, 28: 142-48.
26. Dietz, S., H. Sültmann, Y. J. Du, E. Reisinger, A. L. Riediger, A. L. Volckmar, A. Stenzinger, M. Schlesner, D. Jäger, M. Hohenfellner, S. Duensing, C. Grüllich, and S. Pahernik. 2017. 'Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy', Oncotarget, 8: 74049-57.
27. Dimopoulos, M. A., H. Goldschmidt, R. Niesvizky, D. Joshua, W. J. Chng, A. Oriol, R. Z. Orlowski, H. Ludwig, T. Facon, R. Hajek, K. Weisel, V. Hungria, L. Minuk, S. Feng, A. Zahlten-Kumeli, A. S. Kimball, and P. Moreau. 2017. 'Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial', Lancet Oncology, 18: 1327-37.
28. Dittrich, T., T. Bochtler, C. Kimmich, N. Becker, A. Jauch, H. Goldschmidt, A. D. Ho, U. Hegenbart, and S. O. Schönland. 2017. 'AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis', Blood, 130: 632-42.
29. Engeland, C. E., S. Bossow, A. W. Hudacek, B. Hoyler, J. Förster, R. Veinalde, D. Jäger, R. Cattaneo, G. Ungerechts, and C. Springfeld. 2017. 'A Tupaia paramyxovirus vector system for targeting and transgene expression', Journal of General Virology, 98: 2248-57.
30. Fan, F., M. H. Bashari, E. Morelli, G. Tonon, S. Malvestiti, S. Vallet, M. Jarahian, A. Seckinger, D. Hose, L. Bakiri, C. Sun, Y. Hu, C. R. Ball, H. Glimm, M. Sattler, H. Goldschmidt, E. F. Wagner, P. Tassone, D. Jaeger, and K. Podar. 2017. 'The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment', Leukemia, 31: 1570-81.
31. Fernau, S., K. Mehlis, J. Schildmann, S. Krause, and E. C. Winkler. 2017. 'The Role of Physicians in Rationing Cancer Care. Attitudes of German Oncologists', Oncology Research and Treatment, 40: 490-94.
32. Fricke, F., J. Lee, M. Michalak, U. Warnken, I. Hausser, M. Suarez-Carmona, N. Halama, M. Schnölzer, J. Kopitz, and J. Gebert. 2017. 'TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells', Cell Communication and Signaling, 15: e1-e14.
33. Giesel, F. L., B. Hadaschik, J. Cardinale, J. Radtke, M. Vinsensia, W. Lehnert, C. Kesch, Y. Tolstov, S. Singer, N. Grabe, S. Duensing, M. Schäfer, O. C. Neels, W. Mier, U. Haberkorn, K. Kopka, and C. Kratochwil. 2017. 'F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients', European Journal of Nuclear Medicine and Molecular Imaging, 44: 678-88.
34. Goebell, P. J., C. Doehn, C. Grüllich, V. Grünwald, T. Steiner, R. Ehness, and M. Welslau. 2017. 'The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape', Future Oncol, 13: 1463-71.
35. Goldschmidt, H., H. M. Lokhorst, E. K. Mai, B. van der Holt, I. W. Blau, S. Zweegman, K. C. Weisel, E. Vellenga, M. Pfreundschuh, M. J. Kersten, C. Scheid, S. Croockewit, R. Raymakers, D. Hose, A. Potamianou, A. Jauch, J. Hillengass, M. Stevens-Kroef, M. S. Raab, A. Broijl, H. W. Lindemann, G. M. J. Bos, P. Brossart, M. van Marwijk Kooy, P. Ypma, U. Duehrsen, R. M. Schaafsma, U. Bertsch, T. Hielscher, L. Jarari, H. J. Salwender, and P. Sonneveld. 2017. 'Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial', Leukemia.
36. Goldschmidt, H., P. Moreau, H. Ludwig, R. Niesvizky, W. J. Chng, D. Joshua, K. Weisel, A. Spencer, R. Z. Orlowski, S. Feng, K. S. Iskander, and M. A. Dimopoulos. 2017. 'Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study', Leuk Lymphoma: 1-11.
37. Granzow, M., U. Hegenbart, K. Hinderhofer, D. Hose, A. Seckinger, T. Bochtler, K. Hemminki, H. Goldschmidt, S. O. Schonland, and A. Jauch. 2017. 'Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis', Haematologica, 102: 1281-90.
38. Gross, J. P., J. Nattenmüller, S. Hemmer, D. Tichy, J. Krzykalla, H. Goldschmidt, U. Bertsch, S. Delorme, H. U. Kauczor, J. Hillengass, and M. Merz. 2017. 'Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trial', Oncotarget, 8: 68460-71.
39. Grüllich, C. 2017. '[Immunotherapy as modern tumor treatment]', Radiologe, 57: 822-25.
40. Haag, G. M., A. Byl, D. Jäger, and A. K. Berger. 2017. 'Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg', Oncology, 92: 291-98.
41. Haag, G. M., G. Stocker, J. Quidde, D. Jaeger, and F. Lordick. 2017. 'Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study', BMC Cancer, 17: e1-e8.
42. Hajda, J., M. Lehmann, O. Krebs, M. Kieser, K. Geletneky, D. Jäger, M. Dahm, B. Huber, T. Schöning, O. Sedlaczek, A. Stenzinger, N. Halama, V. Daniel, B. Leuchs, A. Angelova, J. Rommelaere, C. E. Engeland, C. Springfeld, and G. Ungerechts. 2017. 'A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol', BMC Cancer, 17: 576.
43. Halvarsson, B. M., A. K. Wihlborg, M. Ali, K. Lemonakis, E. Johnsson, A. Niroula, C. Cibulskis, N. Weinhold, A. Försti, E. Alici, C. Langer, M. Pfreundschuh, H. Goldschmidt, U. H. Mellqvist, I. Turesson, A. Waage, K. Hemminki, T. Golub, H. Nahi, U. Gullberg, M. Hansson, and B. Nilsson. 2017. 'Direct evidence for a polygenic etiology in familial multiple myeloma', Blood Adv, 1: 619-23.
44. Hari, P., M. V. Mateos, R. Abonour, S. Knop, W. Bensinger, H. Ludwig, K. Song, R. Hajek, P. Moreau, D. S. Siegel, S. Feng, M. Obreja, S. K. Aggarwal, K. Iskander, and H. Goldschmidt. 2017. 'Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes', Leukemia, 31: 2630-41.
45. Hassel, J. C., H. Jiang, C. Bender, J. Winkler, A. Sevko, I. Shevchenko, N. Halama, A. Dimitrakopoulou-Strauss, W. E. Haefeli, D. Jäger, A. Enk, J. Utikal, and V. Umansky. 2017. 'Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)', Oncoimmunology, 6: e1326440.
46. Hatiboglu, G., M. Hohenfellner, A. Arslan, B. Hadaschik, D. Teber, J. P. Radtke, P. Hallscheidt, Y. Tolstov, W. Roth, C. Grüllich, J. Huesing, S. Duensing, and S. Pahernik. 2017. 'Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma', Langenbecks Arch Surg, 402: 637-44.
47. Hegenbart, U., T. Bochtler, A. Benner, N. Becker, C. Kimmich, A. V. Kristen, J. Beimler, E. Hund, M. Zorn, A. Freiberger, M. Gawlik, H. Goldschmidt, D. Hose, A. Jauch, A. D. Ho, and S. O. Schönland. 2017. 'Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up', Haematologica, 102: 1424-31.
48. Heining, C., P. Horak, S. Gröschel, H. Glimm, and S. Fröhling. 2017. 'Personalized oncology', Radiologe, 57: 804-11.
49. Herfs, M., R. Longuespee, C. M. Quick, P. Roncarati, M. Suarez-Carmona, P. Hubert, A. Lebeau, D. Bruyere, G. Mazzucchelli, N. Smargiasso, D. Baiwir, K. Lai, A. Dunn, F. Obregon, E. J. Yang, E. De Pauw, C. P. Crum, and P. Delvenne. 2017. 'Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma', Journal of Pathology, 241: 522-33.
50. Hillengass, J., L. A. Moulopoulos, S. Delorme, V. Koutoulidis, J. Mosebach, T. Hielscher, M. Drake, S. V. Rajkumar, B. Oestergaard, N. Abildgaard, M. Hinge, T. Plesner, Y. Suehara, K. Matsue, N. Withofs, J. Caers, A. Waage, H. Goldschmidt, M. A. Dimopoulos, S. Lentzsch, B. Durie, and E. Terpos. 2017. 'Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group', Blood Cancer Journal, 7.
51. Hofer, L., C. Gasch, G. Hatiboglu, J. Motsch, C. Grüllich, S. Duensing, and M. Hohenfellner. 2017. '[Level IV inferior vena cava tumor thrombus : A rare diagnosis in patients with renal cell carcinoma]', Urologe A, 56: 868-75.
52. Horak, P., B. Klink, C. Heining, S. Gröschel, B. Hutter, M. Fröhlich, S. Uhrig, D. Hübschmann, M. Schlesner, R. Eils, D. Richter, K. Pfütze, C. Geörg, B. Meissburger, S. Wolf, A. Schulz, R. Penzel, E. Herpel, M. Kirchner, A. Lier, V. Endris, S. Singer, P. Schirmacher, W. Weichert, A. Stenzinger, R. F. Schlenk, E. Schröck, B. Brors, C. von Kalle, H. Glimm, and S. Fröhling. 2017. 'Precision oncology based on omics data: The NCT Heidelberg experience', International Journal of Cancer, 141: 877-86.
53. Huang, Z., D. T. W. Jones, Y. Wu, P. Lichter, and M. Zapatka. 2017. 'confFuse: High-Confidence Fusion Gene Detection across Tumor Entities', Front Genet, 8: 1-10.
54. Huhn, S., N. Weinhold, J. Nickel, M. Pritsch, T. Hielscher, M. Hummel, U. Bertsch, B. Huegle-Doerr, M. Vogel, R. Angermund, M. Hanel, H. J. Salwender, K. Weisel, J. Durig, M. Gorner, H. Kirchner, N. Peter, U. Graeven, F. Lordick, M. Hoffmann, P. Reimer, I. W. Blau, A. Jauch, K. Dembowsky, T. Mohler, P. Wuchter, and H. Goldschmidt. 2017. 'Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial', Bone Marrow Transplantation, 52: 1194-98.
55. Ihrig, A., I. Maatouk, S. Fink, S. Pahernik, C. Süsal, J. Huber, M. Hohenfellner, M. Zeier, and C. Grüllich. 2017. 'Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer', Prog Transplant, 27: 365-68.
56. Kather, J. N., T. Hermann, Y. Bukschat, T. Kramer, L. R. Schad, and F. G. Zöllner. 2017. 'Polyphonic sonification of electrocardiography signals for diagnosis of cardiac pathologies', Scientific Reports, 7: e1-e7.
57. Kather, J. N., J. Poleszczuk, M. Suarez-Carmona, J. Krisam, P. Charoentong, N. A. Valous, C. A. Weis, L. Tavernar, F. Leiss, E. Herpel, F. Klupp, A. Ulrich, M. Schneider, A. Marx, D. Jaeger, and N. Halama. 2017. 'In silico modeling of immunotherapy and stroma-targeting therapies in human colorectal cancer', Cancer Res, 77: 6442-52.
58. Kather, J. N., A. Weidner, U. Attenberger, Y. Bukschat, C. A. Weis, M. Weis, L. R. Schad, and F. G. Zöllner. 2017. 'Color-coded visualization of magnetic resonance imaging multiparametric maps', Scientific Reports, 7: e1-e11.
59. Kather, J. N., F. G. Zöllner, L. R. Schad, S. M. Melchers, H. P. Sinn, A. Marx, T. Gaiser, and C. A. Weis. 2017. 'Identification of a characteristic vascular belt zone in human colorectal cancer', PLoS One, 12: e1-e19.
60. Kesch, C., M. Vinsensia, J. P. Radtke, H. P. Schlemmer, M. Heller, E. Ellert, T. Holland-Letz, S. Duensing, N. Grabe, A. Afshar-Oromieh, K. Wieczorek, M. Schäfer, O. C. Neels, J. Cardinale, C. Kratochwil, M. Hohenfellner, K. Kopka, U. Haberkorn, B. A. Hadaschik, and F. L. Giesel. 2017. 'Intraindividual Comparison of F-18-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study', Journal of Nuclear Medicine, 58: 1805-10.
61. Klassen, O., M. E. Schmidt, C. M. Ulrich, A. Schneeweiss, K. Potthoff, K. Steindorf, and J. Wiskemann. 2017. 'Muscle strength in breast cancer patients receiving different treatment regimes', Journal of Cachexia Sarcopenia and Muscle, 8: 305-16.
62. Koellensperger, E., L. C. Bonnert, I. Zoernig, F. Marme, S. Sandmann, G. Germann, F. Gramley, and U. Leimer. 2017. 'The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction', Stem Cell Res Ther, 8: e1-e19.
63. Köhler, B. C., N. Waldburger, K. Schlamp, D. Jäger, K. H. Weiss, H. Schulze-Bergkamen, P. Schirmacher, and C. Springfeld. 2017. 'Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy', Oncotarget, 8: 59991-98.
64. Kreycy, N., C. Gotzian, T. Fleming, C. Flechtenmacher, N. Grabe, P. Plinkert, J. Hess, and K. Zaoui. 2017. 'Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma', BMC Cancer, 17: e1-e9.
65. Kumar, S. K., M. A. Dimopoulos, E. Kastritis, E. Terpos, H. Nahi, H. Goldschmidt, J. Hillengass, X. Leleu, M. Beksac, M. Alsina, A. Oriol, M. Cavo, E. M. Ocio, M. V. Mateos, E. K. O'Donnell, R. Vij, H. M. Lokhorst, N. W. C. J. van de Donk, C. Min, T. Mark, I. Turesson, M. Hansson, H. Ludwig, S. Jagannath, M. Delforge, C. Kyriakou, P. Hari, U. Mellqvist, S. Z. Usmani, D. Dytfeld, A. Z. Badros, P. Moreau, K. Kim, P. R. Otero, J. H. Lee, C. Shustik, D. Waller, W. J. Chng, S. Ozaki, J. J. Lee, J. de la Rubia, H. S. Eom, L. Rosinol, J. J. Lahuerta, A. Sureda, J. S. Kim, and B. G. M. Durie. 2017. 'Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study', Leukemia, 31: 2443-48.
66. Laban, S., G. Giebel, N. Klümper, A. Schröck, J. Doescher, G. Spagnoli, J. Thierauf, M. N. Theodoraki, R. Remark, S. Gnjatic, R. Krupar, A. G. Sikora, G. Litjens, N. Grabe, G. Kristiansen, F. Bootz, P. J. Schuler, C. Brunner, J. Brägelmann, T. K. Hoffmann, and S. Perner. 2017. 'MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy', Oncotarget, 8: 14719-35.
67. Laryionava, K., P. Heussner, W. Hiddemann, and E. C. Winkler. 2017. '"Rather one more chemo than one less...": Oncologists and Oncology Nurses' Reasons for Aggressive Treatment of Young Adults with Advanced Cancer', Oncologist, 23: 256-66.
68. Law, P. J., A. Sud, J. S. Mitchell, M. Henrion, G. Orlando, O. Lenive, P. Broderick, H. E. Speedy, D. C. Johnson, M. Kaiser, N. Weinhold, R. Cooke, N. J. Sunter, G. H. Jackson, G. Summerfield, R. J. Harris, A. R. Pettitt, D. J. Allsup, J. Carmichael, J. R. Bailey, G. Pratt, T. Rahman, C. Pepper, C. Fegan, E. P. von Strandmann, A. Engert, A. Försti, B. W. Chen, M. I. da Silva, H. Thomsen, P. Hoffmann, M. M. Noethen, L. Eisele, K. H. Jöckel, J. M. Allan, A. J. Swerdlow, H. Goldschmidt, D. Catovsky, G. J. Morgan, K. Hemminki, and R. S. Houlston. 2017. 'Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci', Scientific Reports, 7.
69. Legrand, C., F. Tuorto, M. Hartmann, R. Liebers, D. Jacob, M. Helm, and F. Lyko. 2017. 'Statistically robust methylation calling for whole-transcriptome bisulfite sequencing reveals distinct methylation patterns for mouse RNAs', Genome Research, 27: 1589-96.
70. Li, N., D. C. Johnson, N. Weinhold, S. Kimber, S. E. Dobbins, J. S. Mitchell, B. Kinnersley, A. Sud, P. J. Law, G. Orlando, M. Scales, C. P. Wardell, A. Försti, P. H. Hoang, M. Went, A. Holroyd, F. Hariri, T. Pastinen, T. Meissner, H. Goldschmidt, K. Hemminki, G. J. Morgan, M. Kaiser, and R. S. Houlston. 2017. 'Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism', Cell Rep, 20: 2556-64.
71. Liebers, N., T. Holland-Letz, M. Welschof, A. Hogset, D. Jäger, M. A. E. Arndt, and J. Krauss. 2017. 'Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase', J Exp Ther Oncol, 12: 113-20.
72. Lisenko, K., P. Pavel, M. Kriegsmann, T. Bruckner, J. Hillengass, H. Goldschmidt, M. Witzens-Harig, A. D. Ho, and P. Wuchter. 2017. 'Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation', Biology of Blood and Marrow Transplantation, 23: 684-90.
73. Lisenko, K., S. Sauer, T. Bruckner, G. Egerer, H. Goldschmidt, J. Hillengass, J. W. Schmier, S. Shah, M. Witzens-Harig, A. D. Ho, and P. Wuchter. 2017. 'High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting', BMC Cancer, 17: e1-e10.
74. Lisenko, K., S. Schönland, U. Hegenbart, K. Wallenwein, U. Braun, E. K. Mai, J. Hillengass, H. Goldschmidt, A. Jauch, A. D. Ho, M. Raab, and M. Hundemer. 2017. 'Potential Therapeutic Targets in Plasma Cell Disorders: A Flow Cytometry Study', Cytometry Part B-Clinical Cytometry, 92: 145-52.
75. Lisenko, K., P. Wuchter, M. Hansberg, A. Mangatter, A. Benner, A. D. Ho, H. Goldschmidt, U. Hegenbart, and S. Schönland. 2017. 'Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients', Biol Blood Marrow Transplant, 23: 1870-78.
76. Ludwig, H., M. Delforge, T. Facon, H. Einsele, F. Gay, P. Moreau, H. Avet-Loiseau, M. Boccadoro, R. Hajek, M. Mohty, M. Cavo, M. A. Dimopoulos, J. F. San-Miguel, E. Terpos, S. Zweegman, L. Garderet, M. V. Mateos, G. Cook, X. Leleu, H. Goldschmidt, G. Jackson, M. Kaiser, K. Weisel, Nwcj van de Donk, A. Waage, M. Beksac, U. H. Mellqvist, M. Engelhardt, J. Caers, C. Driessen, and P. Sonneveld. 2017. 'Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network', Leukemia.
77. Macauda, A., D. Calvetti, G. Maccari, K. Hemminki, A. Forsti, H. Goldschmidt, N. Weinhold, R. Houlston, V. Andersen, U. Vogel, G. Buda, J. Varkonyi, A. Sureda, J. Martinez Lopez, M. Watek, A. Butrym, M. E. Sarasquete, M. Dudzinski, A. Jurczyszyn, A. Druzd-Sitek, M. Kruszewski, E. Subocz, M. Petrini, E. Iskierka-Jazdzewska, M. Razny, G. Szombath, H. Marques, D. Zawirska, D. Chraniuk, J. Halka, S. E. H. Jacobsen, G. Mazur, R. G. Sanz, C. Dumontet, V. Moreno, A. Stepien, K. Beider, M. Pelosini, R. M. Reis, M. Krawczyk-Kulis, M. Rymko, H. Avet-Loiseau, F. Lesueur, N. Grzasko, O. Ostrovsky, K. Jamroziak, A. J. Vangsted, A. Jerez, W. Tomczak, J. M. Zaucha, K. Kadar, J. Sainz, A. Nagler, S. Landi, F. Gemignani, and F. Canzian. 2017. 'Identification of miRSNPs associated with the risk of multiple myeloma', International Journal of Cancer, 140: 526-34.
78. Macher-Goeppinger, S., M. Keith, V. Endris, R. Penzel, K. E. Tagscherer, S. Pahernik, M. Hohenfellner, H. Gardner, C. Grüllich, P. Schirmacher, and W. Roth. 2017. 'MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker', Oncotarget, 8: 1046-57.
79. Mehlis, K., C. Becker, C. Christ, K. Laryionava, W. Hiddemann, P. Heussner, and E. C. Winkler. 2017. 'Frequency and Timing of Decisions to Limit Intensive Medical Care and Tumor-Specific Therapy in University Hematology and Oncology', Deutsche Medizinische Wochenschrift, 142: e116-e23.
80. Menzer, C., C. Gruellich, and J. C. Hassel. 2017. 'Editorial on the use of immunotherapy in renal-cell carcinoma-promising results in combination therapy with ipilimumab and nivolumab', Translational Cancer Research, 6: S208-S11.
81. Merz, M., A. Jauch, T. Hielscher, E. K. Mai, A. Seckinger, D. Hose, U. Bertsch, K. Neben, M. S. Raab, H. Salwender, I. W. Blau, H. W. Lindemann, I. Schmidt-Wolf, C. Scheid, M. Haenel, K. Weisel, H. Goldschmidt, and J. Hillengass. 2017. 'Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation', Haematologica, 102: 1432-38.
82. Merz, M., L. Kellermann, W. Poenisch, H. J. Tischler, J. Kohnke, W. Knauf, and H. Goldschmidt. 2017. 'Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey', Annals of Hematology, 96: 987-93.
83. Merz, M., M. S. Raab, H. Goldschmidt, and J. Hillengass. 2017. 'Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma', Journal of Cancer Research and Clinical Oncology, 143: 2521-26.
84. Meziane, I., S. Huhn, M. I. da Silva, N. Weinhold, C. Campo, J. Nickel, P. Hoffmann, M. M. Nöthen, K. H. Jöckel, S. Landi, J. S. Mitchell, D. Johnson, A. Jauch, G. J. Morgan, R. Houlston, H. Goldschmidt, P. Milani, G. Merlini, D. Rowcieno, P. Hawkins, U. Hegenbart, G. Palladini, A. Wechalekar, A. Försti, S. O. Schönland, and K. Hemminki. 2017. 'Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts', Haematologica, 102: E411-E14.
85. Moreau, P., D. Joshua, W. J. Chng, A. Palumbo, H. Goldschmidt, R. Hajek, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosinol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, H. H. Gillenwater, N. Mohamed, S. Aggarwal, S. Feng, and M. A. Dimopoulos. 2017. 'Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study', Leukemia, 31: 115-22.
86. Moreau, P., J. S. Miguel, P. Sonneveld, M. V. Mateos, E. Zamagni, H. Avet-Loiseau, R. Hajek, M. A. Dimopoulos, H. Ludwig, H. Einsele, S. Zweegman, T. Facon, M. Cavo, E. Terpos, H. Goldschmidt, M. Attal, C. Buske, and ESMO Guidelines Comm. 2017. 'Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up', Annals of Oncology, 28: iv52-iv61.
87. Muckenhuber, A., A. K. Berger, A. M. Schlitter, K. Steiger, B. Konukiewitz, A. Trumpp, R. Eils, J. Werner, H. Friess, I. Esposito, G. Kloppel, G. O. Ceyhan, M. Jesinghaus, C. Denkert, M. Bahra, A. Stenzinger, M. R. Sprick, D. Jäger, C. Springfeld, and W. Weichert. 2017. 'Pancreatic Ductal Adenocarcinoma Subtyping using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response', Clin Cancer Res.
88. Nattenmüller, J., R. Wochner, T. Muley, M. Steins, S. Hummler, B. Teucher, J. Wiskemann, H. U. Kauczor, M. O. Wielputz, and C. P. Heussel. 2017. 'Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients', PLoS One, 12: e1-e18.
89. Neuber, B., J. Y. Dai, W. A. Waraich, M. H. S. Awwad, M. Engelhardt, M. Schmitt, S. Medenhoff, M. Witzens-Harig, A. D. Ho, H. Goldschmidt, and M. Hundemer. 2017. 'Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells', Oncotarget, 8: 98200-14.
90. Nientiedt, C., M. Heller, V. Endris, A. L. Volckmar, S. Zschabitz, M. A. Tapia-Laliena, A. Duensing, D. Jager, P. Schirmacher, H. Sultmann, A. Stenzinger, M. Hohenfellner, C. Grullich, and S. Duensing. 2017. 'Mutations in BRCA2 and taxane resistance in prostate cancer', Sci Rep, 7: e1-e10.
91. Ose, D., I. Baudendistel, S. Pohlmann, E. C. Winkler, A. Kunz, and J. Szecsenyi. 2017. '[Personal health records on the Internet. A narrative review of attitudes, expectations, utilization and effects on health outcomes]', Z Evid Fortbild Qual Gesundhwes, 122: 9-21.
92. Ose, D., A. Kunz, S. Pohlmann, H. Hofmann, M. Qreini, J. Krisam, L. Uhlmann, C. Jacke, E. C. Winkler, H. J. Salize, and J. Szecsenyi. 2017. 'A Personal Electronic Health Record: Study Protocol of a Feasibility Study on Implementation in a Real-World Health Care Setting', JMIR Res Protoc, 6: e33.
93. Ose, D., E. C. Winkler, S. Berger, I. Baudendistel, M. Kamradt, F. Eckrich, and J. Szecsenyi. 2017. 'Complexity of care and strategies of self-management in patients with colorectal cancer', Patient Preference and Adherence, 11: 731-42.
94. Pfeiffenberger, J., Zimmermann T., D.N. Gotthardt, C. Springfeld, W. Stremmel, P. Schirmacher, H. Schulze-Bergkamen, A. Mehrabi, C.W. Michalski, K. Hoffmann, N. Kortes, B. Radeleff, U. Haberkorn, C. Kratochwil, K. H. Weiss, and C. Grüllich. 2017. 'Outcome Results of Treatment with Selective Internal Radiation Therapie (SIRT) in Patients with Hepatocellular Carcinoma: A Single Center Experience', Journal of Cancer Therapy, 8: 349-59.
95. Podar, K., and D. Jäger. 2017. 'Targeting the immune niche within the bone marrow microenvironment: The rise of immunotherapy in Multiple Myeloma', Curr Cancer Drug Targets, 17.
96. Preisner, F., U. Leimer, S. Sandmann, I. Zoernig, G. Germann, and E. Koellensperger. 2017. 'Impact of Human Adipose Tissue-Derived Stem Cells on Malignant Melanoma Cells in An In Vitro Co-culture Model', Stem Cell Rev.
97. Rapp, C., R. Warta, S. Stamova, A. Nowrouzi, C. Geisenberger, Z. Gal, S. Roesch, S. Dettling, S. Juenger, M. Bucur, C. Jungk, P. DaoTrong, R. Ahmadi, F. Sahm, D. Reuss, V. Fermi, E. Herpel, V. Eckstein, N. Grabe, C. Schramm, M. A. Weigand, J. Debus, A. von Deimling, A. Unterberg, A. Abdollahi, P. Beckhove, and C. Herold-Mende. 2017. 'Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens', Acta Neuropathologica, 134: 297-316.
98. Rojas-Moraleda, R., W. Xiong, N. Halama, K. Breitkopf-Heinlein, S. Dooley, L. Salinas, D. W. Heermann, and N. A. Valous. 2017. 'Robust detection and segmentation of cell nuclei in biomedical images based on a computational topology framework', Medical Image Analysis, 38: 90-103.
99. Rosenberger, F., J. Wiskemann, S. Vallet, G. M. Haag, E. Schembri, D. Jäger, and C. Grüllich. 2017. 'Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial', Support Care Cancer, 25: 3655-64.
100. Rusakiewicz, S., A. Perier, M. Semeraro, J. M. Pitt, E. P. von Strandmann, K. S. Reiners, S. Aspeslagh, C. Piperoglou, F. Vely, A. Ivagnes, S. Jegou, N. Halama, L. Chaigneau, P. Validire, C. Christidis, T. Perniceni, B. Landi, A. Berger, N. Isambert, J. Domont, S. Bonvalot, P. Terrier, J. Adam, J. M. Coindre, J. F. Emile, V. Poirier-Colame, K. Chaba, B. Rocha, A. Caignard, A. Toubert, D. Enot, J. Koch, A. Marabelle, M. Lambert, S. Caillat-Zucman, S. Leyvraz, C. Auclair, E. Vivier, A. Eggermont, C. Borg, J. Y. Blay, A. Le Cesne, O. Mir, and L. Zitvogel. 2017. 'NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients', Oncoimmunology, 6: e1-e13.
101. Sachpekidis, C., A. Dimitrakopoulou-Strauss, S. Delorme, and H. Goldschmidt. 2017. 'Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient', Diagnostics (Basel), 7: 1-5.
102. Sachpekidis, C., J. Hillengass, H. Goldschmidt, H. Anwar, U. Haberkorn, and A. Dimitrakopoulou-Strauss. 2017. 'Quantitative analysis of (18)F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma', Am J Nucl Med Mol Imaging, 7: 148-56.
103. Sachpekidis, C., J. Hillengass, H. Goldschmidt, B. Wagner, U. Haberkorn, K. Kopka, and A. Dimitrakopoulou-Strauss. 2017. 'Treatment response evaluation with F-18-FDG PET/CT and F-18-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation', European Journal of Nuclear Medicine and Molecular Imaging, 44: 50-62.
104. Schleidgen, S., S. Fernau, H. Fleischer, C. Schickhardt, A. K. Ossa, and E. C. Winkler. 2017. 'Applying systems biology to biomedical research and health care: a precising definition of systems medicine', BMC Health Services Research, 17: e1-e16.
105. Schmidt, M. E., J. Wiskemann, C. M. Ulrich, A. Schneeweiss, and K. Steindorf. 2017. 'Self-reported physical activity behavior of breast cancer survivors during and after adjuvant therapy: 12 months follow-up of two randomized exercise intervention trials', Acta Oncologica, 56: 618-27.
106. Schmitt, M., A. G. Hückelhoven, M. Hundemer, A. Schmitt, S. Lipp, M. Emde, H. Salwender, M. Hänel, K. Weisel, U. Bertsch, J. Dürig, A. D. Ho, I. W. Blau, H. Goldschmidt, A. Seckinger, and D. Hose. 2017. 'Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial', Oncotarget, 8: 84847-62.
107. Sisic, L., S. Blank, H. Nienhüser, G. M. Haag, D. Jäger, T. Bruckner, K. Ott, T. Schmidt, and A. Ulrich. 2017. 'The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma', Surg Oncol: 1-12.
108. Sisic, L., M. J. Strowitzki, S. Blank, H. Nienhueser, S. Dorr, G. M. Haag, D. Jäger, K. Ott, M. W. Buchler, A. Ulrich, and T. Schmidt. 2017. 'Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis', Gastric Cancer, 21: 552-68.
109. Steindorf, K., J. Wiskemann, C. M. Ulrich, and M. E. Schmidt. 2017. 'Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial', Breast Cancer Research and Treatment, 162: 489-99.
110. Strobel, O., T. Hank, U. Hinz, F. Bergmann, L. Schneider, C. Springfeld, D. Jäger, P. Schirmacher, T. Hackert, and M. W. Büchler. 2017. 'Pancreatic Cancer Surgery The New R-status Counts', Annals of Surgery, 265: 565-73.
111. Suarez-Carmona, M., J. Lesage, D. Cataldo, and C. Gilles. 2017. 'EMT and inflammation: inseparable actors of cancer progression', Molecular Oncology, 11: 805-23.
112. Thomsen, H., C. Campo, N. Weinhold, M. I. da Silva, L. Pour, E. Gregora, P. Vodicka, L. Vodickova, P. Hoffmann, M. M. Nöthen, K. H. Jöckel, C. Langer, R. Hajek, H. Goldschmidt, K. Hemminki, and A. Försti. 2017. 'Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)', European Journal of Haematology, 99: 70-79.
113. Ungerechts, G., C. E. Engeland, C. J. Buchholz, J. Eberle, H. Fechner, K. Geletneky, P. S. Holm, F. Kreppel, F. Kühnel, K. S. Lang, M. F. Leber, A. Marchini, M. Moehler, M. D. Mühlebach, J. Rommelaere, C. Springfeld, U. M. Lauer, and D. M. Nettelbeck. 2017. 'Virotherapy Research in Germany: From Engineering to Translation', Human Gene Therapy, 28: 800-19.
114. Veinalde, R., C. Grossardt, L. Hartmann, M. C. Bourgeois-Daigneault, J. C. Bell, D. Jaeger, C. von Kalle, G. Ungerechts, and C. E. Engeland. 2017. 'Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation', Oncoimmunology, 6.
115. Viziteu, E., B. Klein, J. Basbous, Y. L. Lin, C. Hirtz, C. Gourzones, L. Tiers, A. Bruyer, L. Vincent, C. Grandmougin, A. Seckinger, H. Goldschmidt, A. Constantinou, P. Pasero, D. Hose, and J. Moreaux. 2017. 'RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma', Leukemia, 31: 2104-13.
116. Welte, S. E., J. Wiskemann, F. Scharhag-Rosenberger, R. Förster, T. Bostel, T. Bruckner, I. Schlampp, E. Meyerhof, T. Sprave, N. H. Nicolay, J. Debus, and H. Rief. 2017. 'Differentiated resistance training of the paravertebral muscles in patients with unstable spinal bone metastasis under concomitant radiotherapy: study protocol for a randomized pilot trial', Trials, 18: e1-e7.
117. Welters, M. J. P., W. Ma, S. J. Santegoets, R. Goedemans, I. Ehsan, E. S. Jordanova, V. J. van Ham, V. van Unen, F. Koning, S. I. van Egmond, P. Charoentong, Z. Trajanoski, L. A. van der Velden, and S. H. van der Burg. 2017. 'Intratumoral HPV16-specific T-cells constitute a type 1 oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer', Clin Cancer Res, 24: 634-47.
118. Will, L., F. L. Giesel, M. T. Freitag, A. K. Berger, W. Mier, K. Kopka, S. A. Koerber, H. Rathke, C. Kremer, C. Kratochwil, H. U. Kauczor, U. Haberkorn, and T. F. Weber. 2017. 'Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients', Cancer Imaging, 17: e1-e7.
119. Winkler, E.    . 2017. 'Verhältnis von personalisierter zu evidenzbasierter Medizin', Forum: e1-e5.
120. Wiskemann, J., B. Herzog, R. Kuehl, M. E. Schmidt, K. Steindorf, R. Schwerdtfeger, P. Dreger, and M. Bohus. 2017. 'Impact of HSCT Conditioning and Glucocorticoid Dose on Exercise Adherence and Response', Medicine and Science in Sports and Exercise, 49: 2143-50.
121. Wiskemann, J., M. E. Schmidt, O. Klassen, J. Debus, C. M. Ulrich, K. Potthoff, and K. Steindorf. 2017. 'Effects of 12-week resistance training during radiotherapy in breast cancer patients', Scandinavian Journal of Medicine & Science in Sports, 27: 1500-10.
122. Wu, B., M. Slabicki, L. Sellner, S. Dietrich, X. Liu, A. Jethwa, J. Hullein, T. Walther, L. Wagner, Z. Huang, M. Zapatka, and T. Zenz. 2017. 'MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia', Br J Haematol, 179: 421-29.
123. Wuchter, P., M. Hundemer, A. Schmitt, M. Witzens-Harig, P. Pavel, J. Hillengass, H. Goldschmidt, A. D. Ho, and K. Lisenko. 2017. 'Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices', Transfusion Medicine, 27: 36-42.
124. Xu, J., N. Pfarr, V. Endris, E. K. Mai, N. H. M. Hanafiah, N. Lehners, R. Penzel, W. Weichert, A. D. Ho, P. Schirmacher, H. Goldschmidt, M. Andrulis, and M. S. Raab. 2017. 'Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation', Oncogenesis, 6: e1-e5.
125. Yamamoto, Y., A. Saito, A. Tateishi, H. Shimojo, H. Kanno, S. Tsuchiya, K. I. Ito, E. Cosatto, H. P. Graf, R. R. Moraleda, R. Eils, and N. Grabe. 2017. 'Quantitative diagnosis of breast tumors by morphometric classification of microenvironmental myoepithelial cells using a machine learning approach', Sci Rep, 7: e1-e12.
126. Zschäbitz, S., F. Lasitschka, B. Hadaschik, R. D. Hofheinz, K. Jentsch-Ullrich, M. Grüner, D. Jäger, and C. Grüllich. 2017. 'Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell canceer relapsed after hifh-dose chemotherapy and stem cell transplantationl', Eur J Cancer, 76: 1-7.
127. Zschäbitz, S., S. Vallet, B. Hadaschik, D. Debatin, S. Fuxius, A. Karcher, S. Pahernik, C. Spath, S. Duensing, D. Jäger, M. Hohenfellner, and C. Grüllich. 2017. 'Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers', Journal of Cancer, 8: 507-12.

1. Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, Haldipur P, Kawauchi D, Risch T, Warnatz HJ, Worst BC, Ju B, Orr BA, Zeid R, Polaski DR, Segura-Wang M, Waszak SM, Jones DT, Kool M, Hovestadt V, Buchhalter I, Sieber L, Johann P, Chavez L, Gröschel S, Ryzhova M, Korshunov A, Chen W, Chizhikov VV, Millen KJ, Amstislavskiy V, Lehrach H, Yaspo ML, Eils R, Lichter P, Korbel JO, Pfister SM, Bradner JE, Northcott PA. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature. 2016;530(7588):57-62.
2. Zschäbitz S, Lasitschka F, Jäger D, Grüllich C. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors. Annals of Oncology. 2016;27(7):1356-60.
3. Haag G, Stocker G. Adenokarzinom des Ösophagus und des Magens - palliative Konzepte. Trillium-Krebsmedizin. 2016;25(2).
4. Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016;101(7):872-8.
5. Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia. 2016:E1-E12.
6. Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab M, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J. Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur Radiol. 2016;26(11):3939-48.
7. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Grobner S, Brabetz S, Chavez L, Bens S, Gröschel S, Kratochwil F, Wittmann A, Sieber L, Geörg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schuller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Frühwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M. Atypical Teratoid Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. 2016;29(3):379-93.
8. Avellino R, Havermans M, Erpelinck C, Sanders MA, Hoogenboezem R, van de Werken HJ, Rombouts E, van Lom K, van Strien PM, Gebhard C, Rehli M, Pimanda J, Beck D, Erkeland S, Kuiken T, de Looper H, Gröschel S, Touw I, Bindels E, Delwel R. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation. Blood. 2016;127(24):2991-3003.
9. Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. American journal of hematology. 2016;91(11):E473-E7.
10. Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jaeger D, Heikenwalder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Koehler BC. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7(8):E1-E10.
11. Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain, behavior, and immunity. 2016;52:98-105.
12. Jensen AD, Poulakis M, Vanoni V, Uhl M, Chaudhri N, Federspil PA, Freier K, Krauss J, Debus J. Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? Radiation oncology. 2016;11(1):90E1-E9.
13. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Investigators E. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. The Lancet Oncology. 2016;17(1):27-38.
14. Halama N. CCR5 inhibition in colorectal cancer patients. Transl Cancer Res. 2016;5:S366-S7.
15. Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J. Chetomin, targeting HIF-1 alpha/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer. 2016;114(5):519-23.
16. Schmoch T, Gal Z, Mock A, Mossemann J, Lahrmann B, Grabe N, Schmezer P, Lasitschka F, Beckhove P, Unterberg A, Herold-Mende C. Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. Anticancer Res. 2016;36(4):1489-96.
17. Rios-Tamayo R, Lupianez CB, Campa D, Hielscher T, Weinhold N, Martinez-Lopez J, Jerez A, Landi S, Jamroziak K, Dumontet C, Watek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, Garcia-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Forsti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016;7(37):59029-48.
18. Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):E116-E9.
19. Bouman A, Knegt L, Gröschel S, Erpelinck C, Sanders M, Delwel R, Kuijpers T, Cobben JM. Congenital thrombocytopenia in a neonate with an interstitial microdeletion of 3q26.2q26.31. Am J Med Genet A. 2016;170(2):504-9.
20. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016;30(4):937-46.
21. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2016;375(14):1319-31.
22. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Thery C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vely F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):E1-E13.
23. Kuehl R, Schmidt ME, Dreger P, Steindorf K, Bohus M, Wiskemann J. Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016;24(10):4327-37.
24. Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W. Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011. Oncol Lett. 2016;12(6):5043-51.
25. Kittas A, Delobelle A, Schmitt S, Breuhahn K, Guziolowski C, Grabe N. Directed random walks and constraint programming reveal active pathways in hepatocyte growth factor signaling. The FEBS journal. 2016;283(2):350-60.
26. Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS. Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol Oncol. 2016;34(4):200-7.
27. Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C. Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer. Z Gastroenterol. 2016;54(5):426-30.
28. Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, Roth W, Grüllich C, Huesing J, Duensing S, Pahernik S. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbeck's archives of surgery. 2016:E1-E8.
29. Wiskemann J, Schmidt ME, Klassen O, Debus J, Ulrich CM, Potthoff K, Steindorf K. Effects of 12-week resistance training during radiotherapy in breast cancer patients. Scandinavian journal of medicine & science in sports. 2016.
30. Wanjek M, Senner V, F. S-R, Halle M. Effects of different weight loss intervention programmes in health clubs - an observational multicenter study. European Journal of Sport Science. 2016;16(7):859-67.
31. Apostolidis L, Bergmann F, Jäger D, Winkler EC. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med. 2016;5(9):2261-7.
32. Mehlis K, Winkler EC. Ethical analysis of life-prolonging treatment. For protection of self-determination and protection against overtreatment. Onkologe. 2016;22(11):844-51.
33. Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, Brenner H. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Scientific reports. 2016;6:25467E1-E10.
34. Wiskemann J, Scharhag-Rosenberger F. The evolving role of exercise in cancer patients: recent developments, recommendations and future directions 2016. Future oncology. 2016;12(13):E1-E4.
35. Wiskemann J, Schommer K, Jaeger D, Scharhag-Rosenberger F. Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case report. Medicine. 2016;95(29):E1-E6.
36. Winkler EC, Heussner P. Farsighted Planning of Treatment and Therapy Limitation Considerations from medico-ethical and psycho-oncological View. Dtsch Med Wochenschr. 2016;141(6):394-8.
37. Ziegler C, Finke J, Grüllich C. Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95. Leukemia Lymphoma. 2016;57(1):177-82.
38. Winkler EC, Wiemann S. Findings made in gene panel to whole genome sequencing: data, knowledge, ethics - and consequences? Expert Rev Mol Diagn. 2016;16(12):1259-70.
39. Lisenko K, Schönland SO, Jauch A, Andrulis M, Rocken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Med. 2016;5(7):1464-72.
40. Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2016;30(4):873-82.
41. Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016. 1-16
42. Friedel M, Andre S, Goldschmidt H, Gabius HJ, Schwartz-Albiez R. Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor. Glycobiology. 2016;26(10):1048-58.
43. Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P, Grp IMW. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016;30(5):1071-8.
44. Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Försti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia. 2016;30(4):883-8.
45. Campo C, Da Silva Filho MI, Weinhold N, Goldschmidt H, Hemminki K, Merz M, Försti A. Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci. Neurochemical research. 2016.
46. Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Joud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nothen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.
47. Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Noethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016;7:10290E1-E7.
48. Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. European journal of nuclear medicine and molecular imaging. 2016;43(3):489-98.
49. Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Hoss A, Haberer T, Jakel O, Munter MW, Schulz-Ertner D, Huber PE, Debus J. High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016;118(2):272-80.
50. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Konigsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet Oncology. 2016;17(12):1697-708.
51. Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Hofer T, Trumpp A, Halama N, Hassel JC, Strobel O, Buchler M, Sahin U, Offringa R. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):E1-E13.
52. Kosaloglu Z, Zörnig I, Halama N, Kaiser I, Buchhalter I, Grabe N, Eils R, Schlesner M, Califano A, Jäger D. Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. Oncoimmunology. 2016;5(11):E1-E10.
53. Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot and feasibility studies. 2016;2:18E1-E0.
54. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Maqueda MA, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer. 2016;59:160-70.
55. Jäger D, Halama N, Zörnig I, Klug P, Krauss J, Haag GM. Immunotherapy of Colorectal Cancer. Oncol Res Treat. 2016;39(6):346-50.
56. Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. J Neurooncol. 2016;130(1):221-8.
57. Kosaloglu Z, Bitzer J, Halama N, Huang ZQ, Zapatka M, Schneeweiss A, Jäger D, Zörnig I. In silico SNP analysis of the breast cancer antigen NY-BR-1. BMC Cancer. 2016;16:901E1-E12.
58. Hemminki K, Försti A, Tuuminen R, Hemminki O, Goldschmidt H, Sundquist K, Sundquist J, Li X. The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications. Scientific reports. 2016;6:28500E1-E7.
59. Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S. Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. Br J Haematol. 2016;174(1):127-35.
60. Eckrich F, Baudendistel I, Ose D, Winkler EC. Influence of electronic medical records (EMR) on the physician-patient relationship: a systematic review of the medical and ethical implications. Ethik Med. 2016;28(4):295-310.
61. Heining C, Richter D, Gröschel S, Glimm H, Fröhling S. Integration der Genomsequenzierung in die klinische Hämato-Onkologie – Eine Möglichkeit für „personalisierte“ Therapien. TumorDiagn u Ther. 2016;37(06):332-6.
62. Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Georg C, Richter D, Pfarr N, Pfutze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harbor molecular case studies. 2016;2(6):E1-E13.
63. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology. 2016;17(8):E328-E46.
64. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of clinical oncology. 2016;34(13):1544-57.
65. Wiskemann J, Dehler D. Körperliches Aktivitätsverhalten postoperativer Darmkrebspatienten und die Anwendbarkeit sporttherapeutischer Maßnahmen in Fallbeispielen. B & G. 2016;32(2):55-9.
66. Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662.
67. Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. International journal of cancer. 2016;139(2):424-32.
68. Du Y, Grüllich C, Hadaschik B, Hatiboglu G, Hohenfellner M, Pahernik S. Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. Clinical genitourinary cancer. 2016;14(4):e379-85.
69. Grüllich C, Vallet S, Hecht C, Duensing S, Hadaschik B, Jäger D, Hohenfellner M, Pahernik S. Local salvage therapy for late (>/=2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. Urologic oncology. 2016;34(5):238 E9-E17.
70. Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, Strobel O, Jäger D, Ulrich A, Büchler MW. Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg. 2016;264(3):457-63.
71. Echterdiek F, Janikovits J, Staffa L, Muller M, Lahrmann B, Frühschütz M, Hartog B, Nelius N, Benner A, Tariverdian M, von Knebel Doeberitz M, Grabe N, Kloor M. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology. 2016;5(2):E1-E8.
72. Lehners N, Hayden PJ, Goldschmidt H, Raab MS. Management of high-risk Myeloma: an evidence-based review of treatment strategies. Expert Rev Hematol. 2016;9(8):753-65.
73. Bashari MH, Fan FJ, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 2016;18:26 E1-E15.
74. Merz M, Hillengass J, Goldschmidt H. Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma. Journal of cancer research and clinical oncology. 2016;142(1):247-51.
75. Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM. Moving oncolytic viruses into the clinic: clinical-grade production purification and characterization of diverse oncolytic viruses. Mol Ther-Meth Clin D. 2016;3:E1-E12.
76. Li N, Johnson DC, Weinhold N, Studd JB, Orlando G, Mirabella F, Mitchell JS, Meissner T, Kaiser M, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Nat Commun. 2016;7:13656 E1-E9.
77. Deisenroth A, Sontgerath R, Schuster AJ, von Busch C, Huber G, Eckert K, Kulozik AE, Wiskemann J. Muscle strength and quality of life in patients with childhood cancer at early phase of primary treatment. Pediatr Hemat Oncol. 2016;33(6):393-407.
78. Klassen O, Schmidt ME, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J. Muscle strength in breast cancer patients receiving different treatment regimes. Journal of cachexia, sarcopenia and muscle. 2016:E1-E12.
79. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;28:142-8.
80. Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology. 2016;17(7):883-95.
81. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology. 2016;17(11):1590-8.
82. Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Piperoglou C, Vely F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. 2016;6(1):E1-E13.
83. Korkmaz-Icöz S, Al Said S, Radovits T, Li S, Brune M, Hegedus P, Atmanli A, Ruppert M, Brlecic P, Lehmann LH, Lahrmann B, Grabe N, Yoshikawa Y, Yasui H, Most P, Karck M, Szabo G. Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway. Cardiovascular diabetology. 2016;15:75E1-E16.
84. Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-Cancer Analysis of Copy Number Changes in Programmed Death-Ligand 1 (PD-L1, CD274) - Associations with Gene Expression, Mutational Load, and Survival. Gene Chromosome Canc. 2016;55(8):626-39.
85. Lotz J, Olesch J, Müller B, Polzin T, Galuschka P, Lotz JM, Heldmann S, Laue H, Gonzalez-Vallinas M, Warth A, Lahrmann B, Grabe N, Sedlaczek O, Breuhahn K, Modersitzki J. Patch-Based Nonlinear Image Registration for Gigapixel Whole Slide Images. Ieee T Bio-Med Eng. 2016;63(9):1812-9.
86. Haense N, Atmaca A, Pauligk C, Steinmetz K, Marme F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420E1-E10.
87. Ungar N, Wiskemann J, Sieverding M. Physical Activity Enjoyment and Self-Efficacy As Predictors of Cancer Patients' Physical Activity Level. Frontiers in psychology. 2016;7:898 E1-E10.
88. Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia Lymphoma. 2016;57(12):2833-8.
89. Wiskemann J, Hummler S, Diepold C, Keil M, Abel U, Steindorf K, Beckhove P, Ulrich CM, Steins M, Thomas M. POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment. BMC Cancer. 2016;16:499 E1-E9.
90. Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK. Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Alcohol Clin Exp Res. 2016;40(10):2094-101.
91. Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer letters. 2016;381(2):296-304.
92. Vallet S, Bashari MH, Fan FJ, Malvestiti S, Schneeweiss A, Wuchter P, Jäger D, Podar K. Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway. PloS one. 2016;11(3):E1-E18.
93. Wilms B, Schmid SM, Luley K, Wiskemann J, Lehnert H. Prevention and treatment of cachexia. Exercise and nutritional therapy. Internist. 2016;57(10):971-7.
94. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jäger D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016;16(1):734E1-E9.
95. Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128(4):594-602.
96. Merz M, Moehler TM, Ritsch J, Bauerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J. Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur Radiol. 2016;26(5):1404-11.
97. Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M. Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells. Cancer Res. 2016;76(8):2219-30.
98. Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, Eichmüller SB, Jäger D, Waterboer T, Pawlita M, Brenner H. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;7(13):16420-32.
99. Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengass J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer. 2016;16:290 E1-E10.
100. Burkhardt D, Bartosova M, Schaefer B, Grabe N, Lahrmann B, Nasser H, Freise C, Schneider A, Lingnau A, Degenhardt P, Ranchin B, Sallay P, Cerkauskiene R, Malina M, Ariceta G, Schmitt CP, Querfeld U. Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. PloS one. 2016;11(11):E1-E14.
101. De Souza Silveira R, Carlsohn A, Langen G, Mayer F, Scharhag-Rosenberger F. Reliability and day-to-day variability of peak fat oxidation during treadmill ergometry. Journal of the International Society of Sports Nutrition. 2016;13(4):E1-E7.
102. Schmidt ME, Meynkohn A, Habermann N, Wiskemann J, Oelmann J, Hof H, Wessels S, Klassen O, Debus J, Potthoff K, Steindorf K, Ulrich CM. Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial. Int J Radiat Oncol. 2016;94(2):329-37.
103. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497-503.
104. Ungar N, Sieverding M, Weidner G, Ulrich CM, Wiskemann J. A self-regulation-based intervention to increase physical activity in cancer patients. Psychology, health & medicine. 2016;21(2):163-75.
105. Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, Ulrich A. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 2016;16:949E1-E9.
106. Mai EK, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731-41.
107. Valous NA, Lahrmann B, Halama N, Bergmann F, Jäger D, Grabe N. Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors. Medical physics. 2016;43(6):2936-44.
108. Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun. 2016;7:ncomms11845.
109. Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC medicine. 2016;14(1):170 E1-E16.
110. Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic oncology. 2016;34(10):433 e1-8.
111. Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H, Group GCSW, the D. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016;62:1-8.
112. Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-33.
113. Moschetta M, Kawano Y, Podar K. Targeting the Bone Marrow Microenvironment. Cancer treatment and research. 2016;169:63-102.
114. Schmidt M, Mock A, Jungk C, Sahm F, Ull AT, Warta R, Lamszus K, Gousias K, Ketter R, Roesch S, Rapp C, Schefzyk S, Urbschat S, Lahrmann B, Kessler AF, Löhr M, Senft C, Grabe N, Reuss D, Beckhove P, Westphal M, von Deimling A, Unterberg A, Simon M, Herold-Mende C. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget. 2016;7(12):14551-68.
115. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, Miguel JS, van de Donk NWCJ, Einsele H, Blade J, Durie BGM, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62.
116. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016;29(4):587-601.
117. Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2016;16(6):329-34 E1-E7.
118. Hassel JC, Lee SB, Meiss F, Meier F, Dimitrakopoulou-Strauss A, Jäger D, Enk AH. Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology. 2016;5(4):E1-E5.
119. Weiss J, Gajek T, Köhler BC, Haefeli WE. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions. Pharmaceutics. 2016;8(1):E1-E13.
120. Heining C, von Kalle C. What functions do oncological centers of excellence have in future research? Onkologe. 2016;22(3):152-7.

1. Andersen JP, Bogsted M, Dybkaer K, Mellqvist UH, Morgan GJ, Goldschmidt H, Dimopoulos MA, Einsele H, San Miguel J, Palumbo A, Sonneveld P, Johnsen HE. Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. Plos One. 2015;10(1):e0116966.
2. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jager D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology. 2015;4(4):e998538.
3. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N, Transp ESBM. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transpl. 2015;50(2):209-215.
4. Bashari MH, Fan F, Arn M, Vallet S, Opferman J, Cardone MH, Schneeweiss A, Jaeger D, Podar K. Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications. Breast. 2015;24:S37-S38.
5. Baudendistel I, Winkler E, Kamradt M, Brophy S, Längst G, Eckrich F, Heinze O, Bergh B, Szecsenyi J, Ose D. The patients' active role in managing a personal electronic health record: a qualitative analysis. Support Care Cancer. 2015;23(9):2613-21.
6. Baudendistel I, Winkler E, Kamradt M, Längst G, Eckrich F, Heinze O, Bergh B, Szecsenyi J, Ose D. Personal Electronic Health Records: Understanding User Requirements and Needs in Chronic Cancer Care. J Med Internet Res. 2015;17(5).
7. Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH, Hecker M, Goerge T, Umansky L, Beckhove P, Utikal J, Gorzelanny C, Diaz-Valdes N, Umansky V, Schneider SW. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153-3163.
8. Bayo P, Jou A, Stenzinger A, Shao C, Gross M, Jensen A, Grabe N, Mende CH, Rados PV, Debus J, Weichert W, Plinkert PK, Lichter P, Freier K, Hess J. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Mol Oncol. 2015;9(8):1704-19.
9. Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroentero. 2015;21(16):4911-4918.
10. Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015;29(7):1555-1563.
11. Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer. 2015;18(2):314-325.
12. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schonland SO. Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. J Clin Oncol. 2015;33(12):1371-1377.
13. Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garcia-Sanz R, Buda G, Gemignani F, Rios R, Vangsted AJ, Dumontet C, Martinez-Lopez J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SEH, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer. 2015;136(5):E351-E358.
14. Carl D, Grüllich C, Hering S, Schabet M. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC research notes. 2015;8:316.
15. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609-619.
16. Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dancik V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MA, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell reports. 2015;10:755-770.
17. Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, Hundemer M, Hillengass J, Alexi R, Goldschmidt H, Chen BA, Ho AD, Schmitt A. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 2015;55(2):275-283.
18. Das T, Safferling K, Rausch S, Grabe N, Boehm H, Spatz JP. A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat Cell Biol. 2015;17(3):276-287.
19. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BGM, Terpos E. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. J Clin Oncol. 2015;33(6):657-664.
20. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2015;100(10):1327-33.
21. Dreikhausen L, Blank S, Sisic L, Heger U, Weichert W, Jäger D, Bruckner T, Giese N, Grenacher L, Falk C, Ott K, Schmidt T. Association of angiogenic factors with prognosis in esophageal cancer. Bmc Cancer. 2015;15:121.
22. Fernandez-Ulibarri I, Hammer K, Arndt MAE, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer. 2015;136(9):2228-2240.
23. Fichtner S, Hose D, Engelhardt M, Meissner T, Neuber B, Krasniqi F, Raab M, Schonland S, Ho AD, Goldschmidt H, Hundemer M. Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. Clin Cancer Res. 2015;21(7):1712-1721.
24. Freudlsperger C, Horn D, Weissfuss S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, Hoffmann J, Freier K, Hess J. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer. 2015;136(12):2775-2785.
25. Funk S, Mark R, Bayo P, Flechtenmacher C, Grabe N, Angel P, Plinkert PK, Hess J. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer. 2015;136(9):2037-2046.
26. Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB. Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice. Int J Cancer. 2015;136(11):2588-2597.
27. Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RG, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta neuropathologica. 2015;130(3):419-34.
28. George B, Horn D, Bayo P, Zaoui K, Flechtenmacher C, Grabe N, Plinkert P, Krizhanovsky V, Hess J. Regulation and function of Myb-binding protein 1A (MYBBP1A) in cellular senescence and pathogenesis of head and neck cancer. Cancer Lett. 2015;358(2):191-9.
29. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015;21(12):2039-51.
30. Gollhofer SM, Wiskemann J, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Hof H, Potthoff K, Steindorf K. Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. Bmc Cancer. 2015;15:186.
31. Haag GM, Herrmann T, Jaeger D, Stremmel W, Schemmer P, Sauer P, Gotthardt DN. Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. BMC gastroenterology. 2015;15:171.
32. Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Büchler MW, Springfeld C, Jäger D, Debus J, Combs SE. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol. 2015;13:1-7.
33. Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, Schmitt M. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100(7):e285-8.
34. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell research 2015;25(2):208-224.
35. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25(3):399-400.
36. Hecksteden A, Kraushaar J, Scharhag-Rosenberger F, Theisen D, Senn S, Meyer T. Individual response to exercise training - a statistical perspective. Journal of applied physiology 2015;118(12):1450-1459.
37. Heining C, Richter D, Gröschel S, H. G, Fröling S. Integration der Genomsequenzierung in die klinische Hämato-Onkologie. klinikarzt. 2015;44(10):436-440.
38. Hillengass J, Stoll J, Zechmann CM, Kunz C, Wagner B, Heiss C, Sumkauskaite M, Moehler TM, Schlemmer HP, Goldschmidt H, Delorme S. The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur Radiol. 2015;25(3):745-750.
39. Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications. Urologe. 2015;54(6):800-803.
40. Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. Bmc Cancer. 2015;15:392.
41. Höfner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jäger D, Grüllich C. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World J Urol. 2015;33(6):833-839.
42. Huber J, Ihrig A, Winkler E, Brechtel A, Friederich HC, Herzog W, Frank M, Grüllich C, Hallscheidt P, Zeier M, Pahernik S, Hohenfellner M. Interdisciplinary counseling service for renal malignancies: a patient-centered approach to raise guideline adherence. Urol Oncol. 2015;33(1):23 e1-7.
43. Husedzinovic A, Ose D, Schickhardt C, Fröhling S, Winkler EC. Stakeholders' perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet. 2015;23(12):1607-14.
44. Iacobelli S, de Wreede LC, Schonland S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kroger N, Gahrton G, CMWP E, Subcomm PCD. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transpl. 2015;50(4):505-510.
45. Jäger D, Ma JH, Mardiak J, Ye DW, Korbenfeld E, Zemanova M, Ahn H, Guo J, Leonhartsberger N, Stauch K, Böckenhoff A, Yu J, Escudier B. Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study. Clin Genitourin Canc. 2015;13(2):156-164.
46. Jiang HH, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352-2360.
47. Kamradt M, Baudendistel I, Längst G, Kiel M, Eckrich F, Winkler E, Szecsenyi J, Ose D. Collaboration and communication in colorectal cancer care: a qualitative study of the challenges experienced by patients and health care professionals. Family practice. 2015;32(6):686-93.
48. Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J, Bazhin AV. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Brit J Cancer. 2015;112(6):1027-1036.
49. Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, Konig R, Bernhard H, Machlenkin A, Boutros M, Beckhove P. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. Embo Mol Med. 2015;7(4):450-463.
50. Kiesgen S, Arndt MAE, Körber C, Arnold U, Weber T, Halama N, Keller A, Bötticher B, Schlegelmilch A, Liebers N, Cremer M, Herold-Mende C, Dyckhoff G, Federspil PA, Jensen AD, Jäger D, Kontermann RE, Mier W, Krauss J. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Lett. 2015;357(1):364-373.
51. Kittas A, Barozet A, Sereshti J, Grabe N, Tsoka S. CytoASP: a Cytoscape app for qualitative consistency reasoning, prediction and repair in biological networks. BMC systems biology. 2015;9:34.
52. Klupp F, Diers J, Kahlert C, Neumann L, Halama N, Franz C, Schmidt T, Lasitschka F, Warth A, Weitz J, Koch M, Schneider M, Ulrich A. Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma. Ann Surg Oncol. 2015;10.1245/s10434-015-4485-4.
53. Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. Bmc Cancer. 2015;15(1):919.
54. Kuehl R, Scharhag-Rosenberger F, Schommer K, Schmidt ME, Dreger P, Huber G, Bohus M, Ulrich CM, Wiskemann J. Exercise Intensity Classification in Cancer Patients Undergoing Allogeneic HCT. Med Sci Sport Exer. 2015;47(5):889-895.
55. Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126(17):1996-2004.
56. Laryionava K, Heussner P, Hiddemann W, Winkler EC. Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. Support Care Cancer. 2015;23(3):715-721.
57. Lisenko K, Schonland S, Hegenbart U, Wallenwein K, Braun U, Mai EK, Hillengass J, Raab M, Jauch A, Ho AD, Goldschmidt H, Hundemer M. Potential therapeutic targets in plasma cell disorders: A flow cytometry study. Cytometry Part B, Clinical cytometry. 2015;10.1002/cyto.b.21351.
58. Lohr J, Mock A, Beckhove P, Herold-Mende C. Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. Anticancer Res. 2015;35(5):2681-2690.
59. Lorenzen S, Knorrenschild JR, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51(5):569-576.
60. Lotz J, Olesch J, Muller B, Polzin T, Galuschka P, Lotz J, Heldmann S, Breuhahn K, Gonzalez M, Lahrmann B, Grabe N, Laue H, Sedlaczek O, Warth A, Modersitzki J. Patch-Based Nonlinear Image Registration for Gigapixel Whole Slide Images. IEEE Transactions on Biomedical Engineering. 2015;10.1109/tbme.2015.2503122:1-1.
61. Lupa DMW, Kalfalah F, Safferling K, Boukamp P, Poschmann G, Volpi E, Götz-Rösch C, Bernerd F, Haag L, Huelnenthal U, Fritsche E, Boege F, Grabe N, Tigges J, Stühler K, Krutmann J. Characterization of Skin Aging-Associated Secreted Proteins (SAASP) Produced by Dermal Fibroblasts Isolated from Intrinsically Aged Human Skin. J Invest Dermatol. 2015;135(8):1954-1968.
62. Machiels JP, Specenier P, Krauss J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemoth Pharm. 2015;76(1):13-20.
63. Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721-9.
64. Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica. 2015;100(6):818-25.
65. Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Transl Oncol. 2015;8(6):487-496.
66. Meissner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC medical genomics. 2015;8:85.
67. Merz M, Moehler TM, Ritsch J, Bauerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J. Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur Radiol. 2015;26(5):1404-11.
68. Merz M, Ritsch J, Kunz C, Wagner B, Sauer S, Hose D, Moehler T, Delorme S, Goldschmidt H, Zechmann C, Hillengass J. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma. Clin Cancer Res. 2015;21(1):106-112.
69. Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964-9.
70. Merz M, Schweizer L, Kentar M, Schneider T, Goldschmidt H, Hillengass J. Extramedullary relapse after accidental head injury in a patient with multiple myeloma. Ann Hematol. 2015;94(2):351-353.
71. Nienhueser H, Kunzmann R, Sisic L, Blank S, Strowitzk MJ, Bruckner T, Jäger D, Weichert W, Ulrich A, Büchler MW, Ott K, Schmidt T. Surgery of Gastric Cancer and Esophageal Cancer: Does Age Matter? J Surg Oncol. 2015;112(4):387-395.
72. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9.
73. Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Czlonkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. Liver Int. 2015;35(5):1615-1622.
74. Pfeil TA, Laryionava K, Reiter-Theil S, Hiddemann W, Winkler EC. What Keeps Oncologists From Addressing Palliative Care Early on With Incurable Cancer Patients? An Active Stance Seems Key. Oncologist. 2015;20(1):56-61.
75. Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, Eichmüller SB, Jäger D, Enk A, Beckhove P. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. Cancer Immunol Immun. 2015;64:1369-1381.
76. Podar K. Toward optimizing pomalidomide therapy in MM patients. Blood. 2015;125(26):3968-9.
77. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, Benner A, Büchler MW, Jäger D, Halama N, Khazaie K, Weitz J, Beckhove P. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis (vol 125, pg 739, 2015). J Clin Invest. 2015;125(3):1364-1364.
78. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, Benner A, Büchler MW, Jäger D, Halama N, Khazaie K, Weitz J, Beckhove P. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125(2):739-751.
79. Reuter T, Warta R, Theile D, Meid AD, Rigalli JP, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J. Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's archives of pharmacology. 2015;388(11):1141-50.
80. Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. American journal of nuclear medicine and molecular imaging. 2015;5(5):469-78.
81. Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med. 2015;40(6):e300-7.
82. Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, Haberkorn U, Schlemmer HP, Delorme S, Dimitrakopoulou-Strauss A. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. American journal of nuclear medicine and molecular imaging. 2015;5(5):479-92.
83. Safferling K, Sütterlin T, Grabe N. how wounds heal. systembiologiede. 2015(09):8-12.
84. San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100(10):1334-9.
85. Scharhag-Rosenberger F, Kuehl R, Klassen O, Schommer K, Schmidt ME, Ulrich CM, Wiskemann J, Steindorf K. Exercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations. J Cancer Surviv. 2015;10.1007/s11764-015-0437-z.
86. Scharhag-Rosenberger F, Wiskemann J, Scharhag J. Cardiopulmonary exercise testing in cancer patients: should we really refrain from considering it for preparticipation screening? Oncologist. 2015;20(2):228.
87. Schirrmacher V, Schlude C, Weitz J, Beckhove P. Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase I clinical study. Int J Oncol. 2015;46(1):71-77.
88. Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer. 2015;137(2):471-480.
89. Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Büchler MW, Ott K. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–1347.
90. Schmidt T, Sisic L, Sterzing F, Haag GM, Kunzmann R, Grenacher L, Weichert W, Jäger D, Büchler MW, Ott K. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)]. Chirurg. 2015;86(10):955-62.
91. Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015;4(4):e1001217.
92. Schneider M, Korzeniewski N, Merkle K, Schüler J, Grüllich C, Hadaschik B, Hohenfellner M, Duensing S. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies. Urol Oncol. 2015;33(2):72 e1-7.
93. Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, Safi S, Utikal J, Hoffmann H, Umansky V. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol. 2015;180(3):467-474.
94. Schott S, Vallet S, Tower RJ, Noor S, Tiwari S, Schem C, Busch C. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. Invest New Drug. 2015;33(4):816-26.
95. Schrader CH, Kolb M, Zaoui K, Flechtenmacher C, Grabe N, Weber KJ, Hielscher T, Plinkert PK, Hess J. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer. 2015;14:107.
96. Schuol S, Schickhardt C, Wiemann S, Bartram CR, Tanner K, Eils R, Meder B, Richter D, Glimm H, von Kalle C, Winkler EC. So rare we need to hunt for them: reframing the ethical debate on incidental findings. Genome Med. 2015;7(1):83.
97. Schwamb B, Pick R, Fernandez SBM, Völp K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J, Zörnig I, Hammerschmidt M, Nowak M, Penzel R, Zatloukal K, Joos S, Rieker RJ, Agaimy A, Söder S, Reid-Lombardo K, Kendrick ML, Bardsley MR, Hayashi Y, Asuzu DT, Syed SA, Ordog T, Zörnig M. FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer. 2015;137(6):1318-1329.
98. Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D. miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression. Oncotarget. 2015;6(36):39165-83.
99. Seidensaal K, Nollert A, Feige AH, Muller M, Fleming T, Gunkel N, Zaoui K, Grabe N, Weichert W, Weber KJ, Plinkert P, Simon C, Hess J. Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. Mol Cancer. 2015;14(1):204.
100. Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Th. 2015;15(4):505-516
101. Sklenarova H, Haun MW, Krümpelmann A, Friederich HC, Huber J, Thomas M, Winkler EC, Girgis A, Dinkel A, Herzog W, Hartmann M. Psychometric evaluation of the German Version of the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C-G) of cancer patients. Eur J Cancer Care. 2015;24(6):884-97.
102. Sklenarova H, Krümpelmann A, Haun MW, Friederich HC, Huber J, Thomas M, Winkler EC, Herzog W, Hartmann M. When Do We Need to Care About the Caregiver? Supportive Care Needs, Anxiety, and Depression Among Informal Caregivers of Patients With Cancer and Cancer Survivors. Cancer. 2015;121(9):1513-1519.
103. Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S905-14.
104. Staffa L, Echterdiek F, Nelius N, Benner A, Werft W, Lahrmann B, Grabe N, Schneider M, Tariverdian M, Doeberitz MV, Blaker H, Kloor M. Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome - Molecular Alterations and Association with Clinical Parameters. Plos One. 2015;10(3).
105. Steindorf K, Clauss D, Wiskemann J, Schmidt ME. Physical Activity and Gastrointestinal Cancers: Primary and Tertiary Preventive Effects and Possible Biological Mechanisms. Sports. 2015;3(3):145-148.
106. Tauchert FK, Bankstahl US, Winkler EC, Hofheinz R, Marschner N, Quidde J, Hipp M, Hoeffkes HG, Weber M, Trojan J, Van Kampen M, Brueckl WM, Jaeger E, Al-Batran SE, Grp AQW. Changing symptom burden in cancer patients: Does physician-patient communication cover physical, psychological and social discomfort? A Survey among 2009 German patients. J Clin Oncol. 2015;33(15).
107. Teichgräber V, Monasterio C, Chaitanya K, Boger R, Gordon K, Dieterle T, Jäger D, Bauer S. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci. 2015;60(2):264-272.
108. Theile D, Allendorf D, Köhler BC, Jassowicz A, Weiss J. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines. J Pharm Pharmacol. 2015;67(11):1575-84.
109. Ungar N, Sieverding M, Ulrich CM, Wiskemann J. What explains the intention to be physically active in cancer patients? Different determinants for active and insufficiently active patients. Journal of psychosocial oncology. 2015;33(1):15-33.
110. Vallet S, Pahernik S, Höfner T, Tosev G, Hadaschik B, Duensing S, Sedlaczek O, Hohenfellner M, Jäger D, Grüllich C, NCT NCTD. Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clin Genitourin Canc. 2015;13(3):E145-E152.
111. Vogel A, Kasper S, Weichert W, Bitzer M, Block A, Riess H, Schulze-Bergkamen H, Moehler MH, Merx KE, Endris V, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Kubicka S. Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2015;33(15).
112. Vogel A, Kullmann F, Kunzmann V, Riess H, Al-Batran SE, Oettle H, Plentz R, Siveke J, Springfeld C. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat. 2015;38(11):596-603.
113. Waldera Lupa DM, Kalfalah F, Safferling K, Boukamp P, Poschmann G, Volpi E, Gotz-Rosch C, Bernerd F, Haag L, Huebenthal U, Fritsche E, Boege F, Grabe N, Tigges J, Stuhler K, Krutmann J. Characterization of Skin Aging-Associated Secreted Proteins (SAASP) Produced by Dermal Fibroblasts Isolated from Intrinsically Aged Human Skin. J Invest Dermatol. 2015;135(8):1954-68.
114. Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M. T cell-based targeted immunotherapies for patients with multiple myeloma. Int J Cancer. 2015;136(8):1751-68.
115. Weber T, Mavratzas A, Kiesgen S, Haase S, Botticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. Journal of immunology research. 2015;2015:561814.
116. Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2015;101(3):e116-9.
117. Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Duber C, Lang HK, Otto G, Worns MA, Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35(2):591-600.
118. Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Worns MA, Galle PR, Schulze-Bergkamen H. Predictive Scores in Primary Biliary Cirrhosis A Retrospective Single Center Analysis of 204 Patients. J Clin Gastroenterol. 2015;49(5):438-447.
119. Winkler E, Schildmann J. Decision making with patients with advanced cancer. A contribution from clinical ethics. Onkologe. 2015;21(7):630-636.
120. Wiskemann J, Friedmann-Bette B. Potenzial körperlicher Aktivität in Prävention und Therapie chronisscher Erkrankungen. Aktuel Ernahrungsmed. 2015;40(389-408):20.
121. Wiskemann J, Kleindienst N, Kuehl R, Dreger P, Schwerdtfeger R, Bohus M. Effects of physical exercise on survival after allogeneic stem cell transplantation. Int J Cancer. 2015;137(11):2749-2756.
122. Wiskemann J, Kuehl R, Dreger P, Huber G, Kleindienst N, Ulrich CM, Bohus M. Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) - Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation. Bmc Cancer. 2015;15:619.
123. Zhou XG, Li JL, Marx C, Tolstov Y, Rauch G, Herpel E, Macher-Goeppinger S, Roth W, Grullich C, Pahernik S, Hohenfellner M, Duensing S. Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma Prognostic and Translational Implications. Transl Oncol. 2015;8(6):480-486.
124. Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jäger D. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer. 2015;136(1):138-151.

Lehr-/Handbücher

1. Brücken bauen. Das Marsilius-Kolleg und seine fellows 2008-2014.
   Hrsg.: Just T, Rausch T, Schneidmueller B.
   Medizinethik als Grenzgang.
   Winkler EC.
   ISBN 978-3-8253-6368-0; 2014, S.248-250.
   Verlag: Universitätsverlag Winter, Heidelberg
2. Computational biophysics of the skin.
   Hrsg.: Querleux B.
   Graphical multi-scale modeling of epidermal homeostasis with EPISIM.
   Suetterlin T, Grabe N.
   ISBN 978-981-4463-84-3; 2014, S. 421-460.
   Verlag: Pan Stanford Publishing, Singapore
3. Fatigue bei Krebserkrankungen.
   Hrsg.: Heim R, Weis J.
   Sport- und Bewegungstherapie.
   Baumann FT, Wiskemann J.
   ISBN 978-3-7945-2946-9; 2014, S.154-165.
   Verlag: Schattauer Verlag, Stuttgart
4. Therapeutic Antibodies, 2nd Edition.
   Hrsg.: Duebel S, Reichert JM.
   Antibody targeted drugs: from chemical immunoconjugates to recombinant fusion proteins.
   Krauss J, Mavratzas A, Arndt MAE, Kiesgen S.
   ISBN 978-3-527-32937-3; 2014 Sept.
   Verlag: Wiley VCH

Zeitschriften

1. Efficacy of subcutaneous Bortezomib in the management of patients with multiple myeloma or relapsed mantle cell lymphoma
   Podar K.
   Clinical Medicine Insights: Therapeutics. 2014:6; 15-23. doi: 10.4137/CMT.S9308.
2. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
   Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opfermann JT, Sattler M, Anderson KC, Jaeger D, Podar K.
   Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8.
3. Generation of "LYmph Node Derived Antibody Libraries" (LYNDAL) for selecting fully human antiviral antibody fragments with therapeutic potential.
   Diebolder P, Keller A, Haase S, Schlegelmilch A, Kiefer JD, Karimi T, Weber T, Moldenhauer G, Kehm
   R, Eis-Hübinger AM, Jaeger D, Federspil PA, Herold-Mende C, Dyckhoff G, Kontermann RE, Arndt MA, Krauss J.
   MAbs. 2014 Jan-Feb;6(1):130-42.
4. Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.
   Koehler BC, Jaeger D, Schulze-Bergkamen H.
   World J Gastroenterol. 2014 Feb 28;20(8):1923-34. doi: 10.3748/wjg.v20.i8.1923.
5. Pan-Bcl-2 inhibitor Obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
   Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H.
   PLOS ONE 2014. (in press)
6. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg
   Berger AK, Abel U, Komander C, Harig S, Jaeger D, Springfeld C.
   Pancreatology. 2014 May-Jun;14(3):211-5. doi: 10.1016/j.pan.2014.03.004. Epub 2014 Mar 18.
7. Ethische Herausforderungen der Genomsequenzierung in der translationalen Forschung und Antworten aus dem EURAT-Projekt.
   Winkler EC, Schickhardt C.
   J Lab Med. 2014;38(4):211-220. doi: 10.1515/labmed-2014-0027, August 2014.
8. Advance care planning in oncology – ethical and medical competences are needed.
   Schildmann J, Winkler EC.
   Oncol Res Treat. 2014;37(1-2). doi: 10.1159/000358160. 2014 Jan 24.
9. Efficacy of exercise training in SCT patients-who benefits most?
   Wiskemann J, Kuehl R, Dreger P, Schwerdtfeger R, Huber G, Ulrich CM, Jaeger D, Bohus, M.
   Bone Marrow Transplant. 2014 Mar;49(3):443-8. doi: 10.1038/bmt.2013.194. Epub 2013 Dec 9.
10. Multidisciplinary health care needs of psychologically distressed cancer patients in a Comprehensive Cancer Center.
    Schiel RO, Brechtel A, Hartmann M, Taubert A, Walther J, Wiskemann J, Roetzer I, Becker N, Jaeger D, Herzog W, Friederich HC.
    Dtsch Med Wochenschr. 2014 Mar;139(12):587-91. doi: 10.1055/s-0034-1369856. Epub 2014 Mar 11.
11. The big mystery.
    Delorme S, Jaeger D.
    Radiologe. 2014 Feb;54(2):106. doi: 10.1007/s00117-013-2543-0.
12. Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer - a single cancer-center experience.
    Haag GM, Apostolidis L, Jaeger D.
    Tumori. 2014 May-Jun;100(3):237-42. doi: 10.1700/1578.17188.
13. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G1, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
    Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.
14. Assessing patient-caregiver communication in cancer-a psychometric validation of the Cancer Communication Assessment Tool (CCAT-PF) in a German sample.
    Haun MW, Sklenarova H, Winkler EC, Huber J, Thomas M, Siminoff LA, Woll M, Brechtel A, Herzog W, Hartmann M.
    Support Care Cancer. 2014 Sep;22(9):2473-8. doi: 10.1007/s00520-014-2241-0. Epub 2014 Apr 11.
15. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D, Gal Z, Warta R, Rigalli J, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G, Weiss J
    Cancer Biol Ther. 2014 April; 15:4, 436-442. doi: 10.4161/cbt.27632. Epub 2014 Jan 21.
16. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zoernig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmueller SB, Jaeger D.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980. [Epub ahead of print].
17. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.
    Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M.
    J Pathol. 2014 Jul 16. doi: 10.1002/path.4405. [Epub ahead of print]
18. Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma.
    Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, von Deimling A, Beckhove P, Mogler C, Goidts V, Unterberg A, Eckstein V, Herold-Mende C.
    J Pathol. 2014 Sep;234(1):23-33. doi: 10.1002/path.4366.
19. Stem cell Transplantation for Eradication of Minimal Pancreatic Cancer persisting after surgical Excision (STEMPACE Trial, ISRCTN47877138): study protocol for a phase II study.
    Schmitz-Winnethal FH, Schmidt T, Lehmann M, Beckhove P, Kieser M, Ho AD, Dreger, Buechler MW.
    BMC Cancer. 2014 Mar 10;14:168. doi: 10.1186/1471-2407-14-168.
20. A vaccine targeting mutant IDH1 induces antitumour immunity.
    Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmueller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M.
    Nature. 2014 Aug 21;512(7514):327-327. doi: 10.1038/nature13387.
21. Randomized controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life.
    Steindorf K, Schmidt ME, Klassen O, Ulrich C, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K.
    Ann Oncol. 2014 Aug 5; pii:mdu374.
22. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
    Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, Hundemer M, Hillengass J, Alexi R, Goldschmidt H, Chen BA, Ho AD, Schmitt A.
    Transfusion. 2014 Aug 13. doi: 10.1111/trf.12813.
23. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
    Breitkreutz I, Heiss C, Perne A, Beimler J, Jaeger D, Egerer G, Ho AD, Neben K, Zeier M, Goldschmidt H, Raab MS.
    Bone Marrow Transpl. 2014 Aug 4. doi: 10.1038/bmt.2014.165.
24. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
    Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudziński M, Weinhold N, Reis RM, Canzian F.
    Int J Cancer. 2014 Jul 28. doi: 10.1002/ijc.29101.
25. European Perspective on Multiple Myeloma Treatment Strategies in 2014.
    Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A.
    Oncologist. 2014 Aug;19(8):829-844.
26. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma.
    Weinhold N, Foersti A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, Noethen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schoenland SO, Hemminki K.
    Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.208.
27. Extramedullary relapse after accidental head injury in a patient with multiple myeloma.
    Merz M, Schweizer L, Kentar M, Schneider T, Goldschmidt H, Hillengass J.
    Ann Hematol. 2014 Jun 29. [Epub ahead of print]
28. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
    Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.
    J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329.
29. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.
    Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B.
    Oncotarget. 2014 May 15;5(9):2487-98.
30. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.
    Wolf MB, Murray F, Kilk K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, Kauczor HU, Weber MA.
    Eur J Radiol. 2014 Jul;83(7):1222-30. doi: 10.1016/j.ejrad.2014.02.008.
31. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
    Hundemer M, Engelhardt M, Bruckner T, Kraeker S, Schmitt A, Sauer S, Neben K, Witzens-Harig M, Goldschmidt H, Ho AD, Wuchter P.
    J Clin Apheresis. 2014 Apr 26. doi: 10.1002/jca.21323.
32. Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology.
    Andrulis M, Baeuerle T, Goldschmidt H, Delorme S, Landgren O, Schirmacher P, Hillengass J.
    Eur J Radiol. 2014 Jun;83(6):970-4. doi: 10.1016/j.ejrad.2014.03.005.
33. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
    Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F.
    Leuk Lymphoma. 2014 Jun 16:1-3. [Epub ahead of print] No abstract available.
34. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK, Hillengass J, Listl K, Kilk K, Hielscher T, Landgren O, Delorme S, Goldschmidt H, Kauczor HU, Weber MA.
    Int J Cancer. 2014 Apr 7. doi: 10.1002/ijc.28877.
35. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C, Goldschmidt H, Hose D, Pan L, Cheng C, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol I. 2014 Jul;41(7):1343-53. doi: 10.1007/s00259-014-2721-y.
36. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
    Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS, Jauch A, Neben K, Hose D, Egerer G, Weber MA, Delorme S, Goldschmidt H, Hillengass J.
    Leukemia. 2014 Sep;28(9):1902-8. doi: 10.1038/leu.2014.75.
37. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
    Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schoenland SO.
    Amyloid. 2014 Mar;21(1):9-17. doi: 10.3109/13506129.2013.854766.
38. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.
    Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ, Yong K, Walker BA, Hoffmann P, Muehleisen TW, Langer C, Doerner E, Joeckel KH, Eisele L, Noethen MM, Hose D, Davies FE, Goldschmidt H, Morgan GJ, Hemminki K, Houlston RS.
    Blood. 2014 Apr 17;123(16):2513-7; quiz 2593. doi: 10.1182/blood-2013-10-532283.
39. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
    Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, Goldschmidt H, Hillengass J.
    Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.
40. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.
    Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.
    Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330.
41. Inherited genetic susceptibility to multiple myeloma.
    Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, Hemminki K, Houlston RS.
    Leukemia. 2014 Mar;28(3):518-24. doi: 10.1038/leu.2013.344.
42. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
    Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B.
    Brit J Haematol. 2014 Feb;164(4):613-6. doi: 10.1111/bjh.12660.
43. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M, Adam P, Goldschmidt H, Fend F, Kanz L, Weisel K.
    Cl Lymph Myelom Leuk. 2014 Feb;14(1):e7-e11. doi: 10.1016/j.clml.2013.07.101.
44. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
    Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Haenel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.
    Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585.
45. IMWG consensus on risk stratification in multiple myeloma.
    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.
    Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247.
46. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.
    Hillengass J, Weber MA, Kilk K, Listl K, Wagner-Gund B, Hillengass M, Hielscher T, Farid A, Neben K, Delorme S, Landgren O, Goldschmidt H.
    Leukemia. 2014 Jan;28(1):174-8. doi: 10.1038/leu.2013.244.
47. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.
    Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz C, Benner A, Falk C, Weitz J, Koch M.
    Brit J Cancer. 2014 Jan 21;110(2):441-9. doi: 10.1038/bjc.2013.745.
48. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.
    Chen H, Werner S, Tao S, Zoernig I, Brenner H.
    Cancer Lett. 2014 May 1;346(2):178-87. doi: 10.1016/j.canlet.2014.01.007.
49. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
    Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jaeger D, von Kalle C, Ungerechts G.
    Mol Ther. 2014 Aug 26. doi: 10.1038/mt.2014.160.
50. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
    Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jaeger D, von Kalle C, Ungerechts G.
    Cancer Gene Ther. 2014 Aug 22. doi: 10.1038/cgt.2014.40.
51. Primary transcriptome map of the hyperthermophilic archaeon Thermococcus kodakarensis.
    Jaeger D, Foerstner KU, Sharma CM, Santangelo TJ, Reeve JN.
    BMC Genomics. 2014 Aug 16;15(1):684.
52. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
    Hoefner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jaeger D, Gruellich C.
    World J Urol. 2014 Aug 12. doi: 10.1007/s00345-014-1375-5
53. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zoernig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jaeger D.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980.
54. Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.
    Potthoff K, Habl G, Bruckner T, Suppan C, Hassel J, Jaeger D, Indorf M, Debus J.
    BMC Cancer. 2014 Apr 17;14:270. doi: 10.1186/1471-2407-14-270.
55. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
    Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jaeger D, Buechler M, Bruckner T, Siewert J, Ott K.
    Gastric Cancer. 2014 Apr 11. doi: 10.1007/s10120-014-0367-x
56. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
    Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jaeger D, Buechler MW, Weitz J, Koch M.
    BMC Cancer. 2014 Mar 11;14:174. doi: 10.1186/1471-2407-14-174.
57. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
    Karakhanova S, Mosl B, Harig S, von Ahn K, Fritz J, Schmidt J, Jaeger D, Werner J, Bazhin AV.
    Int J Mol Sci. 2014 Mar 7;15(3):4104-25. doi: 10.3390/ijms15034104.
58. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, Koenig J, Hoppe-Lotichius M, Hansen T, Pitton MB, Dueber C, Otto G, Schuchmann M, Galle PR, Woerns MA.
    J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.
59. Predictive Scores in Primary Biliary Cirrhosis: A Retrospective Single Center Analysis of 204 Patients.
    Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Woerns MA, Galle PR, Schulze-Bergkamen H.
    J Clin Gastroenterol. 2014 Jul 10.  doi: 10.1097/MCG.0000000000000176
60. Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.
    Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Tuereci O.
    Cancer Immunol Immun. 2014 Aug 28. doi: 10.1007/s00262-014-1596-x
61. Classification of exercise intensities in hematological cancer patients during and after allo-HSCT.
    Kuehl R, Scharhag-Rosenberger F, Schommer K, Schmidt ME, Dreger P, Huber G, Bohus M, Ulrich CM, Wiskemann J.
    Med Sci Sport Exer. 2014 Sep 8. [Epub ahead of print]
62. Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy.
    Klassen O, Schmidt ME, Scharhag-Rosenberger F, Sorkin M, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J.
    Acta Oncol. 2014 May 16:1-10.
63. Irisin does not mediate resistance training-induced alterations in resting metabolic rate.
    Scharhag-Rosenberger F, Meyer T, Wegmann M, Ruppenthal S, Kaestner L, Morsch A, Hecksteden A.
    Med Sci Sports Exer. 2014 Sep;46(9):1736-43. doi: 10.1249/MSS.0000000000000286.
64. Blood lactate concentrations are mildly affected by mobile gas exchange measurements.
    Scharhag-Rosenberger F, Wochatz M, Otto C, Cassel M, Mayer F, Scharhag J.
    Int J Sports Med. 2014 Jun;35(7):590-4. doi: 10.1055/s-0033-1354386.
65. Can more than one incremental cycling test be performed within one day?
    Scharhag-Rosenberger F, Carlsohn A, Lundby C, Schueler S, Mayer F, Scharhag J.
    Eur J Sport Sci. 2014;14(5):459-67. doi: 10.1080/17461391.2013.853208.
66. Limited benefit of Fatmax-test to derive training prescriptions.
    Schwindling S, Scharhag-Rosenberger F, Kindermann W, Meyer T.
    Int J Sports Med. 2014 Apr;35(4):280-5. doi: 10.1055/s-0033-1349106.
67. Wissenschaftliche Studien zu körperlichem Training bei onkologischen Patienten: Empfehlungen zu den Erhebungsmethoden.
    Scharhag-Rosenberger F, Becker T, Streckmann F, Schmidt K, Berling A, Bernardi A, Engeroff T, Exner AK, Gutekunst K, Hofmeister D, Jensen W, Kaehnert H, Kneis S, Limbach M, Mau-Moelle A, Roecker K, Schmidt M, Schmidt T, Stoeckel T, Wehrle A, Wisemann J, Zimmer P, Zopf E, Steindorf K.
    Deutsche Zeitschrift für Sportmedizin. 2014 – in print.
68. Nebenwirkungsorientierte Behandlungspfade für die bewegungstherapeutische Betreuung von onkologischen Patienten.
    Wiskemann J, Scharhag-Rosenberger F.
    B & G. 2014 30(4):146-150. doi: 10.1055/s-0034-1384418
69. Physical performance and psychosocial status in lung cancer patients: results from a pilot study.
    Hummler S, Thomas M, Hoffmann B, Gaertner P, Zoz M, Huber G, Ulrich CM, Wiskemann J.
    Oncol Res Treat. 2014;37(1-2):36-41. doi: 10.1159/000358157.
70. Exercise in patients with non-small cell lung cancer.
    Kuehr L, Wiskemann J, Abel U, Ulrich CM, Hummler S, Thomas M.
    Med Sci Sports Exer. 2014 Apr;46(4):656-63. doi: 10.1249/MSS.0000000000000158.
71. Impact of resistance training in cancer survivors: a meta-analysis.
    Strasser B, Steindorf K, Wiskemann J, Ulrich N.
    Med Sci Sports Exer. 2013 Nov;45(11):2080-90. doi: 10.1249/MSS.0b013e31829a3b63.
72. Exercise in breast cancer patients: impact on health.
    Schmidt M, Wiskemann J. Steindorf K.
    Breast Cancer Management. 2014 Vol. 3, No. 3, Pages 241-250 , doi: 10.2217/bmt.14.12
73. What explains the intention to be physically active in cancer patients? – Different determinants for active and insufficiently active patients.
    Ungar N, Sieverding M, Ulrich CM, Wiskemann J.
    Psychosocial Oncology. 2014 (accepted)
74. Factors influencing willingness for participation in an exercise intervention study in breast cancer patients during radiotherapy.
    Gollhofer SM, Wiskemann J, Schmidt M, Klassen O, Ulrich CM, Oelmann J, Hof H, Pottkopff K, Steindorf K.
    BMC Cancer. 2014 (submitted and under review)
75. Standards der Sportmedizin: Krafttraining als Supportivtherapie bei onkologischen Patienten.
    Wiskemann J, Steindorf K.
    Deutsche Zeitschrift für Sportmedizin. 2014 65(1):22-24.
76. Potential physiologic and molecular mechanisms linking endurance and resistance training with beneficial effects for cancer patients.
    Steindorf K, Schmidt ME, Wiskemann J, Ulrich CM.
    Deutsche Zeitschrift für Sportmedizin. 2014 (accepted)
77. Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor Small Molecules in Oncology.
    Gruellich C.
    Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12.
78. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review).
    Georgi B, Korzeniewski N, Hadaschik B, Gruellich C, Roth W, Sültmann H, Pahernik S, Hohenfellner M, Duensing S.
    Int J Oncol. 2014 Oct;45(4):1337-44. doi: 10.3892/ijo.2014.2567.
79. Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactive in patients’ sera after full hematopoitic regeneration from allogeneic stem cell transplantation.
    Ziegler C, Finke J, Gruellich C.
    Transp Immunol. 2014 May;30(4):136-9. doi: 10.1016/j.trim.2014.03.005.
80. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
    Roeder F, Lehner B, Schmitt T, Kasper B, Egerer G, Sedlaczek O, Gruellich C, Mechtersheimer G, Wuchter P, Hensley FW, Huber PE, Debus J, Bischof M.
    BMC Cancer. 2014 May 20;14:350. doi: 10.1186/1471-2407-14-350.
81. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M, Schueler J, Hoefflin R, Korzeniewski N, Gruellich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.
    Urol Oncol. 2014 Aug;32(6):877-84. doi: 10.1016/j.urolonc.2014.03.011.
82. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal—Implications for targeted therapies.
    Schneider M, Korzeniewski N, Merkle K, Schueler J, Gruellich C, Hadaschik B, Hohenfellner M, Duensing S.
    Urol Oncol. 2014 Jul 1. pii: S1078-1439(14)00206-3. doi: 10.1016/j.urolonc.2014.06.001.
83. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
    Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K.
    BMC Cancer. 2014 Feb 3;14:58. doi: 10.1186/1471-2407-14-58.
84. Is preoperative chemotherapy followed by surgery the appropriate treatmet for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruchner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Bueckler M, Ott K.
    Ann Surg Oncol. 2014 May;21(5):1739-48. doi: 10.1245/s10434-013-3462-z.
85. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Kraemer A, Klein B, Raab MS.
    Oncotarget. 2014 Sep 26. [Epub ahead of print]
86. A gene expression signature for high-risk multiple myeloma.
    Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P.
    Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8.
    Erratum in: Leukemia. 2014 May;28(5):1178-80.
87. T cell-based targeted immunotherapies for patients with multiple myeloma.
    Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M.
    Int J Cancer. 2014 Sep 6. doi: 10.1002/ijc.29190.
88. Aprepitant, Granisetron and Dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose Melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
    Schmitt T, Goldschmidt H, Neben K, Freiberger A, Huesing J, Gronkowski M, Thalheimer M, Pelzl LH, Mikus G, Burhenne J, Ho AD, Egerer G.
    J Clin Oncol. 2014 Oct 20;32(30):3413-20. doi: 10.1200/JCO.2013.55.0095.
89. State of the art treatment of progressive or refractory multiple myeloma.
    Schmidt-Wolf IG, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M.
    Dtsch Med Wochenschr. 2014 Oct;139(41):2091-5. doi: 10.1055/s-0034-1387268.
90. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.
    Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H.
    PLoS One. 2014 Oct 16;9(10):e110591. doi: 10.1371/journal.pone.0110591. eCollection 2014.
91. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I, Hammer K, Arndt MA, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM.
    Int J Cancer. 2014 Oct 10. doi: 10.1002/ijc.29258.
92. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
    Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jaeger D, Buechler MW, Debus J.
    Ann Surg Oncol. 2014 Aug;21(8):2801-7. doi: 10.1245/s10434-014-3607-8.

Patentanmeldungen

1. EP 14 18 399.2
   Construct for the delivery of a molecule into the cytoplasm of a cell
   Erfinder: Kiesgen S, Arndt MA, Krauss J.

Books/Manuals

1. Praxisfelder angewandter Ethik: ethische Orientierung in Medizin, Politik, Technik und Wirtschaft.
   Hrsg.: Steger F, Hillerbrand R.
   Praktische Urteilskraft und institutionelle Ethik als Voraussetzungen für eine gute Entscheidungspraxis in der Klinik.
   Winkler EC.
   ISBN 978-3897857537; 2013, S. 67-80.
   Verlag: mentis, Münster
2. Current & emerging therapeutics for multiple myeloma.
   Hrsg.: Raje N, Jagannath.
   Future directions.
   Podar K.
   e-ISBN: 978-1-78084-228-8; Sep 2013, S. 114-135. doi: 10.2217/ebo.13.249.
   Verlag: Future Medicine, London
3. Advances in biology and therapy of multiple myeloma: volume 1: basic science.
   Hrsg.: Munshi NC, Anderson KC.
   Targeting multiple myeloma tumor angiogenesis: focus on VEGF.
   Podar K, Anderson KC.
   e-ISBN: 978-1-4614-4666-8; 2013, S. 283-299. doi: 10.1007/978-1-4614-4666-8_15.
   Verlag: Springer Science+Business Media, New York
4. Psychoonkologie
   Hrsg.: Dorfmueller M, Dietzfelbinger H.
   Onkologische Ethik.
   Winkler EC.
   ISBN: 978-3-437-31602-9; 2013, 2. Auflage, S. 477-497. doi: -.
   Verlag: Elsevier Urban und Fischer

Journals

1. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Witzens-Harig M, Hose D, Juenger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P.
   Blood. 2013 May 30;121(22):4493-503. doi: 10.1182/blood-2012-05-429415. Epub 2013 Apr 19.
2. Die Urologie im Konzept der „Comprehensive Cancer Center“.
   Hadaschik B, Pahernik S, Gruellich C, Sueltmann H, Jaeger D, von Kalle C, Duensing S, Hohenfellner M.
   Der Urologe.  2013/9:1283-1289. DOI: 10.1007/s00120-013-3313-3.
3. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
   Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Foersti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Noethen MM, Muehleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Doerner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.
   Nat Genet. 2013 Oct;45(10):1221-5. doi: 10.1038/ng.2733. Epub 2013 Aug 18.
4. Onkologische Therapien – was sind patientenrelevante Endpunkte? Ehmann M, Haerter M, Rambach R, Winkler E.
   Onkologie. 2013; 36(suppl 6):5-8. doi: 10.1159/000353716.
5. Multimodal oncological therapy concepts, chemotherapy and immunosuppressive drugs: effects on surgical morbidity and mortality. Berger AK, Jaeger D.
   Chirurg. 2013; 84(11) 930-6; doi: 10.1007/s00104-013-2512-1.
6. Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
   Gronau M, Jaeger D, Enk AH, Hassel JC.
   Internal Med. 2013;52(1):151-2. Epub 2013 Jan 1.
7. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort.
   Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jaeger D, Buechler MW, Debus J.
   Strahlenther Onkol. 2013 Sep;189(9):738-44. doi: 10.1007/s00066-013-0391-5. Epub 2013 Jul 31.
8. Personalisierte Medizin und Informed consent: klinische und ethische Erwaegungen im Rahmen der Entwicklung einer best practice Leitlinie fuer die biobankbasierte Ganzgenomforschung in der Onkologie. Winkler EC, Ose D, Glimm H, Tanner K, von Kalle C.
   Ethik Med. (2013)25:195-203. doi:10.1007/s00481-013-0273-5.
9. Stathmin regulates keratinocyte proliferation and migration during cutaneous regeneration.
   Schmitt S, Safferling K, Westphal K, Hrabowski M, Mueller U, Angel P, Wiechert L, Ehemann V, Mueller B, Holland-Cunz S, Stichel D, Harder N, Rohr K, Germann G, Matthaeus F, Schirmacher P, Grabe N, Breuhahn K.
   PLoS One. 2013 Sep 16;8(9):e75075. doi: 10.1371/journal.pone.0075075. eCollection 2013.
10. Antitumor T cells responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
    Horn T, Grab J, Schusdziarra J, Schmid S, Maurer T, Nawroth R, Wolf P, Pritsch M, Gschwend JE, Kuebler HR, Beckhove P
    Int J Cancer. 2013 Nov;133(9):2145-56. doi: 10.1002/ijc.28233. Epub 2013 Jul 11.
11. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas
    Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Hoefler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J.
    J Clin Invest. 2013 Jun 3;123(6):2488-501. doi: 10.1172/JCI67010. Epub 2013 May 1.
12. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models
    Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, Grabe N, Veltkamp R.
    Brain Pathol. 2013 Jan;23(1):34-44. doi: 10.1111/j.1750-3639.2012.00614.x. Epub 2012 Aug 7.
13. Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery.
    Koffler J, Holzinger D, Sanhueza GA, Flechtenmacher C, Zaoui K, Lahrmann B, Grabe N, Plinkert PK, Hess J.
    Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1493-500. doi: 10.1007/s00405-012-2201-6. Epub 2012 Oct 5.
14. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
    Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, Beckhove P.
    Oncoimmunology. 2013 Jun 1;2(6):e24962. Epub 2013 May 15.
15. B cell-regulated immune responses in tumor models and cancer patients.
    Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C.
    Oncoimmunology. 2013 Jul 1;2(7):e25443.
16. Adoptive immunotherapy of metastatic breast cancer: present and future.
    Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C.
    Cancer Metast Rev. 2013 32(1-2):309-320.
17. Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.
    Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C.
    Cancer Metast Rev. 2013; 32: 163-78.
18. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.
    Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, Heil J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F.
    Cancer Immunol Immun. 2013 Jun;62(6):1053-60. doi: 10.1007/s00262-013-1414-x. Epub 2013 Apr 18.
19. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
    Khan MW, Keshavarzian A, Gounaris E, Melson JE, Cheon EC, Blatner NR, Chen ZE, Tsai FN, Lee G, Ryu H, Barrett TA, Bentrem DJ, Beckhove P, Khazaie K.
    Clin Cancer Res. 2013 May 1;19(9):2342-54. doi: 10.1158/1078-0432.CCR-12-2623. Epub 2013 Mar 13.
20. Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. Potthoff K, Schmidt ME, Wiskemann J, Hof H, Klassen O, Habermann N, Beckhove P, Debus J, Ulrich CM, Steindorf K.
    BMC Cancer. 2013 Mar 28;13:162. doi: 10.1186/1471-2407-13-162.
21. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
    Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C.
    Cancer Immunol Immun. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.
22. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
    Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V.
    J Immunol. 2013 Mar 1;190(5):2464-71. doi: 10.4049/jimmunol.1202781. Epub 2013 Jan 28.
23. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
    Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von Knebel Doeberitz M, Kloor M.
    Cancer Immunol Immun. 2013 Jan;62(1):27-37. doi: 10.1007/s00262-012-1303-8. Epub 2012 Jun 23.
24. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
    Combs SE, Habermehl D, Kieser M, Dreher C, Werner J, Haselmann R, Jaekel O, Jaeger D, Buechler MW, Debus J.
    BMC Cancer. 2013 Sep 14;13:419. doi: 10.1186/1471-2407-13-419.
25. Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.
    Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D, Klein B.
    Haematologica. 2013 Sep;98(9):1442-9. doi: 10.3324/haematol.2012.066944. Epub 2013 Apr 12.
26. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
    Avet-Loiseau, H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G.
    Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.
27. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.
    Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.
    Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330. Epub 2014 Jan 21.
28. Targeting the BRAF V600E mutation in multiple myeloma.
    Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.
    Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.
29. Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?
    Lamers J, Hartmann M, Goldschmidt H, Brechtel A, Hillengass J, Herzog W.
    Psychooncology. 2013 Apr;22 (10):2313-2320. doi: 10.1002/pon.3284. [Epub ahead of print]
30. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.
    Shah R, Stieltjes B, Andrulis M, Pfeiffer R, Sumkauskaite M, Delorme S, Schlemmer HP, Goldschmidt H, Landgren O, Hillengass J.
    Ann Hematol. 2013 Nov;92(11):1553-7. doi: 10.1007/s00277-013-1786-1. Epub 2013 May 17.
31. Meeting report in the 4th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
    Hillengass J, Maximilian M, Goldschmidt H.
    J Cancer Res Clin. 2013 Nov;139(11):1807-11. doi: 10.1007/s00432-013-1468-3. Epub 2013 Jul 18.
32. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
    Gahrton G, Iacobelli S, Bjoerkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schoenland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kroeger N.
    Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
33. Wound healing revised: a novel reepithelialization mechanism revealed by in vitro and in silico models.
    Safferling K, Suetterlin T, Westphal K, Ernst C, Breuhan K, James M, Jaeger D, Halama N, Grabe N.
    J Cell Biol. 2013 Nov 25;203(4):691-709. doi: 10.1083/jcb.201212020.
34. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
    Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.
    PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.
35. Gene expression-based prediction of myeloma cells sensitivity to histone deacetylase inhibitors.
    Moreaux J, Reme T, Leonard W, Veyrune JL. Requirand G, Goldschmidt H, Hose D, Klein B.
    Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.
36. Hepatitis B virus infection is associated with deletion of chronmosome 8p in multiple myeloma.
    Becker N, Byl A, Friedrich S, Jauch A, Schnitzler P, Egerer G, Ho AD, Goldschmidt H, Neben K
    Eur J Haematol. 2013 Apr;90(4):279-85. doi: 10.1111/ejh.12018. Epub 2012 Nov 22.
37. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.
    Lancet Oncol. 2013 Oct;14(11):1055-66. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
38. Bortezomib-based versus Nonbortezomib-basedinduction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
    J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
39. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC.
    Lancet Oncol. 2013 Oct;14(11):1129-40. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19.
40. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.
    Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfel.d C.
    Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.
41. Advanced-stage pancreatic cancer: therapy options.
    Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buechler MW.
    Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30.
42. A reliable risk score for stage IV esophagogasstric cancer.
    Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Blaeker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jaeger D, Buechler M, Siewert JR, Ott K.
    Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.00.83505. Epub 2013 Jan 31.
43. Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.
    Schmitt S, Hielscher T, Baldus C, Neben K, Egerer G, Hillengaß J, Raab M, Hose D, Ho AD, Bergner R, Goldschmidt H, Moehler TM.
    Int J Hematol. 2013 Jun;97(6):765-72. doi: 10.1007/s12185-013-1320-1. Epub 2013 Apr 25.
44. Posterior reversible leukoencephalopathy syndrome associated with pazopanib.
    Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K.
    Case Rep Oncol. 2013 Apr 6;6(1):204-8. doi: 10.1159/000350742. Print 2013 Jan.
45. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
    Aigner J, Marmé F, Smetanay K, Schuetz F, Jaeger D, Schneeweiss A.
    Anticancer Res. 2013 Aug;33(8):3407-13.
46. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
    Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jaeger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.
    Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.
47. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue.
    Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, Herpel E, Kloor M, Ulrich A, Schneider M, Ulrich CM, Robins H.
    Cancer Immunol Immun. 2013 Sep;62(9):1453-61. doi: 10.1007/s00262-013-1446-2. Epub 2013 Jun 16.
48. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.
    Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, Hengel H, Jaeger D, Schneweis KE, Eis-Huebinger AM, Roggendorf M, Krauss J.
    P Natl Acad Sci USA. 2013 Apr 23;110(17):6760-5. doi: 10.1073/pnas.1220019110. Epub 2013 Apr 8.
49. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.
    Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, Bergmann F, Debus J, Jaeger D, Buechler M, Werner J.
    Ann Surg Oncol. 2013 Mar;20(3):964-72. doi: 10.1245/s10434-012-2762-z. Epub 2012 Dec 12.
50. Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
    Berger AK, Weber TF, Jaeger D, Springfeld C.
    Onkologie. 2013;36(12):763-5. doi: 10.1159/000356811. Epub 2013 Nov 20.
51. Improvement of surgical results for pancreatic cancer.
    Hartwig W, Werner J, Jaeger D, Debus J, Buechler MW.
    Lancet Oncol. 2013 Oct;14(11):e476-85. doi: 10.1016/S1470-2045(13)70172-4.
52. Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG).
    Sisic L, Blank S, Weichert W, Jaeger D, Springfeld C, Hochreiter M, Buechler M, Ott K.
    Langenbeck Arch Surg. 2013 Oct;398(7):973-81. doi: 10.1007/s00423-013-1101-6. Epub 2013 Jul 26.
53. New treatment strategies for multiple myeloma.
    Goldschmidt H, Nitschmann S.
    Internist. 2013 Jul;54(7):892-6. doi: 10.1007/s00108-013-3299-3.
54. Therapeutic strategies in multiple myeloma: the future role of bendamustine
    Goldschmidt H, Kropff M, Muegge LO, Poenisch W.
    Onkologie. 2013;36 Suppl 1:19-26. doi: 10.1159/000346107. Epub 2013 Jan 28.
55. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
    Vallet S, Podar K.
    Expert Opin Biol Th. 2013 Jun;13 Suppl 1:S35-53. doi: 10.1517/14712598.2013.807337. Epub 2013 Jun 17. Review.
56. Multistage histopathological image segmentation of Iba1-stained murine microglias in a focal ischemia model: methodological workflow and expert validation.
    Valous NA, Lahrmann B, Zhou W, Veltkamp R, Grabe N.
    J Neurosci Meth. 213 (2013) 250-262. doi: 10.1016/j.jneumeth.2012.12.017.
57. Thalidomide maintenance therapy maturates the T-cell compartment and compromises antigen specific antitumor immunity in patients with multiple myeloma.
    Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M.
    Exp Hematol. 2013 Mar;41(3):231-40. doi: 10.1016/j.exphem.2012.10.018. Epub 2012 Nov 8.
58. Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients.
    Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H, Neben K.
    Cancer. 2013 Jul 1;119(13):2438-46. doi: 10.1002/cncr.28104. Epub 2013 Apr 10.
59. Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.
    Munder M, Engelhardt M, Knies D, Medenhoff S, Wabnitz G, Luckner-Minden C, Feldmeyer N, Voss RH, Kropf P, Mueller I, Conradi R, Samstag Y, Theobald M, Ho AD, Goldschmidt H, Hundemer M.
    PLoS One. 2013 May 23;8(5):e63521
60. The glycome of normal and malignant plasma cells.
    Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.
    PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.
61. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
    Weinhold N, Johnson DC, Chubb D, Chen B, Foersti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Noethen MM, Muehleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K.
    Nat Genet. 2013 May;45(5):522-5. doi: 10.1038/ng.2583. Epub 2013 Mar 17.
62. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.
    Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE.
    PLoS One. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. eCollection 2013.
63. Progression in smoldering myeloma Is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
    J Clin Oncol. 2013 Dec 1;31(34):4325-32. doi: 10.1200/JCO.2012.48.4923. Epub 2013 Oct 21.
64. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.
    Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jaeger D, Buechler M, Ott K.
    Langenbeck Arch Surg. 2013 Feb;398(2):211-20. doi: 10.1007/s00423-012-1034-5. Epub 2012 Dec 7.
65. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
    Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jaeger D, Buechler M, Siewert JR, Lordick F.
    Langenbeck Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27.
66. Rationing cancer care: a survey among the members of the german society of hematology and oncology.
    Krause SW, Schildmann J, Lotze Ch, Winkler EC.
    J Natl Compr Canc Netw. 2013 Jun 1;11(6):658-65.
67. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Woerns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstaetter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.
    Digest Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.
68. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9.
    Fritsch K, Finke J, Gruellich C.
    Ann Hematol. 2013 Dec;92(12):1603-9. doi: 10.1007/s00277-013-1846-6. Epub 2013 Jul 28.
    
69. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
    Marmé F, Aigner J, Lorenzo Bermejo J, Sinn P, Sohn C, Jaeger D, Schneeweiss A.
    Int J Cancer. 2013 Aug 15;133(4):1006-15. doi: 10.1002/ijc.28094. Epub 2013 Mar 16.
70. Semantic Focusing Allows Fully Automated Single-Layer Slide Scanning of Cervical Cytology Slides.
    Lahrmann B, Valous NA, Eisenmann U, Wentzensen N, Grabe N.
    PloS  One. 8(4): e61441. doi: 10.1371/journal.pone.0061441.
71. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.
    Halama N, Spille A, Lerchl T, Brand K, Herpel E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C, Weitz J, Grabe N, Jaeger D, Zoernig I.
    OncoImmunology. 2:4, e24116; April 2013. doi: 10.4161/onci.24116.
72. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
    Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.
73. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
    Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jaeger D, Schulze-Bergkamen H.
    PLoS One. 2013 Oct 3;8(10):e76446. doi: 10.1371/journal.pone.0076446. eCollection 2013.
74. CD24 polymorphisms in breast cancer: impact on prognosis and risk.
    Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jaeger D, Flesch-Janys D, Chang-Claude J, Marmé F.
    Breast Cancer Res Tr. 2013 Feb;137(3):927-37. doi: 10.1007/s10549-012-2325-9. Epub 2013 Jan 13.
75. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway.
    Holzinger D, Flechtenmacher C, Henfling N, Kaden I, Grabe N, Lahrmann B, Schmitt M, Hess J, Pawlita M, Bosch FX.
    Int J Cancer. 2013 Sep 15;133(6):1389-99. doi: 10.1002/ijc.28142. Epub 2013 Mar 29.
76. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
    Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM.
    Oncology. 2013;84(1):6-13. doi: 10.1159/000342425. Epub 2012 Oct 13.
77. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
    Elsing C, Herrmann C, Hannig CV, Stremmel W, Jaeger D, Herrmann T.
    Oncology. 2013;85(5):262-8. doi: 10.1159/000355690. Epub 2013 Oct 29.
78. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
    Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schaekel K, Garbi N, Jaeger D, Weitz J, Schmitz-Winnenthal H, Haemmerling GJ, Beckhove P.
    Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.
79. Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance.
    Zoernig I, Ziegelmeier C, Lahrmann B, Grabe N, Jaeger D, Halama N.
    Oncol Rep. 2013 May;29(5):1697-700. doi: 10.3892/or.2013.2324. Epub 2013 Mar 5.
80. Bridging the scales: semantic integration of quantitative SBML in graphical multi-cellular models and simulations with EPISIM and COPASI.
    Suetterlin T, Kolb C, Dickhaus H, Jaeger D, Grabe N.
    Bioinformatics. 2013 Jan 15;29(2):223-9. doi: 10.1093/bioinformatics/bts659. Epub 2012 Nov 18.
81. Urology in the concept of comprehensive cancer centers
    Hadaschik B, Pahernik S, Gruellich C, Sueltmann H, Jaeger D, von Kalle C, Duensing S, Hohenfellner M.
    Urologe A. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3.
82. B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort.
    Zschaebitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, Miller JW, Song X, Maneval DR, Beresford SA, Lane D, Shikany JM, Ulrich CM.
    Am J Clin Nutr. 2013 Feb;97(2):332-43. doi: 10.3945/ajcn.112.034736. Epub 2012 Dec 19.
83. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
    Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P.
    Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101.
84. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, Moehler T, Goldschmidt H, Schmidt-Wolf IG.
    Hematol Oncol. 2013 Dec;31(4):197-200. doi: 10.1002/hon.2043.

Lehr-/Handbücher

1. Prävention und Versorgung.
   Hrsg.: Kirch W, Hoffmann T, Pfaff H.
   Patientenorientierte Versorgungsforschung – Grundlagen, Methoden und Perspektiven.
   Ose D, Freund T, Winkler EC, Ludt S.
   ISBN 978-3-13-169451-5; 2012, S. 464-477.
   Verlag: Thieme, Stuttgart
   
   
2. Multiple myeloma – a new era of treatment strategies.
   Hrsg.: Podar K, Anderson KC.
   Guideline to multiple myeloma treatment strategies.
   Podar K, Kaufmann JL, Laubach J, Lonial S, Richardson PG, Anderson KC.
   ISBN: 978-1-60805-609-5.
   e-ISBN: 978-1-60805-297-4; 2012, S. 73-87.
   doi: 10.2174/97816080529741120101.
   Verlag: bentham science publishers
   
   
3. Multiple myeloma – a new era of treatment strategies.
   Hrsg.: Podar K, Anderson KC.
   New therapeutic strategies in multiple myeloma.
   Podar K, Hideshima T, Chauhan D, Anderson KC.
   ISBN: 978-1-60805-609-5.
   e-ISBN: 978-1-60805-297-4; 2012, S. 161-183. doi: 10.2174/97816080529741120101.
   Verlag: bentham science publishers
   
   
4. Multiple myeloma – a new era of treatment strategies.
   Hrsg.: Podar K, Anderson KC.
   Pathogenesis and treatment of bone disease in multiple myeloma.
   Vallet S, Raje N.
   ISBN: 978-1-60805-609-5.
   e-ISBN: 978-1-60805-297-4; 2012, S. 161-183. doi: 10.2174/97816080529741120101.
   Verlag: bentham science publishers
   
   
5. Rationelle Diagnostik und Therapie in der Inneren Medizin.
   Multiples Myelom.
   Goldschmidt H.
   ISBN: 978-3-437-22827-8; 2012, Bd. 11: S. 1-6. doi: -
   06.
   
   
6. Onkologie 2012/2013. Interdisziplinäre Empfehlungen zur Therapie.
   Hrsg.: Preiß J, Dornoff W, Hagmann FG, Schmieder A.
   Multiples Myelom (MM, Plasmozytom).
   Goldschmidt H.
   ISBN: 978-3-86371-042-2; 2012, S. 57-61. doi: -.
   Verlag: W. Zuckschwerdt Verlag, München
   
   
7. Praxisbuch Ethik in der Intensivmedizin.
   Hrsg.: Salomon F.
   Die institutionelle moralische Verantwortung der Klinik.
   Winkler EC.
   ISBN: 978-3-941-46874-0; 2012, S. 123-129. doi: -.
   Verlag: Med. Wissenschaftliche Verlagsgesellschaft, Berlin

Journals

1. Deriving new treatment strategies.
   Podar K.
   Int J Hematol. 2012;1(1)1-6.
   
   
2. Targeting the tumor microenvironment: Focus on angiogenesis.
   Fan F, Schimming A, Jaeger D, Podar K.
   J Oncol. 2012;2012:281261. doi: 10.1155/2012/281261. Epub 2011 Aug 24.
   
   
3. MM-associated anemia: more than “crowding out” HSPCs.
   Podar K.
   Blood. 2012; Sep 27;120(13):2539-40.
   
   
4. Novel  targets and derived small molecule inhibitors in multiple myeloma.
   Podar K.
   Curr Cancer Drug Tar. 2012 Sep;12(7):797-813.
   
   
5. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.
   Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Kraemer A.
   Cancer Res. 2012 Oct 15;72(20):5374-85. doi: 10.1158/0008-5472.CAN 12-2026. Epub 2012 Aug 31.
   
   
6. Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors
   Moreaux J, Rème T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.
   Mol Cancer Ther. 2012 Dec;11(12):2685-92. doi: 10.1158/1535-7163.MCT-12-0721. Epub 2012 Oct 18.
   
   
7. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
   Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.
   PLoS One. 2012;7(7):e42161. doi: 10.1371/journal.pone.0042161. Epub 2012 Jul 31.
   
   
8. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
   Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.
   J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.
   
   
9. A gene expression signature for high-risk multiple myeloma.
   Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P.
   Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8. Erratum in: Leukemia. 2014 May;28(5):1178-80.
   
   
10. Clinical and prognostic role of annexin A2 in multiple myeloma.
    Seckinger A, Meißner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Rème T, Roesen-Wolff A, Jauch A, Schmettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D.
    Blood. 2012 Aug 2;120(5):1087-94. doi: 10.1182/blood-2012-03-415588. Epub 2012 Jun 15.
    
    
11. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and sdurvival in multiple myeloma.
    Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R, Hose D, Delorme S, Goldschmidt H, Neben K.
    Haematologica. 2012 Nov;97(11):1757-60. doi: 10.3324/haematol.2012.065359. Epub 2012 Jun 11.
    
    
12. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
    Dimopoulos MA, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky R.
    Cancer Treat Rev. 2012 Dec;38(8):1012-9. doi: 10.1016/j.ctrv.2012.02.009. Epub 2012 May 18. Review.
    
    
13. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMEnSE consortium.
    Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi S, Canzian F.
    Br J Haematol. 2012 May;157(3):331-8. Epub 2012 Feb 13.
    
    
14. European perspective on multiple myeloma treatment strategies: update following recent congresses.
    Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Hess U, Mellqvist UH, Moreau P, San-Miguel J, Sondergeld P, Sonneveld P, Udvardy M, Palumbo A.
    Oncologist. 2012;17(5):592-606. doi: 10.1634/theoncologist.2011-0391. Epub 2012 May 9.
    
    
15. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S.
    Leukemia Lymphoma. 2012 Sep;53(9):1820-3. doi: 10.3109/10428194.2012.661175. Epub 2012 Mar 1.
    
    
16. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma research (IMMEnSE) consortium.
    Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM.
    Leukemia. 2012 Jun;26(6):1419-22. doi: 10.1038/leu.2011.352. Epub 2011 Dec 20.
    
    
17. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Duehrsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.
    Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8.
    
    
18. Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma a technique to evaluate angiogenic response to therapy?
    Zechmann CM, Traine L, Meißner T, Wagner-Gund B, Giesel FL, Goldschmidt H, Delorme S, Hillengass J.
    Acad Radiol. 2012 Jan;19(1):100-8. doi: 10.1016/j.acra.2011.09.007.
    
    
19. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.
    Broderick P, Chubb D, Johnson DC, Weinhold N, Foersti A, Lloyd A, Olver B, Ma YP, Dobbins SE, Walker BA, Davies FE, Gregory WA, Child JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Muehleisen TW, Noethen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS.
    Nat Genet. 2011 Nov 27;44(1):58-61. doi: 10.1038/ng.993.
    
    
20. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.
    Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.
    Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.
    
    
21. MAGIC (MyelomA Genetics International Consortium).
    Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim CS, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R.
    Leuk Lymphoma. 2012 May;53(5):796-800. doi: 10.3109/10428194.2011.639881. Epub 2012 Jan 3.
    
    
22. Meeting report of the third Heidelberg myeloma workshop: current status and developments in diagnosis and therapy of multiple myeloma.
    Hillengass J, Neben K, Goldschmidt H.
    J Cancer Res Clin. 2012 Jan;138(1):173-8. doi: 10.1007/s00432-011-1071-4. Epub 2011 Sep 30.
    
    
23. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S, Witzens-Harig M, Jaeger D, Podar K.
    Expert Opin Pharmaco. 2012 Mar;13(4):473-94. doi: 10.1517/14656566.2012.656091. Epub 2012 Feb 13.
    
    
24. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jaeger D, Capussotti  L, Kunz R, Buechler MW.
    J Clin Oncol. 2012 Nov 20;30(33):4077-83. doi: 10.1200/JCO.2011.38.2960. Epub 2012 Sep 24.
    
    
25. Eine ethische Orientierungshilfe: Therapieverzicht gegen den Patientenwillen?
    Winkler EC, Marckmann G.
    ÄBW. (4) 2012:140-144.
    
    
26. Aenderung des Therapieziels am Lebensende: Effekte einer Klinik-Leitlinie.
    Jox RJ, Winkler EC, Borasio GD.
    Deut Med Wochenschr. 2012; 137(16):829-833.
    
    
27. Evaluating a patient’s request for life-prolonging treatment: an ethical framework.
    Winkler EC, Hiddemann W, Marckmann G.
    J Med Ethics. 2012 Nov;38(11):647-51. doi: 10.1136/medethics-2011-100333. Epub 2012 Jun 12.
    
    
28. Interdisziplinaere Therapiekonzepte bei kolorektalen Lebermetastasen.
    Schulze-Bergkamen H, Jaeger D.
    Viszeralmedizin. 2012 (28):43-49.
    
    
29. Liver specific deletion of CYLDexon 7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
    Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hoevelmeyer N, Hahn M, Schuchmann M, Jaeger D, Waisman A, Woerns MA, Schulze-Bergkamen H.
    J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21.
    
    
30. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
    Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, Kalle CV, Ungerechts G.
    Cancer Gene Ther. 2012 Mar;19(3):181-91. doi: 10.1038/cgt.2011.75. Epub 2011 Nov 11.
    
    
31. Emerging trends in oncology testing: enhancing the medical value of diagnostics.
    Rohr UP, Walk E, Teichgraeber V, Liesenfeld O, Batria R, Lee JA.
    Clpmag.com. 2012 42(9):8-13
    
    
32. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.
    Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.
    Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.
    
    
33. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinat envelope protein booster.
    Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cataneo R.
    J Virol. 2012 Nov;86(21):11558-66. doi: 10.1128/JVI.01776-12. Epub 2012 Aug 15.
    
    
34. Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study.
    Kasperk C, Haas A, Hillengass J, Weiss C, Neben K, Goldschmidt H, Sommer U, Nawroth P, Meeder PJ, Wiedenhoefer B, Schmidmaier G, Tanner M, Neuhof D, Noeldge G, Grafe IA.
    J Surg Oncol. 2012 Jun 1;105(7):679-86. doi: 10.1002/jso.22101. Epub 2011 Sep 29.
    
    
35. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International myeloma working group study.
    Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.
    
    
36. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
    Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jaeger D, Olson DL, Sattler M, Chauhan D, Anderson KC.
    Brit J Haematol. 2011 Nov;155(4):438-48. doi: 10.1111/j.1365-2141.2011.08864.x. Epub 2011 Sep 19.
    
    
37. 5-Fluorouracil and interferon-α  immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
    Khallouf H, Maerten A, Serba A, Teichgraeber V, Buechler MW, Jaeger D, Schmidt J.
    J Immunother. 2012 Apr;35(3):245-53. doi: 10.1097/CJI.0b013e31824b3a76.
    
    
38. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
    Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jaeger D.
    BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108.
    
    
39. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.
    Combs SE, Kieser M, Habermehl D, Weitz J, Jaeger D, Fossati P, Orrechia R, Engenhart-Cabillic R, Poetter R, Dosanjh M, Jaekel O, Buechler MW, Debus J.
    BMC Cancer. 2012 Apr 3;12:137. doi: 10.1186/1471-2407-12-137.
    
    
40. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).
    Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jaeger D, Luntz SP, Englert S, Rossion I, Koch M, Buechler MW, Kieser M, Weitz J; SYNCHRONOUS trial group.
    BMC Cancer. 2012 Apr 5;12:142. doi: 10.1186/1471-2407-12-142.
    
    
41. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
    Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hoevelmeyer N, Hahn M, Schuchmann M, Jaeger D, Waisman A, Woerns MA, Schulze-Bergkamen H.
    J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21.
    
    
42. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
    Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, Debus J, Jaeger D, Buechler MW, Werner J.
    Surgery. 2012 Sep;152(3 Suppl 1):S33-42. doi: 10.1016/j.surg.2012.05.029. Epub 2012 Jul 6.
    
    
43. Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy.
    Kahlert C, Gaitzsch E, Steinert G, Mogler C, Jansen L, Benner A, Chang-Claude J, Klupp F, Schmidt T, Grabe N, Lahrmann B, Halama N, Weitz J.
    Ann Surg Oncol. 2012 Dec;19(13):4193-201. doi: 10.1245/s10434-012-2518-9. Epub 2012 Aug 10.
    
    
44. The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead.
    Halama N, Zoernig I, Grabe N, Jaeger D.
    Oncoimmunology. 2012 Jan 1;1(1):62-66.
    
    
45. Sequential metastases of colorectal cancer. Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments.
    Keim S, Zoernig I, Spille A, Lahrmann B, Brand K, Herpel E, Grabe N, Jaeger D, Halama N.
    Oncoimmunology. 2012 Aug 1:5,593-599.
    
    
46. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
    Loehr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Foelsch UR, Jaeger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP; CT4001 Study Group.
    Ann Oncol. 2012 May;23(5):1214-22. doi: 10.1093/annonc/mdr379. Epub 2011 Sep 6.
    
    
47. Multistage histopathological image segmentation of Iba1-stained murine microglias in a focal ischemia model: Methodological workflow and expert validation.
    Valous NA, Lahrmann B, Zhou W, Veltkamp R, Grabe N.
    J Neurosci Meth. 213 (2013) 250-262. doi: 10.1016/j.jneumeth.2012.12.017.
    
    
48. Bridging the scales: semantic integration of quantitative SBML in graphical multi-cellular models and simulations with EPISIM and COPASI
    Suetterlin T, Kolb C, Dickhaus H, Jaeger D, Grabe N.
    Bioinformatics.2013 Jan 15;29(2):223-9. doi: 10.1093/bioinformatics/bts659.Epub 2012 Nov 18.
    
    
49. Revisiting the training of logic models of protein signaling networks with ASP.
    Videla S, Guziolowski C, Eduati F, Thiele S, Grabe N, Saez-Rodriguez J, Siegel A.
    Computational Methods in Systems Biology. Series: Lecture Notes in Computer Science. 2012 Vol 7605:342-361.
    
    
50. Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery.
    Koffler J, Holzinger D, Sanhueza GA, Flechtenmacher C, Zaoui K, Lahrmann B, Grabe N, Plinkert PK, Hess J.
    Eur Arch Oto-Rhino-L. 2012 05. October 2012; doi: 10.1007/s00405-012-2201-6.
    
    
51. Potential canonical Wnt pathway activation in high-grade astrocytomas
    Schuele R, Dictus C, Campos B, Wan F, Felsberg J, Ahmadi R, Centner F, Grabe N, Reifenberger G, Bermejo J, Unterberg A, Herold-Mende C.
    The Scientific World Journal. 2012:697313. doi: 10.1100/2012/697313. Epub 2012 Aug 2.
    
    
52. In silico accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types.
    Gupta SK, Srivastava M, Akhoon BA, Gupta SK, Grabe N.
    Infect Genet Evol.  2012 Oct;12(7):1513-8. doi: 10.1016/j.meegid.2012.02.022. Epub 2012 May 24.
    
    
53. Automatic generation of causal networks linking growth factor stimuli to functional cell state changes.
    Guziolowski C, Kittas A, Dittmann F, Grabe N.
    FEBS J.  2012 Sep;279(18):3462-74. doi: 10.1111/j.1742-4658.2012.08616.x. Epub 2012 May 22.
    
    
54. Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
    Jensen AD, Krauss  J, Potthoff  K, Simon C, Nikoghosyan AV, Lossner K, Debus J, Munter MW.
    Radiat Oncol. 2012 Apr 2;7:57. doi: 10.1186/1748-717X-7-57.
    
    
55. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
    Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.
    Invest New Drug. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.
    
    
56. Fulminant liver failure in Wilson's disease with histologic features of postinfantile giant cell hepatitis; cytomegalovirus as the trigger for both?
    Welte S, Gagesch M, Weber A, Longerich T, Millonig G.
    Eur J Gastroenterol Hepatol. 2012 Mar;24(3):328-31. doi: 10.1097/MEG.0b013e3283506843.